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Abstract
The role of DNA methylation based biomarkers in several stages of cancer development
is a rapidly advancing area of research. The aberrancies on the methylation profile of gene
promoters play a critical role in gene silencing, thus contributing in different phases of tu-
mour initiation, progression and recurrence, also associated with predicting the response
to chemotherapeutic agents, therefore leading to a better assessment of the clinical effec-
tiveness of cancer therapies and so of better prognosis. The need for detection of DNA
methylation has become one of the most important assays in early cancer screening.
This work introduces the use of semiconductor technology for detection of DNA methy-
lation based biomarkers in CMOS for early screening of cancer using the Ion-Sensitive
Field-Effect Transistor (ISFET). This enables label-free detection of DNA methylation in
gene markers of interest associated with tumour development in different organs, ultimately
enabling a Point-of-Care (PoC) system for early cancer diagnosis. Towards this goal, we
introduce the concept of ratiometric detection using the “Methylation Cell” which allows
continuous computation of the DNA methylation ratio. This was demonstrated through a
Lab-on-Chip (LoC) system using low power current-mode translinear circuits fabricated in
unmodified CMOS.
Complementary to this, a novel implementation of the “Gilbert Gain Cell” integrated
with ISFET sensors was proposed, referred to as the ISFET based Chemical Gilbert Cell,
a current-mode circuit for differential reaction monitoring of pH signals derived from DNA
methylation reactions. The Cell achieves elimination of common non-idealities of ISFETs
such as drift reduction and temperature variations, while achieving gain tunability.
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Chapter 1
Introduction
1.1 Motivation
We are living in an era that has experienced significant technological revolutions as well as
advances in medicine and health management, improving our quality of life and giving us
the opportunity to be the protagonists of a personalisation trend. Personalised technology
and its applications in the world of healthcare has brought remarkable advances and novel
solutions in early detection, real-time monitoring and therapy of disease, bridging the gap
between the biological problem and methods for a solution.
Over the past few years, bio-inspired technology in combination with the integration of
semiconductors in biomedical applications has created a fertile ground for the development
of methods for offering novel solutions to these problems. These include nanofabrication
of electrode based systems for neural recording with interfacing capabilities to the brain
periphery [1] as well as significant advances in the field of genetic technology [2], with
Point-of-Care diagnostics and on-the-spot testing to be the future of drastically effective
monitoring of critical biological markers and of the personalised application of therapeutic
schemes. These examples reveal that such technologies have been engineered according to
the demands required for therapy and diagnosis.
Never before have we been in this unique position to be able to apply technology so
effectively for treatment of disease. The biggest being the war against cancer.
Cancer, a prominent cause of death worldwide, is exponentially increasing in numbers,
an observation that can be correlated with the genetic predisposition of the individual
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towards the disease as well as the epigenetic inheritance passed by our ancestors and our
environmental influences. Historically, the very first remark on the term epigenetics was
given in 1939 by Conrad Waddington [3], introducing a new perspective on the classification
of biological events that do not influence the genetic code and thus cannot be described by
genetic principles. It was the first time a connection between genetic information and
phenotype was conceived [4], allowing for further definitions of the term to be presented in
the following years. Epigenetics has been established as highly influential in the activity
and expression of key regulatory genes due to its role in applying heritable changes in them
without altering the genetic sequences themselves [5–8].
The field of epigenetics has seen explosive interest in the last decade especially due to
its powerful role in the initiation and progression of various cancer types [9, 10], being
considered as a central driving force in tumour development. One of the key epigenetic
factors and most common epigenetic events in the human genome, playing a critical role in
the mechanisms behind the regulation of genetic functions and of gene expression is DNA
methylation, a chemical modification that can be inherited while keeping the genetic in-
formation unaltered during cell differentiation. DNA methylation has emerged as a highly
promising biomarker1, been actively studied in multiple cancer types, with the methyla-
tion profile to be possible to distinguish tumour types and even predict the response to
chemotherapeutic agents [12–15].
It has been shown by a large number of studies that disruptions in DNA methylation,
in particular genetic regions known as “CpG islands” can be responsible for aberrations in
key regulatory areas of genes, such as their promoter regions, leading to inappropriate gene
expression and thus chromosomal instability [16]. Such changes may lead to gene silencing
by forcing the switching mechanisms, responsible for normal gene expression to turn “off”
instead of “on”. These certain disruptions that can be the consequence of aberrancies in
the methylation levels of such areas are implicated in several steps of tumour development,
progression and recurrence, intricately interacting in the pathogenesis of cancer [17, 18].
This can be validated by the observation that aberrancies in DNA methylation patterns in
the genome of cancer cells can exhibit abnormal transformations, leading to inactivation of
tumour suppressor genes, promotion of oncogenes, deregulation of cell death, DNA repair
irregularities, direct or indirect consequences of epigenetic deregulation [19].
1In cancer research, a biomarker refers to a substance or process that is indicative of the presence of
signs of cancer in the body. It might be either a molecule secreted by a malignancy itself, or a specific
response of the body to the presence of cancer [11].
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Figure 1.1: The future scene of a closed-loop strategy towards cancer management using
semiconductors for DNA methylation detection.
If cancer cannot be entirely prevented, then the earlier it is detected the more the chances
for an effective and well-personalised treatment to the patient, better risk assessment and
thus clinical outcome [20, 21]. For certain cancer types, the patient’s survival rate may drop
dramatically once it is diagnosed with the current diagnostic and screening methods, leading
to higher risks taken by the oncologists for a targeted treatment based on the stage of the
disease progression, affecting the efficiency of the therapy as well as the patient’s quality of
life. Consequently, cancer early detection needs to be reshaped through the development
of assays using well-studied epigenetic biomarkers, such as DNA methylation, that could
offer more sensitive prediction and more accurate prognosis during the stages of cancer
progression.
Since mass population early screening of cancer may still be a challenging topic for
the healthcare sector, early detection systems based on semiconductor technology can be a
promising approach. This could be part of a scheme whereby the epigenetic description of
a tumour could provide the clinician with the initial information about the organ of origin
or the stage of cancer progression through a deeper screening analysis, dependent on the
DNA methylation analysis result. We may call these systems closed-loop detection systems,
as shown in Fig. 1.1.
These systems may ultimately contribute in the monitoring process of cancer and the
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Figure 1.2: Future technological vision for early cancer screening
clinical implications behind cancer management by helping individuals keep track of their
health progression regarding any malignancies that may unexpectedly arise, providing with
an approach for a more precise detection of disease, better prognosis and a closer to the
patient’s profile therapeutic model. For that goal, developing assays that would serve that
need could form an attractive territory for the new generation of early detection systems,
putting semiconductor technology at the centre of attention.
1.2 Technological vision
We believe that genetic testing using DNA methylation as the biomarker for early screening
of cancer will yield a more accurate result for early detection over current methods which
require imaging and possible invasive intervention for diagnosis. The future vision for
the work in this thesis is depicted in Fig. 1.2, whereby the screening methods of cancer
would gradually converge from bulky, slow and expensive which are located in a hospital to
portable, miniaturised, cheap and with local intelligence which can be made available for
the GP clinic, expanding its use to a wider population.
The realisation of this vision is enabled with the use of CMOS technology which brings
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the potential for miniaturisation and low cost, due to the economies of scale of silicon which
over the last few decades have been following Moore’s law, in addition to rapid label-free
DNA detection which has proven to be feasible in under an hour [22].
With CMOS, we demonstrate the first DNA methylation detection system which enables
this vision for early screening of cancer. For this, an integrated CMOS based chemical sensor
is required, with the ability to be developed into a biochemical processing platform. The
ISFET (Ion-Sensitive Field-Effect Transistor) is the sensor that will be used in this research,
allowing a label-free approach for DNA methylation detection which can be miniaturised
and give a rapid result.
Implementing in CMOS consequently has additional benefits which are explored in this
thesis. We show that through utilising local intelligence on the chip, we can combine ISFET
sensors and current-mode circuits to provide building blocks for large scale sensing arrays
to be used in parallel detection of DNA methylation in multiple genetic targets. This will
ultimately reduce the need for large data bandwidth of large scale arrays by reduction of
the output of the circuit to a simple YES/NO answer, which can be defined using 1 bit of
information and therefore can ultimately allow further scaling of ISFET arrays.
1.3 Research objectives
This research focuses on the application of semiconductor technology for detection of DNA
methylation based biomarkers for early screening of cancer using solid state based ion sensors
known as Ion-Sensitive Field-Effect Transistors (ISFETs). The aim is to develop a Lab-on-
Chip (LoC) system forming a link between the CMOS based ISFET technology and a DNA
methylation based platform as a first attempt to detect electrically early signs of genetic
markers associated with tumour growth. This opens up a very promising area of research
in the field of semiconductor technology applied in cancer screening.
This work also introduces the interaction of a specifically applied biochemical platform
with an electronic interface, implemented using ISFET sensors for DNA methylation de-
tection. The signal acquisition (pH change) obtained from the DNA samples will be the
measured output of the ISFETs, whose sensed information is dependent on the instrumenta-
tion chosen for the DNA analysis. This will be designed in CMOS which utilises intelligent
sensor design due to the integrative capability of ISFETs with standard well-known cir-
cuit techniques and provides the ability of real-time continuous detection and processing,
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paving the way for the next generation of real-time DNA methylation specific assays for
early screening and further monitoring of cancer.
The main axons to be explored in this thesis are:
• Development of a proof-of-concept method to determine and validate DNA methy-
lation based biomarkers in genetic assays using the pH sensitive ISFET technology,
with the objective to form the chemical front-end of a label-free based system for DNA
methylation detection.
• Demonstration of a label-free based method for DNA methylation detection in CMOS
in under an hour.
• Formation of the electrical front-end of the system using ISFETs in standard CMOS
by exploiting circuit techniques to perform analogue computation in addition to en-
hancing the signal generated from DNA based reactions (thermocycling/isothermal
reaction) and reducing the amount of data to be transmitted. Main objective here is to
develop low power interfaces, avoiding common non-idealities found in ISFET sensors
and in parallel by highlighting a DNA based computational path that can compute
ratios of DNA methylation, which have been identified as a potential mechanism for
DNA methylation analysis of heterogeneous DNA methylation profiles.
• Development of a Lab-on-Chip system which includes fully integrated chemical and
electrical front-ends with real-time monitoring of input pH signals and local intelli-
gence capable of giving a YES/NO answer based on a ratiometric detection of DNA
methylation.
1.4 Overview
The structure of the thesis can be divided in the following chapters with an overview for
each one presented as below:
1.4.1 Epigenetics and DNA methylation in cancer
This chapter introduces a comprehensive literature review, covering the recent develop-
ments in the field of epigenetics and specifically in their involvement in cancer, focusing on
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the most common and well-studied epigenetic event, DNA methylation. The importance
of DNA methylation as a powerful cancer biomarker is also highlighted as well as its role
in aberrancies in genetic silencing and instability in gene expression, contributing in can-
cer development, emphasising on the significant role of such biomarker in early detection
strategies as well as in cancer prognosis and therapy. The methylation profile of genes that
show epigenetic alterations, contributing in tumorigenesis is also presented, with cases of
highly methylated genes used as good examples associated with certain tumour types. Fi-
nally, the current methods and latest technological revolutions for detecting and analysing
DNA methylation are presented, stating the advantages but also the limiting factors of such
approaches. The chapter concludes by setting the scene for the next generation of systems
for early cancer screening using CMOS based technologies for large scale, high-density DNA
methylation detection.
1.4.2 The Ion-Sensitive Field-Effect Transistor
This chapter presents the fundamental elements needed for an integrated DNA base pair
incorporation detection system which can be used for DNA methylation detection. A brief
review of solid-state chemical sensors is introduced together with their chemical sensing
mechanisms and the introduction of the Ion-Sensitive Field-Effect Transistor (ISFET), the
primary sensor used in this work. The principles of operation of the ISFET sensor is
described and its macromodel is shown. ISFET characteristics and the theory behind the
pH sensitivity that primarily describes it as a sensor are presented. Emphasis is given
on the devices’ CMOS implementation which is shown to have advantages, especially in
applications related to DNA detection. Specific focus is then given on the weak inversion
region of operation which has been chosen for its low power and computational capability.
1.4.3 DNA methylation detection using ISFETs
This chapter presents the development of the chemical front-end of the system required for
DNA methylation detection. This consists of a first proof-of-concept method of primarily
determining and validating the methylation status of a DNA template and additionally
using a commercially available Sentron ISFET microelectrode to detect pH changes during
extension reactions of the DNA template, with known levels of methylation, as a sensitive
as well as specific method for the basis of DNA methylation detection. Through this,
the proof-of-concept of DNA methylation detection using ISFETs was proven. Following
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on from this, the first use of ISFETs in CMOS was demonstrated in real-time using an
optimised biochemical assay at isothermal conditions in a System-on-Chip (SoC) platform.
This proves that DNA methylation can be detected on-chip enabling potential development
of a fully integrated miniaturised system.
1.4.4 An analogue ratiometric method for DNA methylation detection
This chapter presents a ratiometric computation method that can be used for DNA methy-
lation detection. In particular, the concept of the translinear “Methylation Cell” is intro-
duced, using a novel ISFET based readout for the calculation of the ratio between aberrantly
methylated DNA of a gene site possibly correlated to pathogenesis and to unmethylated
DNA of the same gene site showing no aberrancies, therefore corresponding to the normal
status of it. This circuit technique is based on the “translinear principle” to implement
current division of sensed biochemical signals and aims to formulate a process of using the
ratio between methylated and unmethylated DNA as an indication of the level of aberrancy
of methylation existent in tumour suppressor genes of interest. Analysis of such ratiometric
markers will be based upon the proportion of methylated sites presented above a pre-defined
threshold value, sensed using ISFETs in standard CMOS. Further to this effort of intro-
ducing the ratiometric approach, a fabricated system consisting of both ISFET sensors and
circuitry to compute the ratio is presented in a typical 0.35µm CMOS process, integrated in
a Lab-on-Chip (LoC) set-up. Experimental results are presented, proving that pH changes
associated with DNA methylation can be detected in CMOS and that the ratio can be
computed reliably in hardware.
1.4.5 A current-mode approach for differential DNA methylation detec-
tion
In this chapter, an alternative current-mode approach was developed leading to the devel-
opment of an ISFET based Chemical Gilbert Cell, capable for differential amplification of
current signals originated from biochemical reactions of DNA amplification, allowing stable
drift reduction of continuously recording pH signals. It also achieves gain tunability and
low power consumption. The concept was designed and fabricated in a typical 0.35µm
CMOS process, with both biochemical and electrical front-ends been fully integrated in
a Lab-on-Chip (LoC) setup. Experimental results and analysis on the capabilities of the
system follows with the advantages that such configuration can bring to applications where
Introduction 12
ISFETs are integrated at a large scale.
1.4.6 Conclusion
Finally, concluding remarks of this thesis are summarised together with the contributions
of this research. Recommendations for future work are also proposed.
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Chapter 2
Epigenetics and DNA methylation
in cancer
2.1 Introduction
There has been an explosive interest in the field of epigenetics, with recent advances changing
the understanding of many biological phenomena and complex diseases, such as cancer,
a disease that was traditionally viewed as genetic in origin [1]. Cancer is a result of a
multistep process in which aberrant genetic changes such as gene mutations, gene deletions
and chromosomal translocations accumulate, resulting in the transformation of a normal
cell into an invasive or metastatic1 tumour cell [3, 4]. Growing evidence has shown that
acquired epigenetic abnormalities together with genetic alterations participate in processes
of cancer development, Fig. 2.1, causing disruptions in the regulatory mechanisms of genes.
Epigenetic changes are involved in aberrant activation or inactivation of genes, participating
in mechanisms that may influence the homeostasis of gene expression, the disruption of
which is intricately prevalent in the pathogenesis of cancer [5–8].
The growing interest in cancer epigenetics has been derived from the fact that epigenetic
changes are involved in various steps of tumour development and progression being further
augmented by the recent realisation that such changes can be exploited as a powerful tool in
the clinic and as a novel approach for early cancer diagnosis, prediction of clinical outcome,
risk assessment and targeted therapy [7, 12–15]. Epigenetics has evolved as a rapidly devel-
oping area of research, referring to heritable and potentially reversible alterations in gene
1A metastatic tumour is defined as one formed at a location in the body, the cells of which have been
transported from a primary tumour located elsewhere in the body [2].
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Figure 2.1: Epigenetic changes are influenced by both environmental stimuli and genetic
changes. This means that our phenotype is determined by our genotype, the genetic in-
formation we are carrying, and our epigenotype, all the inherited and acquired epigenetic
changes. In case of cancer development, disruptions in both genetic and epigenetic mech-
anisms occur, with DNA methylation, a key epigenetic modification, to play an important
role in detection strategies of cancer. The fact that DNA methylation changes, associ-
ated with a primary tumour source, can be detected in blood circulation makes it a very
attractive cancer biomarker [9–11].
expression that are not coded in the DNA sequence itself. The epigenome of cancer cells
has been extensively studied, having shown that a large number of potential biomarkers
has been identified, specifically DNA methylation, Fig. 2.1, a highly promising molecular
biomarker, one of the most frequent alterations that occur in human malignancies and one
of the most common epigenetic events in the human genome. This plays a critical role in
regulating the mechanisms of gene expression [5, 6, 16, 17].
DNA methylation, a dynamically spreading chemical modification, has been studied
in multiple cancer types, with abnormalities in its patterns identified in particular gene
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regions known as CpG islands, rich in the content of CG bases [13, 14]. The majority
of CpG islands are located in the promoter regions of the genes, areas responsible for the
gene’s transcription and the controlling mechanisms that regulate gene expression, generally
unmethylated in normal cells. Aberrant hypermethylation occurring in the promoter regions
of tumour suppressor genes has been reported to play a significant role in several cellular
mechanisms disrupted or silenced at different stages of cancer progression [13, 17, 18].
Aberrancies during cellular events including phases of cell cycle, cellular apoptosis (process
of programmed cell death), cell differentiation and DNA repair mechanisms are considered
as some of the main causes of inappropriate transcriptional silencing of the genes. These
may result in loss of gene function directly linked to early stages of tumorigenesis in several
cancer cases such as breast, lung, prostate, colorectal, bladder, head and neck, cervical,
ovarian, lymphoma, leukemia, hepatocellular, thyroid, liver and esophageal, correlating
with the malignant progression or tumour burden (referring to the size of the tumour or the
number of cancer cells), as well as to the recurrence of cancer or they may affect whether
or not certain drugs are effective on an individual patient [1, 14, 17, 19].
Therefore, the need for detection of DNA methylation in tumour suppressor genes as-
sociated with the initiation of neoplasias2 in certain organs appears to be of significant
importance for screening and monitoring of cancer at an early stage of tumour develop-
ment, when symptoms have not yet arisen for a diagnosis to be made. That is the time
when an intervention needs to be made and methylation-specific assays need to be devel-
oped to enable systems for early detection, giving a better guidance to a patient, allowing
early diagnosis and patient-centralised screening towards a personalised cancer therapy.
This chapter provides an overview of the rapidly advancing area of epigenetics focusing
on its significant involvement in cancer development. The role of one of the most researched
epigenetic events in tumourigenesis, DNA methylation, is further reviewed, followed by the
effect of aberrancies of DNA methylation in gene inactivation using examples of where
hypermethylated genes have been used as diagnostic markers in several types of cancer,
based on their DNA methylation profile changes during tumour progression. A brief analysis
on the methods and technologies used for DNA methylation detection is then presented,
including single-loci based and genome-wide approaches, with the chapter concluding with
the description of electrical analysis techniques and computational approaches, setting the
scene for semiconductor based methods developed later in this thesis.
2Neoplasia refers to a benign or malignant tumour composed of cells with an abnormal appearance or
an aberrant proliferation pattern [2].
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2.2 Epigenetics in cancer
Cancer is exponentially increasing in numbers, an observation that is not only correlated
with the genetic predisposition of the individual towards the disease but also with the
epi-genomic or epigenetic inheritance passed by our ancestors in combination with our
environmental influences. The term epigenetics was first conceived by Waddington in the
early 1940s, originally introducing the concept of the “epigenetic landscape” to describe the
studies of “the interactions of genes with their environment that bring the phenotype into
being” [20, 21], with a further meaning of a “causal analysis of development”, translated
as to how the developmental decisions are made while the genetic information is converted
into phenotypic traits [22, 23]. The definition of epigenetics ever since its introduction has
however experienced a transient evolution, with a variety of biological events having been
classified of epigenetic origin when no changes to DNA sequences are involved [9, 24].
Epigenetic phenomena have been historically linked to mechanisms that initiate and
regulate heritable patterns of gene function, bridging the gap between the genotype and the
phenotype, playing a critical role in maintaining the normality in events related to the de-
velopment of organisms. They also contribute in establishing the regulation of cell processes
while keeping cellular differentiation well-controlled, enabling the cells to carry the same
genetic information but express a different phenotypic behaviour [9, 25, 26]. An example of
this feature may explain why twins with identical genotypes can be phenotypically different
given the distinct environmental stimulus that may have grown under [26].
While epigenetic mechanisms occur at a higher frequency than genetic changes, they
have a direct effect on the way genes are expressed, allowing the formation of suitable
gene expression patterns without affecting the primary nucleotide sequences as mutations
do. Aberrancies in epigenetic mechanisms can result in inappropriate activation of key
regulatory genes leading to their abnormal expression or to genetic silencing by inhibiting
signal pathways [5, 6, 8, 24]. Screening studies have revealed that most of the critical
processes found in cancer cells, such as silencing of tumour suppressor genes, activation
of oncogenes, aberrant cell cycle processes, defects in DNA repair and dysregulation of
cell death can be triggered directly or indirectly by epigenetic aberrancies. These series
of events can be detrimental for the homeostasis of the cellular regulatory mechanisms,
forming a driving force in the initiation and progression of tumourigenesis [8, 26, 27].
Epigenetic mechanisms comprise three main categories: DNA methylation, histone mod-
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ifications and RNA-mediated gene silencing [28]. The two major epigenetic modifications
are those occurring at a DNA level (DNA methylation) and at a chromatin level (chromatin
remodelling), both of which are considered to be associated with silencing of critical tumour
suppressor genes and activation of oncogenes involved in cancer development. DNA methy-
lation in particular, is a widespread epigenetic modification that plays a critical role in the
regulation of gene expression and thus the genomic stability during development, differenti-
ation but also diseases such as multiple sclerosis, diabetes, schizophrenia and multiple types
of cancer [23].
The disruption of normal methylation patterns resulting in genomic instability and chro-
mosomal aberrations has been recognised as one of the most common molecular alterations
in human neoplasia, with advances in the processes taking part to have brought great aware-
ness to the role of epigenetics as an alternative or complementary mechanism to mutational
events in oncogenesis [29, 30]. Therefore, the fact that epigenetic events are increasingly
recognised for their contribution to oncogenesis, either by occurring in the early stages of
tumour progression or by actually being the initiating events, opens up an exciting new
avenue of research with potential impact in cancer prevention, early detection and treat-
ment through the development of accurate and sensitive methods to detect changes in DNA
methylation patterns [14, 31].
2.3 DNA methylation
DNA methylation is a key epigenetic factor, one of the earliest studied epigenetic modifi-
cations in eukaryotes, the disruption of which has been proposed as one of the causes of
inactivation of a variety of genes, studied in various cancer types [13]. It has been charac-
terised as a stably inherited chemical modification, playing a critical role in the mechanisms
behind genetic functions and gene expression [13]. Disruptions in key areas responsible for
gene regulation such as the gene promoter regions, which are responsible for their normal
expression, may lead in their inhibition by turning those genes from “on” to “off”, as can
be seen in Fig. 2.2. These certain disruptions that are the consequence of aberrancies in
the methylation levels of such areas may significantly influence the mechanisms behind the
initiation as well as the progression or recurrence of cancer or they may affect whether or
not certain drugs are effective as parts of a therapy scheme on an individual patient [14, 32].
DNA methylation or more specifically cytosine methylation is a complex enzyme-driven
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Figure 2.2: DNA methylation disruptions in promoter gene regions in the cases of a normal
cell (top) and a cancer cell (bottom). A CpG island of a promoter region of a tumour
suppressor gene in a normal cell and a cancer cell is represented, with hypermethylation or
aberrant DNA methylation patterns to change the molecular environment of the cell leading
to gene silencing. Figure adapted from [6].
chemical modification occurring almost exclusively at the cytosine DNA base, including the
addition of a methyl group (CH3) to the carbon 5-position of the cytosine ring, as shown in
Fig. 2.3. This is performed by enzymes called DNA methyltransferases (DNMTs) [33],
which are responsible for the maintenance of DNA methylation during DNA replication,
the activity of which increases progressively during the initiation of cancer and also along
with the advancement of the tumour stage of different kinds of cancers [34].
DNA methylation takes place in areas when a guanine base follows a cytosine in clusters
of CG dinucleotides (CpGs), regions well-known as CpG islands3 [35–37] which are found
most often in gene promoters, areas responsible for controlling the expression of a gene. The
presence of methylation in these areas may lead to hypermethylated genetic traits of a gene
promoter, a well-known feature of many tumour suppressor genes that remain silenced dur-
ing cancer development [28]. Also, DNA hypermethylation (aberrant methylation reaching
higher than normal levels) which occurs mostly in CpG islands, is present at higher per-
centages in tumours than genetic mutations do, resulting in higher sensitivity of detection
3CpG islands were originally identified as short regions of CpG-rich DNA, referred to, in 1985 by Bird
et al., as “HTF islands” which contained sites that could generate the action of the methylation-sensitive
restriction enzyme HpaII. They are known as areas of GC-rich dinucleotides, associated with gene silencing
and in general with the ability to provide a way towards the challenge of mapping methylation throughout
the genome [35].
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strategies when used as a biomarker for early screening of cancer [38, 39].
CpG islands are not equally distributed in the human genome, occurring in frequency
of 1 in 80 dinucleotides in half of the human gene promoter regions (length of 500 base
pairs to several thousand base pairs). Latest criteria on the definition of a CpG island
given by [28, 40] proposed that a genomic region of ≥ 500 base pairs with a G+C content
≥ 55% and an observed/expected CpG ratio ≥ 0.65 could estimate the existence of a
CpG island. It has been estimated that around 60% to 90% of CpG sequences in GC-
rich regions are methylated in mammalian genomes. In normal cells the majority of CpG
regions are unmethylated before the onset of cancer, so the associated genes in the promoter
regions located in the CpG islands can be expressed normally [40]. However, in cancer
cells, abnormal DNA methylation patterns occurring in one or several CpG islands of the
gene promoter can cause loss of gene expression leading to the suppression of the gene’s
transcription resulting in gene silencing [8, 17] with some of the genes been hypermethylated
in over 90% of cancer cases. Although the most significant proportion of CpG islands is
located in the 5’ region, occupying around 60% of the human gene promoters [41] (for a
gene’s orientation defined as 5’ to 3’), certain CpG islands can occasionally be found within
the body or at the 3’ end of a gene. CpG islands in these locations are more prone to
methylation occurence, contributing in the disruption of the regulatory mechanisms of gene
expression.
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2.3.1 Gene methylation in cancer
Abnormal DNA methylation at specific transcription sites can result in epigenetic silencing
of genes that protect against tumour formation or that repair DNA, with the disruption
of both to play an important role in tumour initiation [12, 28, 29]. As compared with
normal cells, malignant cells show major disruptions in their DNA methylation patterns,
with global levels of DNA methylation becoming hypomethylated4 in conjunction with DNA
hypermethylation of gene promoters of the CpG islands and increased rate of mutations at
methylated CpG dinucleotides, both ways through which DNA methylation can contribute
to cancer due to the blocked expression of a gene that would otherwise be expressed [1, 16,
17, 30].
DNA hypomethylation is a significant alteration observed in cancer with 20% to 60%
loss of overall methylation being present [23]. Genomic hypomethylation usually involves
repeated DNA sequences and has been hypothesised to contribute to cancer progression
being responsible for the overexpression of proto-oncogenes, the protein products of which
are involved in cancer cell proliferation, invasion and metastasis, leading to elevated mu-
tation rates by destabilising the genome through the promotion of chromosomal instabil-
ity [29, 30, 42]. Given the significance that DNA hypomethylation may have as an epigenetic
alteration, the exact reasons of its origin at a genome-wide level still remain unclear, with its
diagnostic use to be limited given the nature of the detectable signal, since the loss of DNA
methylation is to be detected rather than the gain (i.e. DNA hypermethylation) [39]. On
the other hand, regional hypermethylation of CpG islands within or around the promoter
region of tumour suppressor genes has been the most extensively studied area of research
of DNA methylation in cancer and has been characterised as a well-recognised epigenetic
change that occurs in virtually every type of human neoplasia, participating not only in
precancerous stages but also in the malignant progression, having prognostic impact on
patients with cancer [17, 30, 34, 42].
In the past years there has been a substantial growth of the number of genes known
to undergo CpG promoter hypermethylation in cancer, affecting different molecular path-
ways and cellular processes, including cell-cycle regulation (CDKN2A/p16-INK4 (p16),
CDKN2B/p15-INK4B, CCND2, RB1), DNA repair (MGMT , BRCA1, MLH1), apop-
tosis (DAPK1, TMS1, TP73), metastasis (CDH1, CDH13, PCDH10), detoxification
4DNA hypomethylation: A decreased level of DNA methylation in a DNA sample (CpG site or group
of CpG sites) relative to a reference DNA sample of a normal tissue [14].
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(GSTP1), hormonal regulation (ESR1, ESR2), Ras signalling5 (RASSF1A) and Wnt
signalling6 (APC, DKK1) [17, 38, 42]. The profiles of hypermethylated tumour suppressor
genes, which are specific to cancer types [38], create a unique “hypermethylome” per tumour
type, as has been proposed by Esteller [1]. According to the cancer methylation database
PubMeth [43], the most often reported cancer types associated with DNA hypermethylation
are lung, breast, colorectal, prostate, head and neck, gastric, leukemia, lymphoma and liver,
the occurrence of which indicating that the frequency of disruption in DNA methylation
patterns is potentially present in the majority of cancer types as well [42, 43]. Table 2.1
summarises the most frequently reported genes that are silenced by DNA methylation.
DNA hypermethylation of some genes, such as CDKN2A/p16-INK4, RASSF1A and
MGMT , may be frequently observed in multiple cancer types allowing the detection of a
subset of them, while it may be limited to a particular cancer type. GSTP1 gene can be
used as an example, since it has been found hypermethylated in more than 90% of prostate
cancers but is largely unmethylated in acute myeloid leukemia [17, 44].
DNA methylation of several genes (i.e. CDKN2A/p16-INK4, DAPK1, RASSF1A,
MGMT , APC) has been detected most commonly in serum or plasma of blood samples
using minimally invasive methods and also in sputum as well as in samples derived from
the corresponding primary tumours (i.e. biopsy). The first studies to show that DNA
methylation changes could be detected in serum DNA of cancer patients were reported
by Esteller et al. [45] in NSCLC (Non-Small Cell Lung Cancer) patients and by Wong et
al. [46] demonstrating p16 methylation in plasma and serum of liver cancer patients. What
is more, a considerable number of studies has evaluated the potential of circulating tumour
DNA methylation in serum and plasma for the molecular diagnosis and early detection of a
variety of cancer types [11, 45–50], showing that tumour-specific DNA methylation patterns
can be detected in tumour-derived free circulating DNA from the bloodstream of cancer
patients coming from DNA derived from the primary tumour source of the patient.
Table 2.2 summarises some highly methylated genes investigated in blood circulation
for cancer types such as breast, lung, prostate, colorectal and liver cancer. Even more
interestingly, it has been found that the mean concentration of DNA in plasma samples
from control subjects has been estimated to be around 10 to 18 times less than that from
5Ras signalling: Signalling system that is controlled by Ras proteins, regulators of several aspects of
normal cell growth and malignant transformation [2].
6Wnt signalling: Independent signalling system that can be regulated by proteins involved in the Wnt
pathway, associated with cellular metabolism processes [2].
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Table 2.2: Detection of cancer in circulation using DNA methylation as a biomarker
Tumour Type Gene Serum/ Methylation (%) Ref.
Plasma
Breast cancer RASSF1A S/P 75% [51]
Non-small cell p16, DAPK1 S/P 73% [45]
lung cancer (NSCLC) MGMT , GSTP1 S/P 73% [45]
Prostate cancer GSTP1 S/P 72% [52]
Colorectal cancer CDKN2A/p16-INK4 S 71% [53]
Liver cancer CDKN2B/p15-INK4B S/P 81% [54]
patients within different cancer type groups [47]. Different methods of analysis have been
used by several research groups, as referenced, through the collection and analysis of plasma
or serum samples, showing that the methylation profile of cancer cells detected in the blood
of cancer patients, while avoiding invasive methods of sample acquisition such as biopsies,
offers a very promising application for a Point-of-Care approach towards the early detection
of cancer [48].
Examples of one of the most frequently studied cancer types, lung cancer, have given
significant insight in the methylation levels of tumour suppressor genes as being at a con-
siderably higher degree of alteration in DNA methylation patterns of the cancerous cases
compared to healthy subjects. Of the various genes studied, the commonly hypermethy-
lated ones, as reported in Table 2.2, included: CDKN2A/p16-INK4 (the most frequently
methylated gene among the majority of the genes studied in various cancer types [13]),
DAPK1 and RASSF1A, with a prognostic significance by associating their methylation
status dependent on the stage of cancer progression, with overall survival rates of patients
compared to non-cancerous samples [55–59]. Combination of the DNA hypermethylation
profile of more than one genes in most of the cases resulted in higher sensitivity and speci-
ficity of detection reducing the number of false positives.
Although in many studies the frequency of DNA methylation in serum or plasma samples
has been reported to be lower compared to the same observation in primary tumours,
the levels of methylation were significantly higher in cancerous samples opposed to non-
cancerous ones, reinforced by the fact that most often if DNA methylation is detected in
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serum or plasma then the primary tumour will also be positive for the same alteration [60,
61]. Exceptions to this have been reported in small number of cases [47]. Additionally to the
diagnostic potential that DNA methylation profiling could give for lung cancer detection, it
could provide information on disease prognosis, whereby a panel of hypermethylation genes
(CDKN2A/p16-INK4, RASSF1A, APC, CDH13) could predict the early recurrence of
cancer as reported by Brock et al. [62]. One example of combinatorial schemes of DNA
hypermethylated biomarkers used to detect prostate and lung cancer reported by [62, 63]
showed high sensitivities of detection of cancer cells in the case of prostate cancer and good
accuracy in prediction of tumour progression in the case of lung cancer.
Similarly, in breast cancer, DNA methylation has been proposed as one of the causes
of inactivation of a variety of genes which have been hypermethylated, the most highly
methylated of which were CDKN2A/p16-INK4, associated with increased susceptibility
to breast cancer [64], RASSF1A, a tumour-specific biomarker frequently found as hyper-
methylated in relevant studies [51, 65, 66] which in combination with GSTP1, APC and
DAPK1, as the results shown in Table 2.2 confirm, detected primarily in blood [67, 68],
may enhance the sensitivity of early detection of breast cancer, given its presence in all
grades and stages. DNA methylation profiling could also provide important information on
disease metastasis, with examples reported by Muller et al. [69] and Graff et al. [70], showing
a strong connection between hypermethylation of RASSF1A, BRCA1 and E − cadherin
genes, with disease prognosis being closely related to metastatic behaviour.
In several other cancer cases, the DNA hypermethylation status of genes under investi-
gation was determined, together with its clinical significance as they may be used to indicate
the disease progression. In addition to this, the level of DNA methylation of tumour sup-
pressor genes identified in plasma/serum was reported to increase during the late stages of
tumour development compared to early stages of diagnosis, an observation also made for
cases of recurrence of the disease after curative surgery or chemotherapy applied [71–74].
The frequency of methylation events also varied, depending on the patient (genetic profile,
age, medical history) and the cancer type, highlighting the great potential of using DNA
hypermethylation as a biomarker for the personalised evaluation of early detection of can-
cer, diagnosis as well as for prognosis, recurrence and response to treatment [1, 62]. It is
therefore apparent that there is a need for accurate methods for DNA methylation detection
that could provide multiple information on the status of DNA hypermethylation of several
genes related to cancer cases under investigation, while managing the variation in DNA
methylation in between the individual subjects. The methods used for DNA methylation
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detection, together with the challenges which exist, given the demand for high-throughput
approaches in epigenetic screening, are to be presented in the following section.
2.4 Methods for DNA methylation detection
Over the past few decades, the number of studies on the role of DNA methylation in cancer
development has grown dramatically with several DNA methylation assays developed for the
examination and analysis of gene-specific or genome-wide levels of DNA methylation. Much
effort has been put into the development of early-detection strategies. DNA methylation
changes have been reported to occur early in carcinogenesis and therefore are potentially
good early indicators of the status of the existing disease, or they may even contribute to the
risk assessment of the future development of the disease. For many types of malignancies,
symptoms often do not arise until after the primary tumour has metastasised, contributing
to high mortality rates. Therefore, the development of cancer biomarker assays and the
evaluation of potential markers using standardised techniques, testing their limit of detection
as well as their specificity and sensitivity, would be of great need for early detection strategies
used for screening and thus improving the clinical evaluation and outcome.
The samples used for analysis of DNA methylation biomarkers usually contain high
concentrations of background DNA from the tumour. However, tumour-derived DNA is
difficult to be detected because it is often present in very low concentrations and can be
contaminated substantially with the DNA from the healthy cells. Moreover, DNA methy-
lation is not evenly distributed across the genome. Thus, methods with sensitive detection
capabilities are often needed to identify aberrantly methylated tumour-derived DNA in
body fluids [6, 75]. As has been summarised by [31, 39, 42, 76], the combination of different
types of pre-treatment of sample DNA, followed by different analytical steps, has resulted
in a plethora of techniques available for determining DNA methylation patterns and profiles
at a genome-wide level.
The main principles for DNA methylation analysis, as shown in Fig. 2.4, are based on
three main approaches followed:
• Restriction enzyme digestion: methylated DNA is digested by methylation-sensitive
restriction enzymes.
• Affinity enrichment: methylated DNA is enriched with methylation-specific binding
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proteins or antibodies.
• Sodium bisulfite treatment: DNA is treated with sodium bisulfite, also regarded
as the gold standard for DNA methylation detection.
Treatment with one of these methods allows for further processing of the samples using
powerful techniques, such as high density DNA methylation microarray analysis [77–79],
which has shown great promise on DNA methylation pattern profiling or bisulfite sequenc-
ing, resulting in a single base pair resolution of detection [80, 81]. Also, other approaches
based on optical or electrical methods of detection have been reported as potential ways for
DNA methylation analysis. The principles of the most-widely applied methods for DNA
methylation analysis together with their merits and trade-offs are further discussed in the
following sections.
2.4.1 Restriction enzyme based methods
Restriction enzyme based methods use sequence-specific restriction enzymes with the abil-
ity to “digest” only genetic areas where DNA methylation is present, with HpaII and
SmaI to be the most widely used methylation-sensitive restriction enzymes [31]. DNA
methylation analysis was first conducted by methylation-sensitive restriction enzymes using
Southern blot analysis for visualisation of methylated sites as reported by [82]. Southern
blot analysis was further replaced by methylation-specific polymerase chain reaction (PCR)
based methods i.e. Methylation-Specific Multiplex Ligation dependent Amplification (MS-
MLPA) [83], providing high-throughput (number of samples that can be analysed per run)
of the average ratio of methylated over unmethylated sites.
Several approaches have been developed ever since the first application of methylation-
sensitive restriction based analysis, with the most popular being the Restriction Landmark
Genomic Scanning (RLGS) [84], reported as the first technique for DNA methylation anal-
ysis at a genome-wide scale, followed by array based Differential Methylation Hybridisation
(DMH) [85], which combines array based analysis with restriction digestion, offering a new
approach on differential methylation hybridisation. Moreover, adaptations on DMH and
the array design introduced the method of Comprehensive High-throughput Arrays for Rel-
ative Methylation (CHARM) [86], providing high-density array readouts for genome wide
methylation, allowing methylation discrimination at a CpG locus level. Also the method
of HpaII tiny fragment Enrichment by Ligation-mediated PCR (HELP) [87] was further
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Figure 2.4: Principles for DNA methylation analysis and detection. Figure obtained and
adapted from [42].
proposed, fundamentally based on PCR amplification of restriction fragments followed by
array hybridisation, providing information on the distribution of cytosine methylation in
the genomic regions [42]. What is more, advances in sequencing approaches have brought
further adaptations on the restriction enzyme methods, developing restriction based assays
capable for providing sequence-specific analysis, allowing allele-specific DNA methylation
analysis, an example of which is the integration of the HELP assay with next-generation
sequencing analysis [88].
Although restriction enzyme based methods are highly reliable for analysis of large
amounts of methylated sites, however the use of restriction enzymes can be a limiting factor
especially when global methylation analysis is required, given that restriction enzymes are
dependent on given restriction sites, therefore being unable for large CpG regions coverage
for DNA methylation analysis. Restriction digestion is also prone to generate false positives
in the case of insufficient enzyme cleavage, also lacking to provide methylation information
at a sequence-specific level. Also the requirements for large amounts of DNA for digestions
can be quite challenging especially when the amount of DNA recovered from remote media
is generally low in copy numbers [31, 42].
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2.4.2 Affinity based methods
Chromatin immunoprecipitation (ChIP ) based or affinity enrichment methods are pro-
tein based, useful for the identification of methylated regions in tumours through the inter-
action between methyl-binding proteins or antibodies specific to methylated cytosines [31].
MeDIP (Methyl-DNA immunoprecipitation) [89] is an affinity based approach whereby
methylation analysis is achieved by methylated DNA immunoprecipitation, where anti-
bodies specific to methylated cytosines are used to capture methylated sites, followed by
hybridisation using genomic microarrays, allowing for identification of methylated CpG loci.
MeDIP, coupled with sequencing analysis on the results, introduced MeDIP-seq [90, 91],
bringing the advantage of genome-wide sequence-specific analysis of methylated CpG sites
[39], even quantitatively in the case of Methylation-sensitive Restriction Enzyme sequenc-
ing (MRE-seq) [92], allowing for fast genome-wide analysis while providing sequence-specific
information on a CpG or sequence level [31, 81].
Although the combination of sequencing in the affinity based methods brings certain
advantages compared to the array based approaches, the use of proteins or antibodies to
attach to defined methylated sites adds certain limitations given that they cannot provide
a single-base pair resolution regarding the methylation targets and are difficult to be stan-
dardised. Also the levels of complexity of the method increases considerably when extra
amplification steps are required after the antibodies attachment [81].
2.4.3 Sodium bisulfite based methods
Sodium bisulfite based methods are based on the use of bisulfite conversion to distinguish
methylated from unmethylated cytosines, being considered as a gold-standard approach for
DNA methylation detection. Bisulfite conversion was first introduced by [93], opening a
new era for gene based DNA methylation analysis, allowing methylated DNA to be bisulfite-
treated and then amplified and detected in conjunction with PCR based approaches and
sequencing [94], methods of choice when detection at a single base pair resolution is desired,
allowing methylation information to be preserved after the DNA sample is amplified [75],
independent of the need for restriction enzymes, following a label-free approach [95]. Bisul-
fite treatment of the genomic DNA, derived from a collection of cells which may vary in
their DNA methylation patterns, is useful for mapping the normal and aberrant patterns
of methylation, leading to the conversion of unmethylated cytosines to uracils (U), which
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Figure 2.5: The principle behind bisulfite conversion: DNA strands are chemically treated
with sodium bisulfite so that unmethylated cytosines are converted to uracils whereas
methylated cytosines remain unaltered and preserved through chain extension. Through
bisulfite conversion, DNA is modified in a methylation-dependent way before amplification
of the selected loci starts and so DNA methylation information is not erased, letting specific
genetic regions be examined for their levels of methylation.
are amplified as thymines (T) by PCR amplification, leaving only the methylated cytosines
unaltered, as can be seen in Fig. 2.5, therefore transforming the epigenetic information into
a genetic difference, enabling the use of DNA methylation detection techniques to be fur-
ther applied for analysis of read-outs [14, 42]. The requirements for large-scale sequencing,
based on the original bisulfite sequencing technique by [93], can be a computational map-
ping challenge, with millions of bisulfite reads to be processed and compared to a reference
genome in conjunction with the need for control tests and multiplexing.
Various approaches using bisulfite conversion have been further developed, given the ad-
vantage of the method to be applied on a large DNA spectrum of different origin and varying
amount [96]. One broadly used approach for DNA methylation analysis is Methylation-
Specific PCR (MSP), introduced by Herman et al. [97] as a qualitative method, with the
ability to study DNA methylation at a single CpG locus level. MSP combines the modifi-
cation of DNA using sodium bisulfite followed by a subsequent amplification using primers
that are specific to the methylated genomic region of interest versus the equivalent un-
methylated one. MSP allows fast and sensitive detection of the methylation status of a
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DNA target during the course of methylation-specific PCR amplification without requiring
subsequent analysis of the final products, been considered as a widely applied prognos-
tic tool in the clinic. It is known for its high analytical sensitivity, which can provide a
complete overview of a base-pair resolution of the CpG methylation levels with the ability
for further integration with next-generation sequencing technologies for deeper methylation
data analysis [39, 80]. MSP’s efficacy can however be influenced by the primer design of
the methylation-sensitive areas and the number of PCR cycles. Thus, there is a risk of false
positive results arising as a result of incomplete DNA bisulfite conversion, which is claimed
to be one of the most significant problems when using the methylation technology in early
screening of cancer [6, 75]. Nevertheless, the applicability of the method and the advantage
of high specificity that it provides establishes it as one of the highly preferred techniques
for DNA methylation analysis.
The method of Combined Bisulfite Recognition Analysis (COBRA) was further intro-
duced as a method by Xiong et al. [98], with the ability to differentiate methylated from
unmethylated sequences with the aid of restriction digestion of DNA products combined
with bisulfite conversion and amplification of methylated sequences of a single CpG site,
adding an internal control of the digested products through the use of bisulfite conver-
sion, limited however by the dependence on the restriction enzymes. The technique of
Methylation-Sensitive Single Nucleotide Primer Extension (MS-SNuPE) also followed [99],
as a quantitative method for assessing the differences in DNA methylation of specific CpG
sites based on bisulfite treatment of DNA and a two-steps amplification of the bisulfite
treated sample, resulting in quantifying the level of DNA methylation in the initial DNA
sample, requiring however well-aligned sets of primers for every step of amplification, adding
up in complexity of the process as well as in the consistency of the results. Moreover, quan-
titative PCR based methods on gene-specific analysis such as MethyLight [100], which
combines treatment of small amounts of DNA with sodium bisulfite and DNA amplifica-
tion using fluorescent based real-time PCR, generating real-time quantitative data on CpG
sites of interest or pyrosequencing for DNA methylation analysis [101], which provides a
sequential information on the amount of methylation of multiple CpG loci by substituting
the restriction analysis that COBRA is using with the quantitative pyrosequencing reac-
tion [102], have contributed in enabling a quantitative in addition to qualitative analysis
of DNA methylation levels, with the step of bisulfite sequencing to add an extra step of
confirmation of the DNA methylation analysis result.
In addition to the previous methods analysed, the genome-wide profile of DNA methyla-
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tion sites can be determined using CpG-specific array based technologies, which can access
the methylation status of a large number of genes of the entire genome. These can be
applied in conjunction with bisulfite based analysis methods, allowing for in parallel pro-
filing of multiple DNA methylation patterns at a lower cost compared to sequencing based
approaches. The GoldenGate BeadArray technology by Illumina is one of the examples of
DNA methylation arrays used for multiplexed methylation detection of samples after bisul-
fite treatment and amplification steps are completed, with the products being hybridised
to bead arrays containing 30 beads per CpG site, while utilising DNA probes unique for
the methylated or unmethylated CpG state [103], adaptations which led to the develop-
ment of the Infinium platform (Illumina) [104] with the latest DNA methylation array,
HumanMethylation 450 BeadChip assay (Illumina), been developed for genome-wide DNA
methylation analysis of 450,000 CpGs allowing high resolution analysis [77]. Although DNA
hybridisation arrays may offer reduced DNA input requirements, simpler sample prepara-
tion protocols and data processing compared to sequencing techniques as well as access to
discrete CpG sites and high-throughput sample recovery [104], however possible limitations
related to DNA hybridisation specificity and probe selection specific to the DNA target still
need to be considered.
Nonetheless, next-generation sequencing technologies have shown great promise in pro-
viding more cost-effective approaches of genome-wide analysis, therefore the potential of
parallelising sequencing and array technologies for targeting and screening DNA methy-
lation sites respectively could reduce the trade-offs of both methods while enhancing the
information gathered by the under investigation targets. Table 2.3 provides an overview
of the commonly used DNA methylation detection assays with advantages and limitations
reported for each method.
2.5 DNA methylation ratio in DNA methylation computa-
tional analysis
DNA methylation has also offered a fertile ground for statistical analysis of methylated
regions at a both locus-specific and genome-wide level. Computational tools for high-
throughput epigenetic analysis have experienced a rapid progress, especially given the
current initiatives for mapping of the human epigenome. Reference data sets and global
epigenome maps are now being developed such as the Blueprint by the International Hu-
man Epigenome Consortium (IHEC) [105] and the US National Institutes of Health (NIH)
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Roadmap Epigenomics Mapping Consortium [106], with the ultimate goal to decode the epi-
genetic signature of the human epigenome and to provide accessible resources of epigenetic
maps and profiles of stem cells and somatic tissue types for a better understanding of their
function and the correlation of epigenetic aberrancies with certain disease profiles. This
may expose the effect of DNA methylation to certain CpG sites or promoter regions which
may lead to the suppression of gene activity, an event related to early cancer development.
It is therefore apparent that there is a great demand for high-throughput screening
approaches and high-resolution techniques for deep and in parallel analysis of DNA methy-
lation patterns. Given the use of large scale microarrays and sequencing based methods for
detection and analysis of DNA methylation of several CpG regions in parallel, the need for
techniques to assess the signals derived from DNA methylation measurements as results of
deep DNA methylation analysis of one or more genetic locations is highly important, given
the requirements for a single base pair resolution of the methylation sequential information.
The development of bioinformatic tools and analytical software to satisfy this need is under
rapid development. For most platforms, DNA methylation measurements represent abso-
lute values for a given sample, with the resulting measurements to be expressed in the form
of a ratio fraction, a marker that has been used to assess the percentage of methylation [31].
The ratio is used as a way to express the signal derived from methylated sites against the
sum of the signals from methylated and unmethylated sites as:
%Meth =
M
M + U
× 100% (2.1)
The resulting measurement is fitted on a scale from 0 to 1 or from 0 to 100%, with 0
indicating that no methylated cytosines were identified in the genetic location (CpG locus)
under investigation and 1 or 100% indicating that all cytosines identified were methylated
[31]. This is also mentioned as a β distribution. Examples of the use of the ratio of the
methylated signal intensity have been reported by Bibikova et al. [103] and Hu et al. [107] to
signify the percentage of methylation generated by a high-throughput array analysis of DNA
methylation patterns while distinguishing normal cells from cancer cells and to measure the
methylation percentage level in a sample using the method of Surface-Enhanced Raman
spectroscopy (SERS) respectively.
Moreover, the DNA methylation ratio has been used as a biomarker for prenatal diag-
nosis of genetic abnormalities. Research conducted by Papageorgiou et al. [108] proposed
the use of the ratio of methylation to investigate the DNA methylation pattern of differ-
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entially methylated regions on chromosome 21, abnormalities in which can be related to
genetic disorders such as the Down’s syndrome. The DNA methylation ratio was used as a
biomarker for detection of abnormal genetic traits of the fetus allowing for quantification of
the amount of fetal DNA in free fetal maternal circulating DNA. The ratio was calculated
based on the differences of the methylated regions of chromosome 21 between the mother
and the fetus through the use of the methods MeDIP and quantitative PCR.
In addition to the use of the DNA methylation ratio for DNA methylation analysis of
signals derived from given DNA samples, the use of log(M/U) to quantify DNA methylation
using the ratio of methylated and unmethylated molecules of a given CpG region has also
gained acceptance, especially when used in conjunction with microarray based methylation
analysis methods [86, 109]. The use of log(M/U) may create however constraints given
that M and U are not entirely inversely correlated within CpG regions. Also the use of
M/U may create distortions in the processing analysis when multiple CpG regions are to
be processed, given its ability to assess only independent CpG loci [31]. In this thesis, we
will show how to use integrated circuits to perform computation of the ratio in real-time
using semiconductor based pH sensors.
2.5.1 Other approaches for DNA methylation detection
Additionally to the well-established methods for DNA methylation detection that have been
described above, further attempts have been made on performing DNA methylation analysis
using other detection techniques both optical and electrical, labelled and label-free, with
variable sensitivities and detection limits.
Several label-free optical biosensors for DNA methylation detection have been developed
promising a label-free approach for amplification and analysis of methylated sequences. Pre-
viously reported work by Suter et al. [110] proposed the use of Opto-Fluidic Ring Resonators
(OFRR) for quantitative DNA methylation analysis, combined with the use of methyl-
binding proteins or antibodies to capture methylated sequences in real-time. Although the
proposed method performed a good discrimination between methylation changes in DNA
samples, the method depends on the limitations that affinity based methods are challenged
by as has been mentioned in Section 2.4.2. Also the fact that methyl-binding proteins show
higher specificity to double-stranded DNA opposed to antibodies which tend to bind more
effectively to single-stranded DNA, makes the standardisation of the method a necessary
requirement. Following on from this, Shin et al. [111] proposed the use of arrays of label-
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free silicon microring resonators to detect and quantify DNA methylation in bladder cancer
biomarkers while avoiding the use of methyl-binding proteins. DNA methylation probes
were immobilised on the microrings and methylated or unmethylated genetic targets hy-
bridised to the probes only when complementary matching was to be achieved. The signal
derived from hybridisation was detected as a wavelength shift of the resonators which was
varying based on the gene methylation density. However, the specificity of both [110, 111]
can be highly dependent on the length of the DNA probe therefore affecting the wavelength
shift and thus the signal of detection. Additionally, possible mismatches during hybridisa-
tion may be difficult to be detected with a direct effect to the methods detection sensitivity.
Moreover, Feng et al. [55] suggested the use of a label-free system for optical analysis of
the methylation status of specific CpG sites, offering a fluorescence based detection while
avoiding the use of dye-labeled DNA probes.
In addition to the previously mentioned methods and the use of optical approaches
and/or magnetic beads [116] or the use of nanoparticles [117] in DNA methylation based
methods of detection, which may increase the levels of complexity when the need for large
scale technologies stays paramount, new detection techniques have been proposed, offering
electrical discrimination of methylated from unmethylated molecules, fewer false positives
and good accuracy of detection. Zhang et al. [112] reported the use of an arrayed droplet-
in-oil microfluidic platform deposited on a silicon substrate, combined with Methylation-
Specific PCR (MSP) for methylation-specific DNA amplification and detection, allowing
infusion of minute amounts of DNA sample for array based DNA methylation analysis.
The proposed method performs high-density methylation-specific amplification reactions in
parallel, using micro MSP assays which benefit from the use of microfluidic open chambers
hosting the reaction mixtures after a series of injections, arranged in a circular array set-up,
with the detection results to be analysed using fluorescent dyes.
Moreover, Maki et al. [113] first presented the use of nanowire field effect transistor based
biosensor technology for label-free electrical DNA methylation detection on-chip, avoiding
the use of bisulfite treatment of a DNA sample or of any extra step of DNA amplification.
Magnetic beads are used to capture the methylated DNA targets which are then released
and introduced on the sensing surface of the nanowire based transistor. Changes in the
inherent negative DNA charge due to the captured DNA targets, already recognised by
monoclonal antibodies immobilised on the sensing surface, induce a change in the electrical
properties of the nanowire based transistor, generating an electronic signal as a result of
DNA methylation detection. The method reported good sensitivity of detection and no false
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positives. However, the use of antibodies as well as of tags for detecting targeted sequences
increases the complexity of the method with a secondary limitation of the post-processing
steps added during nanowire fabrication which may affect dramatically the behaviour of
the nanopore as well as the signal to noise ratio, together with the incompatibility of such
patterns with large scale integration using CMOS.
Finally, synthetic solid-state nanopores have also been proposed by Misraidov et al. [114]
to test the electromechanical properties of methylated DNA due to the interruption these
molecules may create to the ionic flow through the pore. The methylation level of DNA
molecules was correlated to changes in the threshold voltage of the nanopore observed dur-
ing the permeation of methylated DNA through the pore. Only one DNA molecule could
permeate each pore at a time due to the small size of the nanopore, forced by the use of
an electric field strong enough to avoid any pore blockage during permeation. The perme-
ability of the pore was expressed with respect to the voltage applied across its membrane
with the efficiency of detection of methylated molecules to be claimed as comparable as to
the one of methyl-binding proteins. One more example of using solid-state nanopores for
detection and quantification of DNA methylation was presented by Shin et al. [115], show-
ing the capability of electrical discrimination between methylated and unmethylated DNA
using methyl-binding proteins at a single methylated CpG site resolution. The number of
methylation sites was determined based on the number of methyl-binding proteins with the
thickness of the nanopore to be defined such that multiple bound proteins could contribute
to the current measured, increasing however the chance for non-specific products. Also,
the electronic signals generated for a given voltage set across the pore were dependent on
the reproducible structural stability of the nanopores. Variations in the shape of nanopores
may also contribute in the ionic noise induced in the detectable signal during the recordings
and thus in low yield per assay.
Hence, after reviewing the most frequently used methods for DNA methylation detection
together with possible limitations that they may be accompanied with, as seen in Table 2.4,
it becomes apparent that what is required to accommodate the needs for a sensitive and spe-
cific approach for such application is first, a technology that would overcome the limitations
of the current methods for DNA methylation detection and further enhance the applicabil-
ity through large scale integration. Such method should be easily accessible to blood based
biomarkers and should be capable of giving a clear sign on the status and aggressiveness
of cancer, avoiding the inherent complexity that such disease has by nature, by reducing
the amount of false positives/negatives. Thus, there is an urgent need for the development
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of DNA methylation detection assays using technologies capable to offer large scale inte-
gration and standardised procedures of fabrication, while meeting the current demands of
healthcare which are simplicity, portability, low cost, accuracy, rapid time to result and
intelligence. This will potentially remove the existing and justified scepticism around the
reliability and sensitivity of a lab based test for cancer screening or of a commonly applied
therapy scheme, which will pave the way for future technology in cancer management, act-
ing as a powerful tool towards the closed-loop detection and guided therapy of cancer. We
believe that there is great potential for this task to be realised using well-established CMOS
technology, due to its inherent capability for large scale integration of microelectronic based
sensing platforms.
2.6 Summary
Epigenetic modifications cause significant dysregulation on the transcriptional activity of
tumour suppressor genes or the pathways responsible for gene expression, being considered
as a central driving force in the molecular pathology of various cancer types, influencing the
stages of tumour initiation and progression through gene inactivation. DNA methylation,
in particular, has been one of the key epigenetic factors as well as an attractive biomarker
involved in human development but also in a number of diseases, especially cancer. The role
of DNA methylation in cancer development is well characterised by aberrancies in methy-
lation patterns of tumour suppressor genes, located in the CpG regions of the promoter
regions of genes, contributing in gene silencing, an event frequently seen and studied in
cancer.
The analysis of DNA methylation based biomarkers is a rapidly advancing area of re-
search, being actively studied in all stages of cancer progression in multiple cancer types,
with the possibility of the methylation profile of genes to distinguish tumour types and
perhaps the response to therapeutic regimes. Already, DNA methylation patterns in cancer
related genes have been identified in blood (i.e. plasma, serum) of cancer patients as well
as in body fluids, apart from tumour biopsies, letting DNA methylation be described as a
very promising biomarker for tumour detection and validation of tumour types as well as
for prediction of the risk of tumour recurrence. Therefore, the need for detection of DNA
methylation patterns appears to be of paramount importance, especially for early screening
of cancer when the disease may not have expressed its signs yet.
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Several well-established methods have been developed for DNA methylation detection
and analysis, providing information at a CpG locus or at a sequence level, with various
sensitivities, resolution and signal densities. Novel methods have also been developed based
on optical or electrical principles of detection, with varying complexities, post-processing
requirements, implementation challenges and cost needs. Nonetheless, the need for accurate
and well-targeted DNA methylation detection strategies is still existent with the require-
ments for large scale analysis of large numbers of samples to continuously increase. Hence,
there is an urgent need for the development of detection assays, using well-established tech-
nologies that would meet these demands, in addition to satisfying some of the current needs
of healthcare technology such as simplicity, portability, sensitivity, low cost, scalability,
rapid time to result and intelligence, ultimately leading to the realisation of a well-targeted
strategy towards cancer screening.
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3.1 Introduction
There has been a tremendous convergence in the last decade seeing CMOS based microtech-
nology play a crucial role in chemical sensing applications. This has been enabled using
solid-state sensors which can be implemented in planar form and fabricated using CMOS
technology, monolithically integrated on a single chip. This now provides opportunity for
chemical sensing platforms to leverage on semiconductor technology which may offer advan-
tages such as scalability, miniaturisation, batch fabrication and integration with intelligent
instrumentation.
This chapter begins with a brief review of the field of solid-state chemical sensing,
focusing on the electrochemical sensing technologies namely voltammetry, conductimetry
and potentiometry, with special mention given to the latter and especially to the Ion-
Sensitive Field-Effect Transistor (ISFET) which will be used for DNA methylation detection
in this thesis. The ISFET as a pH sensor is discussed, followed by some background theory
on its properties, the operational characteristics, the model used to describe its behaviour
and one of its key sensing properties, the sensitivity to pH. Some more information is given
on ISFETs fabricated in unmodified CMOS, emphasising on the advantages of pH sensing
using the native passivation layer used in the CMOS process, avoiding the need for extra
processing steps or for deposition of additional materials to define its sensing capability. Key
works using CMOS ISFETs for biomedical applications are also given, highlighting their
applicability in areas such as DNA detection. The chapter concludes with the principles
of weak inversion operation along with the model used for simulation of CMOS ISFETs in
such region and the device characteristics and non-idealities which exist.
3.2 Solid-state chemical sensing
Several solid-state chemical sensor technologies have been developed based on optical, mag-
netic, piezoelectric, mass-sensitive, thermal, coulometric and frequency based detection of
chemical species among which electrochemical biosensors have been the ones with the most
widespread utility [1, 2]. Electrochemical sensors are based on ion or electron transfer at an
interface created between a sample and a solid-state substrate due to a binding event at the
sensor’s surface, resulting in a direct transduction of the concentration of the sensed ana-
lyte in a detectable signal which is dependent on the type of measurement method chosen.
Also, the dependence of the magnitude of the signal on the equilibrium concentration of the
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analyte instead of the number of absorbing species, combined with additional advantages
such as the minimal complexity due to CMOS implementation, which avoids the need for
fluorescent labels and lenses that optical sensors require, make such sensors ideal for use in
applications that focus on real-time detection and portability [3]. Solid-state electrochem-
ical sensors can perform detection using well-known chemical sensing techniques such as
voltammetry, conductimetry and potentiometry, as have been reviewed by [1, 3] and will
now be discussed.
V oltammetry requires the presence of a three-electrode system consisting of a working,
a counter and a reference electrode to detect a species of interest by imposing a time-varying
potential to the reference electrode, measuring the current flowing through the working elec-
trode which is proportional to the concentration of the analyte to be detected. The method
of detection is called amperometry when the potential applied to the reference electrode is
fixed at an electrode/solution interface, whereby oxidation (the chemical species pass elec-
trons to the electrode) or reduction (the chemical species obtain electrons from the electrode)
is caused, leading to a potential gradient between the reference and the working electrode,
a result of a redox reaction [4, 5]. The concentration of the species is then defined by the
amount of measured current through the working electrode, while the counter electrode is
used to prevent current flow through the reference electrode. Voltammetric sensors may
exhibit lower limits of detection, they provide however more information on the detected
analytes given the time-varying potential being applied. Planar microelectrodes (silver,
platinum or gold) are examples that fall in the category of electrochemical detection using
either non-CMOS based microfabrication or post-CMOS processing [3]. Conductimetry is
based on measuring the conductance of a sample to determine the presence and thus the
concentration of charge carriers. Chemiresistors and chemicapacitors are conductimetric
sensors measuring the change of resistance or capacitance between electrodes selective to
specific species, thus determining their concentration [1, 6].
Finally, potentiometric sensors are based on measuring the potential between an Ion-
Selective Electrode (ISE) and a reference electrode, as can be seen in Fig. 3.1, caused by
a potential difference in solution as a result of a difference in ionic concentration between
the analyte and the reference solution, with a standard liquid junction silver/silver chloride
(Ag/AgCl) electrode to be normally used as a reference. Potentiometric sensors are based
on the measurement of the potential at an electrode under ionic equilibrium conditions,
when no current is flowing during a measurement in presence of a stable, reproducible and
reversible reference system also in contact with the solution [1]. The measured potential,
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Figure 3.1: Potentiometric measurement set-up using an ISE
Emen, developed between the sensing and the reference electrode, defined as the one devel-
oped due to primary ion activity1 on either sides of a selectively permeable membrane, is
governed by the Nernst-equation [1, 8] for a constant activity of the reference solution as:
Emem =
RT
niF
ln
αi,sample
αi,internal
(3.1)
where R is the universal gas constant, T is the absolute temperature in Kelvin, ni is
the charge of the measured primary ion, F is the Faraday constant, αi,sample is the activity
of the measured primary ion i in the sample solution and αi,internal is the activity of the
ion in the ISE’s internal solution. For a known activity of the ion i in the internal solution
(αi,internal), the measured potential can be expressed as:
Emem = constant+ 2.303
RT
niF
logαi,sample (3.2)
which gives a sensitivity of 59ni (mV) for a unit change in pH or a decade variation in ion
activity at T=298K. This derivation, extrapolated for a standard pH sensor, would result
1The activity of an ion in solution, αi, represents its chemical effectiveness that is governed by the
amount and type of other ions in solution. The activity is dependent on the ionic strength of the solution
that takes into account the interaction between ions as represented in the equation αi = γi ci where γi is
the activity coefficient and ci the ionic concentration [7].
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in 59mV change to be considered as the ideal sensitivity, in presence of a Ag/AgCl metal
reference electrode being used in contact with an ionic solution so that a stable potential is
provided.
Field-Effect Transistor (FET) based chemical sensors (ISFETs, Work function FETs,
CHEMFETs or chemical-FETs, EnFETs or Enzyme-FETs) are examples of popular poten-
tiometric based sensors with which different chemical compounds can be sensed by applying
processing techniques on top of the CMOS substrate, such as deposition of ion-selective
membranes on top of the insulating membranes (i.e. CHEMFETs, ISFETs) or by immo-
bilisation of enzymes which react with the analyte of interest in solution, to produce or
consume hydrogen ions (i.e. EnFETs) [2]. FET based chemical sensors belong into the
category of sensors whereby the charge in solution exposed to a floating gate can be sensed
by a stable reference electrode. Among these sensors, only ISFETs and CHEMFETs can be
fully integrated in CMOS, with various implementations resulting in detection of numerous
analytes, as has been summarised by [3]. Among these two, the ISFET has shown the ability
to sense chemical changes that result in changes in the pH of a solution due to the release
of hydrogen ions or protons, H+, even without the need for any additional deposition of an
ion-sensitive layer through post-processing modifications for defining the ionic selectivity of
the sensor when fabricated in standard CMOS [9].
What is desirable for solid-state chemical sensing is the minimisation of post-processing
steps which would reduce cost requirements for fabrication and manufacturing complexity.
Post-processing is required for defining or enhancing the ionic selectivity of the sensors
through the deposition of electrodes on dies or of additional sensing layers. Specifically in
the field of DNA detection, where the requirements for sensor density, large scale integration
and in parallel detection are emerging, in for example sensor arrays for DNA analysis at
a genome or sequential level and label-free semiconductor based sequencing using ISFETs
for monitoring changes in pH resulting from DNA chain extension reactions [10–12]. In the
following section, a brief comparison of the use of solid-state technologies in CMOS applied
for DNA detection is to be shown based on the already mentioned detection principles.
3.3 Label-free DNA detection in CMOS
For applications related to DNA detection in CMOS, various methods have been developed,
examples of which are shown in Table 3.1 and categorised based on the principle of detection.
The Ion-Sensitive Field-Effect Transistor 59
Table 3.1: Solid-state electrochemical sensing methods for DNA detection in CMOS
Method Principle Post Proc. Label-free Scaling Ref.
Amperometric Redox-cycling Yes No Electrode dependent [15]
Potentiometric pH No Yes Moore’s law [12]
Conductimetric Capacitance Yes Yes Electrode dependent [16]
Most of them mainly focus on the use of DNA microarray chips for parallel analysis of a
large number of DNA sites, with or without the additional requirement of post-processing
implementation on the silicon substrate. Traditionally, optical detection techniques have
been used for array based DNA detection, requiring the use of fluorescent markers attached
on DNA target molecules [13, 14]. Known sequences of single-stranded DNA, also referred
to as “DNA probes”, complementary to the DNA targets, are immobilised on the surface of
a DNA microarray chip on defined locations. The principle of detection of DNA microarrays
is based on the event of DNA hybridisation taking place when complementary matching
happens between the DNA probes and the target strands and thus fluorescence where light
is shone.
Moreover, electrochemical techniques based on the principle of redox-cycling have also
been used for CMOS based DNA detection [15, 17] through the use of gold electrodes of pre-
defined size on the sensing site of a DNA microarray. A post-processing step of depositing a
chemical substrate on the surface of the array for DNA probe immobilisation is required for
the event of DNA hybridisation to take place between the DNA probe and the in-solution
DNA target. The detectable signal would be the result of a conducted current when a DNA
match is observed.
CMOS based label-free electrochemical techniques have also been proposed, offering
low-cost solutions by avoiding the use of pre-processing steps such as DNA tagging us-
ing fluorescent labels combined with the need for laboratory equipment for optical signal
detection [12].
Label-free methods following the principle of capacitance based DNA detection have
been proposed by [16, 18–20]. Gold electrodes are used to sense the chemical binding of
DNA strands immobilised on the surface of a silicon chip, with capacitance decrease being
observed in the sensing electrode-electrolyte interface, induced by the event of DNA hy-
bridisation, due to the low dielectric constant that DNA strands are inherently exhibiting.
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Figure 3.2: The Ion-Sensitive Field-Effect Transistor (ISFET)
Finally, CMOS ISFET arrays have been used for electrochemical DNA detection [12, 21],
integrating sensors and microfluidics on a single platform, bypassing the need for pre-
processing or post-processing steps, taking advantage of the capability of ISFET sensors
to be fabricated in standard CMOS, whereby the Si3N4 native CMOS passivation layer can
be used as an sensing membrane.
The principle of DNA detection using the ISFET was first introduced by [10], showing
that when there is a match between a DNA target and a DNA probe, hydrogen ions or
protons, H+, are released, changing the pH of the solution. The ISFET being selective to
H+, can detect resulting changes in pH derived from DNA detection events based on the
principle of DNA chain extension, and therefore can be utilised for applications such as
DNA methylation detection, the analysis of which is to be explained in Chapter 4, enabling
integration with circuit techniques, as described in Chapter 5 and Chapter 6, to provide
more intelligent and robust DNA methylation detecting systems. The mechanism behind
the operation of the ISFET as a pH sensor and its characteristics are to be explored in the
following sections.
3.4 The Ion-Sensitive Field-Effect Transistor (ISFET)
The Ion-Sensitive Field-Effect Transistor (ISFET) was first introduced in the 1970s by Piet
Bergveld [9]. It was originally used for electrophysiological measurements due to its small
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size and fast response time. Since the discovery of its chemical sensing capabilities, it has
been one of the most popular potentiometric sensors, being involved in several applica-
tions from in vivo continuous measurement of blood pH as mentioned in [22], to label-free
DNA detection [12] and genome sequencing [11], forming CMOS based Lab-on-Chip (LoC)
systems comprising of ISFET arrays.
The ISFET was originally implemented using a standard metal oxide semiconductor
field-effect transistor (MOSFET), by omitting the gate metal, replacing it with a remote
gate (standard liquid junction Ag/AgCl reference electrode, VG) to set a stable potential
or gate bias to the solution, as the principles of potentiometric sensors require, exposing
a chemically sensitive insulating membrane to the electrolyte, as can be seen in Fig. 3.2.
Initially, silicon dioxide (SiO2) was used as the sensing membrane exposed to an electrolyte
solution [23]. However, silicon dioxide has been shown to be quite an unstable insulating
layer due to hydration effects causing cracks in the membrane’s surface through the gate.
For this to be overcome, the single layer of SiO2 is replaced by a double layer of it or of a
single layer of other insulating membranes such as silicon nitride (Si3N4), aluminium oxide
(Al2O3) and tantalum oxide (Ta2O5) deposited on top of the silicon dioxide layer when
enhancements in hydrogen ions sensitivity and sensor’s stability are desired [22].
The insulating membrane is used to trap protons on its surface. The activity of protons
is related to the ions in the solution and so is representing the pH of the analyte based on
the definition of the natural logarithm of the hydrogen ion concentration:
pH = −log([H+]) (3.3)
which shows how acidic (minimum pH=1) or alkaline (maximum pH=14) a solution
is. Changes in ionic concentration can result in changes in the charge distribution in the
ISFET’s channel which can be identified as changes in the threshold voltage of the device.
A description of the properties of the ISFET as a pH sensing device along with the physical
and operational characteristics shall now be explained.
3.4.1 ISFET operation
Originally the ISFET was described based on a close comparison to the MOSFET equivalent
model, whereby the MOSFET’s insulating membrane (SiO2) is covered by a polysilicon gate
to create a contact to a top metal, so that the device could be biased with a gate potential.
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Figure 3.3: Shift in the ID-VGS characteristic for variable pH
The definition of the ISFET as a pH sensing device without a metal gate, in contact with
an electrolyte and a reference electrode, can be expanded to an ion-sensitive gate whose
threshold voltage can be modulated by changes in the ionic concentration or the pH of the
solution. The threshold voltage of the ISFET exhibits a dependence on the pH variations
in solution, as can be shown in Fig. 3.3, which can be mathematically derived based on the
threshold voltage of a MOSFET, Vth(MOSFET ), described by Eq. 3.4, as analysed by [22].
Vth(MOSFET ) =
φm − φSi
q
− Qox +QSS +QB
COX
+ 2φf (3.4)
The first term φm - φSi expresses the difference in work function between the gate metal,
φm and the silicon surface, φSi and q is the electronic charge. The second term is consisted of
the charge accumulated in the oxide, Qox, the oxide-silicon interface, QSS , and the depletion
charge in silicon, QB. φf stands for the Fermi potential of the semiconductor and COX for
the insulator capacitance per unit area. The expression of the threshold voltage in the case
of an ISFET, as shown in Eq. 3.5, will differ from Eq. 3.4 in that the work function of the
metal, φm, will be replaced by the terms Eref and xsol which express the potential of the
reference electrode and the potential due to the presence of dipole molecules in the solution
respectively:
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Vth(ISFET ) = Eref − ψo + xsol −
φm
q
+ Vth(MOSFET ) (3.5)
ψo is a pH dependent chemical potential [24] also referred to as the surface dipole
potential [22], whose dependence on pH is given by:
ψo = 2.3
kT
q
α(pHpzc − pH) (3.6)
where pHpzc is the pH at the point of zero charge derived in [24] and α is the deviation
from the Nernstian response, which shall be defined later in this chapter.
As proposed by [2], the chemical potentials Eref , ψo, xsol and
φm
q can be grouped in the
potential Vchem expressed by:
Vchem = Eref + xsol − ψo − φm
q
(3.7)
The pH-sensing capabilities of the ISFET through the use of Eq. 3.7 shall now be
described.
3.4.2 pH sensitivity
The pH sensitivity of the ISFET or the dependence of the electrolyte-insulator potential ψo
on pH can be explained based on the site-binding theory [25] and the Gouy-Chapman-Stern
capacitive double layer model [26, 27]. When the surface of the insulating membrane of the
ISFET comes in contact with an electrolyte of a fixed ionic concentration, the ions of the
solution interact with the membrane, creating accumulation of charge on the surface of the
insulator.
A change in pH in the solution results in a change in the SiO2 potential on the surface
of the gate oxide that is in contact with the solution. The insulating membrane therefore
traps hydrogen ions whose activity is related to the ionic activity of the electrolyte. Given
that the surface of any metal oxide contains hydroxyl groups acting as “binding locations”,
specifically for the case of SiO2, SiOH exist on the surface [22]. These can be protonised
(OH+2 ) thus positively charged, acting as proton acceptors, deprotonised (O
−) thus nega-
tively charged, acting as proton donors or they can be neutral (OH), dependent on the pH
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Figure 3.4: Site-binding model at a SiO2-solution interface. Figure adapted from [22].
of the solution [23, 24]. Fig. 3.4 is an illustration of the mechanism behind the side-binding
theory at the interface between a SiO2 insulating membrane and the solution, responsible
for an equilibrium to be reached between protons in the solution and amphoteric SiOH
surface sites.
The charge accumulated on the insulator’s surface, due to the presence of hydrogen ions,
is dependent on the number of sites available which react with the hydrogen ions present,
based on the reactions:
SiOH 
 SiO− +H+S , with Ka =
[SiO−][H+]S
[SiOH]
(3.8)
SiOH +H+S 
 SiOH
+
2 , with Kb =
[SiOH+2 ]
[SiOH][H+]S
(3.9)
where H+S represents the concentration of hydrogen ions at the insulator’s surface and
Ka and Kb the equilibrium constants of the binding reaction, defining the concentration
species on both sides of the reaction when it is in equilibrium. From Eq. 3.8 and Eq. 3.9
it is clear that a surface that is originally neutral in charge (SiOH) can become positively
charged (SIOH+2 ) after accepting a proton from the solution as well as negatively charged
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Figure 3.5: Charge and potential distribution of electrolyte-insulator (SiO2) interface. The
ionic distribution on the surface of the ISFET together with the formation of the Helmholtz
plane and the Gouy-Chapman layer is illustrated.
(SiO−) after donating a proton to the solution, which explains the term “amphoteric” used
to describe the binding sites of the insulator [22].
The result of a charge build-up at the electrolyte-insulator interface is an equal and
opposite charge, spreading across the double layer, resulting in the Helmholtz plane which
is defined as the charge distribution attracted to the surface sites of the insulator, as well as
the charge that follows a Boltzmann distribution described as the Gouy −Chapman layer,
before it diffuses evenly in the bulk of the solution [3, 26]. The total distribution of charge
can be illustrated in Fig. 3.5. The combination of these two layers result in an almost linear
drop of the potential in the Helmholtz plane followed by an exponential drop through the
Gouy-Chapman layer as the charge diffuses into the electrolyte bulk. The distribution of
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charge in both layers can be modelled using the capacitances CHelm and CGouy in series
given by:
1
Cdiff
=
1
CGouy
+
1
CHelm
(3.10)
where Cdiff is the total capacitance in the double layer, dependent on the pH of the
solution as defined by [27].
Following the hypothesis that the ionic concentration equals to the ionic activity (dilute
sample), the concentration of hydrogen ions bound to the surface of the insulator, [H+]S ,
is related to the concentration of hydrogen ions in the bulk of the solution, [H+], following
the Boltzmann distribution:
[H+]S = [H
+]e−qψo/kT (3.11)
where ψo is the electrolyte-insulator interface potential and can be used to derive the
pH dependence according to Eq. 3.6, k is the Boltzmann constant and T is the absolute
temperature. Following on to that, the pH sensitivity for a Nernstian response, SN , is given
by:
SN =
dEmem
dpH
=
dψo
dpH
=
2.303RT
nF
=
2.303KT
q
= 2.303Ut = 59mV (3.12)
given that RTnF =
kT
q based on the Einstein’s equation.
This results in the definition of pH sensitivity for ISFETs, SISFET , as:
SISFET =
2.303αKT
q
(3.13)
α =
SISFET
SN
=
(
2.3kTCdiff
q2βint
+ 1
)−1
(3.14)
where α is a dimensionless sensitivity parameter, defined in Eq. 3.14 [28], stating the
deviation from the Nernstian response and is in the range of 0 to 1, with 1 representing a
Nernstian sensitivity of 59.2mV/pH at 298K, depending on the intrinsic buffer capacity of
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the oxide surface βint
2 and the equivalent capacitance Cdiff of the double layer, as defined
in Eq. 3.10.
Substituting Eq. 3.13 into Eq. 3.7 results in a more simplistic and widely used form of
Vchem originally presented by [30]:
Vchem = γ +
2.303αkT
q
pH = γ + 2.303αUtpH (3.15)
where γ is a grouping of pH independent chemical potentials and Ut is the temperature
dependent thermal voltage of the ISFET, also expressed as kT/q.
The derivations of the expressions stated above for the ISFET operation can be illus-
trated using the behavioural macromodel of the MOSFET adapted for the ISFET, as can
be seen in Fig. 3.6, originally shown by Martinoia et al. [29]. It includes the standard
MOSFET but adds the double layer capacitance CGouy-CHelm and the reference electrode
potential.
3.5 ISFETs fabricated in CMOS
Following on from the discovery of the ISFET as a pH sensor, attempts have been made for
ISFETs to be fabricated in CMOS. Wong et al. and Bousse et al. [31, 32] were the first to
propose processes of CMOS fabrication, including custom steps to etch away the passivation
and polysilicon gate so that an insulating membrane is added on top of a silicon dioxide
2The intrinsic buffer capacity is defined as βint=
d([SiO−]+[SiOH+2 ])
dpHS
, which is the capability for changes in
the number of surface sites available for a given change in pH [28]. It is described as intrinsic because small
changes can only be buffered in the surface pH and not in the bulk of the solution, under normal conditions.
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Figure 3.7: (a) CMOS ISFET structure, (b) behavioural macromodel.
layer on the substrate. Later, Cane et al. showed that unmodified CMOS implementation
was possible [33], with advances on the process proposed by Bausells et al. [34] using the
‘extended gate’ approach, as can be seen in Fig. 3.7a, by utilising the native top passivation
layer, which tends to be silicon nitride or silicon oxynitride (added by plasma enhanced
chemical vapour deposition (PECVD)) as the sensing membrane, also playing the role of
the insulating membrane for the ISFET. Through this, the polysilicon gate is extended to
the passivation layer using multiple metal layers, all floating, with charge bound to the
surface of the passivation, coupled to the polysilicon gate layers of metal. A comparison
with the original ISFET design of Fig. 3.2 shows the inclusion of the passivation capacitance,
Cpass, which is due to the insulator in contact with the top metal.
From this progress in the field onwards, several CMOS based systems have been de-
veloped, creating the basis for a new area of systems where integrated circuits and ISFET
sensors could co-exist on a single chip. This allows for advantages such as wafer scale pro-
cessing, scalability, which is a great merit for array based systems, miniaturisation of sensor
size, low-cost mass fabrication, integration with well-known circuit techniques, intelligent
sensor processing as well as ease of sample handling through the use of microfluidics to be
realised. ISFETs in CMOS have been largely integrated, creating arrays for several appli-
cations most importantly of biomedical nature, from cell culturing, to electrolyte imaging
to DNA detection. Table 3.2 summarises key works over the last decade in several tech-
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Table 3.2: Comparison of CMOS ISFET arrays over the last decade
Year Tech. Array Size Pixel Size Application Ref.
2001 1.2µm 6 (6 × 1) - blood gas [35]
2004 0.35µm 4 (2 × 2) 2.9 × 6.2µm cell culturing [36]
2005 0.35µm 256 (16 × 16) 12.8 × 12.8µm extracellular imaging [37]
2006 0.18µm 50 (5 × 10) 50 × 50µm DNA detection [38]
2008 0.35µm 33 (3 × 11) 57.5 × 57.5µm electrolyte imaging [39]
2008 0.35µm 256 (16 × 16) 11.6 × 11.6µm extracellular imaging [40]
2008 0.35µm 4 (2 × 2) 11.6 × 11.6µm electrolyte imaging [41]
2009 0.18µm 64 (8 × 8) 20 × 2µm handheld inst. [42]
2009 1.2µm 256 (16 × 16) 105.3 × 81.4µm DNA detection [43]
2010 0.35µm 40 (40 × 1) - DNA detection [21]
2010 0.35µm 64 (8 × 8) 50 × 50µm Opto-chemical imaging [44]
2010 0.35µm 8 (8 × 1) 30 × 100µm - [45]
2011 0.35µm 1.5M 5.1 × 5.1µm DNA detection [11]
2012 0.18µm 9 (3 × 3) 10 × 10µm DNA detection [46]
2012 0.35µm 256 (16 × 16) 14 × 14µm electrolyte imaging [47]
2012 0.35µm 4096 (64 × 64) 10.2 × 10.2µm electrolyte imaging [48]
2013 0.35µm 40 (40 × 1) 104 × 34µm DNA amplification [12]
nologies, showing that this field has been emerging and fast growing, especially for DNA
detection.
3.5.1 Device characteristics in weak inversion
In applications where low power is required in addition to low currents and energy efficient
processing, weak inversion is a suitable region of operation. Specifically in the current-
mode domain, weak inversion enables the use of translinear circuit techniques which can be
used to perform low power processing of ISFET signals on-chip. Weak inversion has been
utilised in this thesis for the realisation of novel circuits such as the ratiometric approach for
detecting DNA methylation using the “Methylation Cell” and the ISFET based Chemical
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Figure 3.8: ISFET IDVGS characteristics (left) and transconductance (right) at pH 7, with
the operational range of weak inversion to be highlighted.
Gilbert Cell, as will be further presented in this thesis.
In order to understand the device operating characteristics and simulate ISFETs in
CMOS operating in weak inversion, an elaborated macromodel is used, as proposed by [49],
based on the initially defined behavioural macromodel as shown in Fig. 3.6.
Fig. 3.9 illustrates this, which includes the capacitance Cpass to describe the passivation
layer of the CMOS ISFET, located between the top metal and the solution, scaling down
the effective gate voltage measured on the surface of the insulating membrane from VG′ to
VG′′ , which indicates the voltage seen by the MOSFET beneath the passivation layer. Cpass
is several orders of magnitude smaller than that of the Helmholtz capacitance, Chelm, and of
Gouy-Chapman capacitance, CGouy, causing minimum attenuation of any biasing potential
applied [49].
The voltage VG′ has also been expressed with respect to the voltage applied to the
reference electrode, VG, the chemically dependent potential, Vchem (3.15), and the input
trapped charge potential, Vtc, which models the measured trapped charge in the passivation
layer, as has been described by [49]:
VG′ = VG − Vtc − Vchem (3.16)
Operation in the weak inversion or sub-threshold region requires low voltage values
between the gate and the source of the device below its threshold voltage, VGS < Vth, with
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the current being exponentially related to the gate-source voltage. As the gate voltage
increases, charge is initially driven away from the channel, forming a ’depletion layer’,
depleted of electrons or holes. A slight further increase in the gate voltage results in electrons
beginning to diffuse from the source to the drain into the channel, forming an electron-rich
(for the case of an NMOS) ’inversion layer’. Thus, the channel created between the drain and
the source of the device is governed solely by the diffusion of charge carriers, as described by
the Boltzmann distribution, rather than by drift [50]. This drain current in weak inversion
is thus described by the expression:
ID = Io exp
VG′′S
nUt
(1− exp −VDS
Ut
) (3.17)
which shows that the drain current of the ISFET is exponentially related to the gate-
source voltage, with Io to stand for a positive constant current resulting from grouping
constants, n the sub-threshold slope coefficient, VG′′ the effective voltage on the gate of the
transistor, which is an attenuated version of the voltage defined by Eq. 3.16 as a result of the
capacitive division due to Cpass, oxide and depletion capacitancies of the MOS transistor
[2] and VDS the drain-source potential. Fig. 3.8(left) depicts a typical ID − VGS ISFET
characteristic of a typical 0.35µm CMOS process, with the weak inversion region of operation
to be represented by drain currents typically in the order of nanoamps. The weak inversion
transconductance is given by the expression:
gm =
ID
nUt
(3.18)
or
gm
ID
=
1
nUt
(3.19)
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with the latter expression to show the transconductance efficiency, Fig. 3.8(right), which
for the weak inversion region is constant, given that n is constant in that region. The peak
of the curve is given by 1/nUt, determined by the weak inversion slope factor n. Operating
in weak inversion provides maximum values of transconductance to current ratio, gm/ID,
which as shown in Fig. 3.8(right) can reach the top 90% of the curve, as illustrated by the
two dotted lines, a region that would satisfy the operation of an ISFET in weak inversion
providing with the maximum intrinsic voltage gain [49].
In addition to this, the ISFET’s sensing capability for pH changes of the solution as a
result of binding of hydrogen ions in the CMOS passivation layer (silicon nitride) can be
interpreted as changes in the ISFET’s drain current, ID, in weak inversion, described by
the equation [49]:
ID = Ioe
VGS−γ−αSNpH
nUt (3.20)
which can also be described with respect to the hydrogen ion concentration ([H+]) by:
ID = Ioe
VGS
nUt Kchem[H+]
α
n (3.21)
where Kchem=e
−γ/nUt stands for a grouping of constant chemical potentials. This leads
to the observation that the drain current of the ISFET biased in weak inversion is expo-
nentially related to the pH of the solution, which in turn is log-related to the hydrogen ion
concentration sensed by the ISFET sensor.
3.5.2 Non-ideal effects
Trapped charge
ISFETs normally suffer from variation in threshold voltage, shown as the DC offset, Vtc
in Eq. 3.16. This is the result of trapped charge left by fabrication which can exist in
the passivation layer on the floating gate. Since the ISFET is effectively a floating gate
MOSFET device, any charge left on the floating gate will have no path to discharge to
ground. As a result it remains trapped inducing an offset. UV radiation has been proposed
as a suitable mechanism to remove this charge [41].
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Drift
Drift is an issue which is very common in most chemical sensors. It normally appears as a
slowly increasing signal at a slower rate than the reaction. In ISFETs, the drift is caused
by the slow conversion of the silicon based insulating surface to a hydrated silicon oxide
or oxynitride layer during contact with the solution [51]. The growth of this surface layer
affects the overall capacitance of the passivation, Cpass, Fig. 3.7, and thus can appear to
be a change in the threshold voltage. Typically differential measurements can be used to
significantly reduce the effects of drift [21] or if the reaction amplitude is larger and at a
faster rate its effects can be negligible.
3.6 Summary
In this chapter, the ISFET as a potentiometric chemical sensor has been briefly reviewed
based on the principles that solid state chemical sensors follow for applications related to
label-free DNA detection. The mechanisms behind ISFET’s operation and its inherent pH
sensitivity compared to the ideal Nernstian have been explained along with the capability
for integration in standard CMOS. This allows the development of systems and large scale
fully integrated platforms consisting of ISFET sensors in the form of arrays with great
benefits especially in biomedical applications, such as DNA detection.
The weak inversion region of operation of the ISFET is shown, emphasising the advan-
tages of low power pH sensing, providing great opportunity for CMOS ISFETs to include
analog computation of signals implemented using novel circuits, as will be described later
in this thesis. We now proceed with describing the use of the ISFET for DNA methylation
detection and proving its utility in CMOS.
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Chapter 4
DNA methylation detection using
ISFETs
4.1 Introduction
Increasing knowledge on the role of epigenetic markers, such as DNA methylation in cancer,
has provided an exceptional opportunity for the evaluation of such epigenetic modifications
as potential cancer biomarkers, highlighting their great future in cancer diagnostics and
disease monitoring schemes as described in Chapter 2. Therefore, the need for detection
of DNA methylation in the promoter region of tumour suppressor genes appears to play a
very important role in early detection of cancer.
Methods for DNA methylation pattern analysis of candidate genes, reported in Chap-
ter 2, have been developed to assess the levels of DNA methylation in cancer cells compared
to normal cells in a gene-specific or genome-wide manner. Each one of them is associated
with several advantages but also possible limitations related to matters of accuracy of de-
tection or complexity through the addition of post-processing steps, especially when the
use of fluorescent labels or affinity based enrichment techniques are involved. Also, matters
such as the need for computational power, the cost of bioinformatic processing and the lack
of the potential for large scale integration can create certain constraints when a method is
to be widely used for genome-wide based applications for DNA methylation detection.
In the last decade, semiconductor technology has impacted healthcare making the use
of integrated circuits provide novel solutions for early detection, diagnosis and therapy of
disease. CMOS technology used for the manufacturing of personal computers and mobile
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phones has been exploited for applications such as genetics, bringing the inherent advan-
tages of CMOS into practice [1, 2]. The basic element of these CMOS based fully integrated
systems, providing with the sensing capability and electrical detection, lies behind a CMOS
based ion sensor, the ISFET (Ion-Sensitive Field-Effect Transistor), the principles of opera-
tion of which have been analysed in Chapter 3. At that point, aiming to apply the benefits
of using the technology of ISFETs in an epigenetically driven application and specifically in
detecting the methylation status of a DNA template towards the early screening of cancer,
the very first proof-of-concept for determining and validating the methylation status of a
DNA template (pUC19 plasmid DNA) is shown, followed by DNA methylation detection
as a result of a DNA chain extension reaction taking place in the presence of a methylated
DNA template. The DNA template was amplified under thermocycling conditions based
on the method of pH-PCR [1], according to which the change in pH observed after the com-
pletion of the DNA chain extension reaction was detected using the commercially available
pH sensitive ISFET technology (ISFET sensor by Sentron Europe B.V.). This is the first
proof-of-concept for ISFET based DNA methylation detection.
Further to the development of the method of using the ISFET as a sensor for detecting
DNA methylation in given genetic areas, the idea of using ISFETs integrated in standard
CMOS technology is further developed into practice, using the multichannel DNA SoC
platform (Appendix D), first described by [1, 3], applied in two different genes (DAPK1,
CDKN2A/p16-INK4 (p16)) with different ratios of DNA methylation under isothermal
conditions of DNA amplification using the method of pH-LAMP [1]. The SoC platform,
is an ion-sensitive semiconductor based platform, bringing simultaneous amplification and
detection of nucleic acids together on a single chip, by performing real-time monitoring of
the pH of a DNA extension reaction using ISFETs as pH sensors, thus sensing the hydrogen
ions (H+) generated as a result of an amplification taking place. In this research, real-time
detection of DNA methylation in CMOS using the SoC platform was achieved, generating
a strong differential signal, therefore distinguishing methylated from unmethylated DNA in
each gene case, proving that DNA methylation can be detected on-chip. This will allow us
to create integrated systems such as the “Methylation Cell” and the ISFET based Chemical
Gilbert Cell as described in Chapter 5 and Chapter 6 respectively.
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Figure 4.1: Biochemical mechanism for H+ release following nucleotide incorporation. Fig-
ure obtained and adapted from [6].
4.2 DNA base pair incorporation detection
The biochemical information needed for DNA methylation to be detected by the ISFETs
is obtained as a result of DNA amplification of the methylated region of the DNA sample
taking place (either under thermocycling or isothermal conditions). This would be based on
a DNA chain extension or elongation reaction, the biochemistry of which was first proposed
by [4] who described the use of an ISFET to monitor the time course of a chain elon-
gation reaction, during which the incorporation of dNTPs (deoxynucleotide triphosphates
or nucleotide bases acting as the essential blocks of a DNA sequence, consisting of four
nucleotides dATP, dTTP, dCTP, dGTP [5]) into a DNA strand results in the production
of hydrogen ions or protons (H+) leading to a growing DNA strand and the production
of pyrophosphate (PPi), resulting in a change in pH, monitored by the ISFET. Later on,
work published by [6] reported a method for detecting DNA and more specifically SNPs,
by monitoring the change in pH during nucleotide incorporation occurring in a DNA chain
extension reaction.
As reported by [6] and shown in Fig. 4.1, while the double-stranded structure of the
“parent” DNA opens, each single strand acts as a template to which the dNTPs (e.g.
dGTP used in Fig. 4.1) are added, following the rules of complementary matching (A pairs
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Figure 4.2: ISFETs can be used as pH sensors to detect methylated DNA (M) and distin-
guish it from unmethylated DNA (U) due to the presence of hydrogen ions (H+) resulting
from an extension reaction taking place in the presence of methylated DNA. For this to
happen, the process of bisulfite conversion (method explained in Section 2.4, Chapter 2)
is applied, which differentiates M from U . DNA strands are treated with sodium bisulfite
so that methylated cytosines remain preserved through a DNA chain extension reaction
whereas unmethylated cytosines are converted to uracils. This is a methylation dependent
pre-amplification modification that is applied to the targeted genetic areas so that DNA
methylation information is kept unaltered throughout the process.
with T, C pairs with G), under the essential presence of the DNA polymerase enzyme which
is immobilised on the ISFET’s surface and the addition of monovalent and divalent ions,
primarily Magnesium (Mg+2) which tends to enhance the activity of DNA polymerase [7].
The dNTPs are incorporated into the growing single-stranded DNA, Fig. 4.1, as the hydroxyl
group from the 3’ terminal of the growing DNA strand performs a nucleophilic “attack” to
the α-phosphate group of the nucleotide base added [8], provided that the phosphate groups
involved in the reaction are fully ionised given the starting pH profile of the reaction [6].
As a result, the incorporation of one nucleotide leads to the production of pyrophosphate
and most importantly to the release of a hydrogen ion from the hydroxyl group of the 3’
terminal of the growing strand, leading to a change in the pH of the reaction due to the
increase of the solution’s acidity. The pH would then be an indication of a single nucleotide
incorporation taking place leading to a DNA extension reaction of a targeted gene site,
monitored by the ISFET.
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Additionally, for a given DNA template (double-stranded) to be amplified and thus
a DNA chain extension reaction to happen, a sequence-specific pair of primers (one for
each strand) or single-stranded oligonucleotides often described as DNA probes, need to be
designed as the starting point of DNA amplification of the target sequence, defining the
start and stop of the DNA strand that is to be copied. Primers can hybridise under specific
temperature conditions, dependent on the nature of the amplification process (in this case
we are referring to thermocycling or isothermal conditions) to their complementary target
sequence, as the starting point of the DNA chain extension followed by the addition of
dNTPs with the aid of the DNA polymerase enzyme, resulting in multiple copies of the
DNA target being produced, leading to its amplification.
For the purpose of this research, single-stranded DNA probes were designed specifically
to identify the region of a methylated DNA target with the sequence of which designed
as the product of sodium bisulfite treatment, a chemical method which as explained in
Section 2.4, Chapter 2, contributes in the enhancement of the signal derived from amplified
methylated sequences, while altering the unmethylated bases, preserving DNA methylation
during amplification. The under amplification methylated DNA target will therefore be
equal to the product of the DNA target after chemical conversion of bisulfite treatment.
The primers would hybridise only to the complementary DNA target sequence where DNA
methylation is existent, aiming for a methylation-specific amplification, the result of which
is to be detected by the ISFET, as can be graphically illustrated in Fig. 4.2.
For the proof-of-concept approach, two DNA amplification techniques were used result-
ing in DNA extension products: (a) Polymerase Chain Reaction (PCR) [9, 10] whereby
DNA is amplified through a thermocycler leading to exponential amplification of products
and (b) Loop-Mediated Isothermal Amplification (LAMP) [11] whereby DNA is amplified
through isothermal conditions, at a stable temperature, without the need for a thermocy-
cler. Both methods were combined with the use of the pH signal recorded by the ISFET
before and after the event of amplification, as an indication of the presence of a reaction
determined by the magnitude of the pH drop [12, 13]. The monitoring of the pH before
and after a PCR and LAMP amplification in the presence of the methylated DNA target
is reflected during the use of the term pH-mediated or pH-sensitive PCR (pH-PCR) and
pH-mediated or pH-sensitive LAMP (pH-LAMP) [1], with the analysis of the methods and
the discussion of the results to be shown in the following sections.
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4.3 DNA methylation detection using pH-PCR
Several molecular biology methods were followed to carry out a structural way of pro-
ducing naturally methylated/unmethylated DNA, validating the presence of methylation
and finally developing a proof-of-concept method for detecting methylated DNA using the
pH-sensitive method pH-PCR in conduction with the ISFET as the pH sensor.
For the realisation of the proof-of-concept method for DNA methylation detection at
first, a gene target (i.e. pUC19 double-stranded plasmid DNA [14]) was selected as the
sample “basis”. The methylation levels of that gene were naturally modelled through the
method of transformation [15] by introducing the target gene in two host bacterial lab-
oratory strains (competent cells) which were “competent” or ready to host the plasmid
that needed to be inserted in the strain. As a result, through the process of cloning [15],
multiple copies of two bacterial strains were produced resulting in producing the DNA tar-
get pUC19 in two forms: a methylated (dcm+) and an unmethylated (dcm−) form. This
was achieved by using two host bacteria: one that was carrying a DNA cytosine methy-
lase or dcm methylase, encoded by the dcm gene of E.coli [16], therefore modifying the
internal cytosines at the 2nd C5-position (C in bold) on both strands within the sequence
(5...CC(A/T )GG...3) leading to methylated plasmids (dcm+), or by using methyltrans-
ferase deficient chemically competent E.coli cells, therefore growing plasmids free of dcm
methylation (dcm−).
As soon as the methylated/unmethylated DNA was produced and then purified, re-
striction enzymes were used to validate the result followed by the quantification of the
DNA extracted from the bacterial strains. This was followed by the process of pH-PCR
amplification of the resulting genetic targets, whereby a methylated gene target would be
amplified specifically with the aid of pre-designed primers (primers designed according to
the information and requirements reported by [5, 7]) that would anneal selectively to it
and thus distinguish it from the unmethylated one. The signal generated from the ampli-
fication of the methylated gene would then be sensed by the ISFET pH sensor, to show
that a methylation-specific pH change as a result of a DNA extension reaction taking place
in presence of methylated DNA can be used as a marker for DNA methylation detection.
Consequently, for a proof-of-concept approach for DNA methylation detection using the
ISFET, two reactions are needed, one resulting to a PCR product and the other resulting
to no PCR product. The materials and methods used for the experimental needs together
with the results of pH detection of amplified methylated DNA are presented in the following
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section.
4.3.1 Materials and Methods
Chemicals, Biolochemicals and Oligonucleotides
Oligonucleotides as primers for PCR/pH-PCR, dNTPs and Truestart
TM
Taq DNA poly-
merase enzyme were supplied by Thermo Fisher Scientific. Other reagents parts of the
PCR buffer such as MgCl2, KCl were supplied by Sigma-Aldrich. Oligonucleotides were
dissolved in Sigma water at desired concentrations upon the first use and stored at -20oC.
Water was supplied by Sigma-Aldrich, otherwise, distilled water was manually sterilised by
filtration using Sterile Acrodiscr Syringe Filters through a 0.2µm Suporr membrane.
Bacterial Strains
To naturally create two different DNA targets, one with DNA methylation being present
and the other with DNA methylation being absent, two different E.coli strains were used.
One Shotr Mach1
TM
-T1r chemically competent E.coli cells (Life Technologies) [17] were
used to allow the growth of pUC19 plasmid DNA with a native percentage of dcm+ methy-
lation present and dcm− competent E.coli cells (New England BioLabs) [18] were used to
allow the growth of pUC19 plasmid DNA free of dcm methylation. The “parent” strain
of Mach1
TM
-T1r E.coli cells was the non-K12 wild-type W strain (ATCC #9637, S.A.
Waksman) whereas the “parent” strain of dcm− E.coli was K12 [18], a cultivated strain in
a laboratory environment.
DNA target
Plasmid DNA pUC19 (GenBank Accession #: L09137) (New England BioLabs), as shown
in Fig. 4.3, is a double-stranded circular molecule of 2686 base pairs length, isolated from the
bacterial strain E.coli (dam+/dcm+), being a commonly used plasmid vector in E.coli [14].
It is known for its small size and the fewer number of genes compared to genomic DNA, being
used as the DNA target in these series of experiments. pUC19 contains several restriction
sites, Fig. 4.3, areas on its “body” that are recognised by restriction enzymes (enzymes
that can selectively cut recognisable DNA sequences). Moreover, as all plasmids, pUC19
as well, carries antibiotic resistance genes that can enable it to survive in an environment
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Figure 4.3: Map of pUC19. Visible are the areas of antibiotic resistance (ApR, where Ap
stands for the antibiotic Ampicillin), the origin of plasmid replication (ori) and the multiple
cloning sites including the actual coding sequence (lac) [14, 21]. Restriction sites are also
shown in bold and regular font.
or medium that contains an antibiotic (usually Ampicillin). pUC19 contains a gene that
makes it resistant to the antibiotic Ampicillin (ApR in Fig. 4.3) [14], which means that
it passes this resistance to the bacterial strain that will be hosting the plasmid, which is
of vital importance given that Ampicillin would let only the bacteria having acquired the
plasmid survive.
For the purpose of this research, pUC19 was introduced in two bacterial E.coli strains,
in order for the internal cytosines of the plasmid DNA to be either methylated by the
dcm methylase, encoded by the dcm gene, contained in Mach1
TM
-T1r E.coli cells, trans-
fering a methyl group at the C5 position of the internal cytosine (in bold) in the sequences
CCAGG and CCTGG [19, 20], or unmethylated by methyltransferase deficient chemically
competent E.coli cells, suitable for growing plasmids that lack of dcm methylation.
Stock solutions and bacterial growth media
Antiobiotic Ampicillin was prepared as 100mg/ml stock solution. It was sterilised by
filtration through a 0.2µm Suporr membrane and kept in aliquots at -20oC. Also, Luria-
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Bertani (LB) bacterial growth medium, a medium commonly used in bacterial cultures,
consisted of 1% (w/v) tryptone, 0.5% (w/v) yeast extract and 1% (w/v) NaCl. Similarly,
Luria-Bertani Agar (LBA) medium was produced by LB solidified with 1.5% (w/v) agar.
Both media were sterilised by autoclaving. 100µg/ml antibiotic Ampicillin was obtained
from stock and then added to LBA medium so that the colonies selected would only be
positive.
Molecular biology methods
Transformation of plasmid DNA into competent cells
Frozen competent cells (One Shotr Mach1
TM
-T1r E.coli cells and dam-/ dcm- competent
E.coli cells) were thawed on ice for each transformation. 1µl of DNA (pUC19) was added
into each of the vials of the competent cells followed by a gentle mix and then kept on
ice for 30min. For the negative controls, 1µl of distilled water, already filtered through a
0.2µm Suporr membrane, was added to 30µl of each of the competent cells and left on
ice for 30min as well. The cells were then heat-shocked for 30sec at 42oC without shaking
and the tubes were placed on ice for 2min. Following that stage, 250µl of LB medium was
added to each vial. The vials, tightly capped, were then inserted in a shaking incubator at
37oC for 1 hour at 225rpm. After that, 50µl of the transformation mixes were spread on
the LBA plates (where 100µg/ml Ampicillin was already added) using sterilised spreaders.
The plates were left inverted in the incubator at 37oC for 16 hours.
Preparation of plasmid DNA - DNA Purification - DNA Quantification
A single colony was selected from each plate of the overnight-grown colonies and then
inoculated in solution of 10ml containing LB medium, 5ml and Ampicillin (100µg/ml),
5ml. The cell culture was left to grow overnight at 37oC for 16 hours at 220rpm in a
shaking incubator. Bacterial cells were harvested by centrifugation at >8,000rpm in a
conventional, table-top microcentrifuge for 3min at room temperature. The plasmid DNA
was then prepared and purified using QIAprep Miniprep kit by Qiagen. Pelleted bacterial
cells were resuspended in 250µl suspended buffer, provided by the kit, and transferred to
a microcentrifuge Eppendorf tube. Another 250µl of alkaline buffer was added and the
tube was gently inverted 4-6 times. This was followed by the addition of 350µl buffer and
then was mixed thoroughly before being centrifuged for 10min at 13,000 rpm in a table-top
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microcentrifuge. The supernatants were applied to a QIAprep spin column provided with
the Miniprep kit and then centrifuged for 30-60sec. The flow-through was discarded and
so the column was washed with 750µl of ethanol buffer followed by a second centrifuge
for 30-60sec. The flow-through was discarded again and the column was centrifuged for
an additional 1min. The obtained plasmid DNA was eluted from the column by 50µl of
sterilised water (which is the final volume of the plasmid DNA) and finally centrifuged for
an additional 1min. For a long-term storage of the plasmid DNA after the transformation,
30% of the cell culture (150µl) was mixed well with 70% of glycerol (350µl) in a 1.5ml
Eppendorf tube, kept frozen at -80oC. Glycerol was used due to its ability to provide both
intracellular and extracellular protection to the sample against long-time freezing.
Purified DNA was then tested and quantified using the NanoDrop ND-1000 Spectropho-
tometer v3.7, at 260µm and 280µm, brought by Thermo Fisher Scientific. 1µl sample was
used for each measurement. In case of a more concentrated quantified DNA (eg. >1µg) after
the NanoDrop quantification, aliquots of 50ng/µl were prepared. The purpose of aliquoting
was also to reduce the continuation of a sample being thawed and frozen consecutively,
therefore preserving the DNA sample from degradation [22].
Restriction enzyme cleavage
Restriction enzymes recognise specific sequences of DNA in areas specified as restriction sites
and then cut them into DNA fragments, called restriction fragments [15]. For the pur-
pose of this work, restriction enzymes were used for the validation of the methylation status
of pUC19, after being prepared through the process of transformation. In general, DNA
isolated from E.coli does not have the same extent of DNA methylation present and more
importantly, methylation added by a dcm methylase inhibits the possibility of the DNA
target to be digested by certain restriction enzymes. In particular, dcm methylases, in
prokaryotes (plasmid DNA) are elements whose role is to protect the host DNA from cleav-
age by the corresponding restriction enzymes. DNA methylation can block, slow the rate
of cleavage or leave the cleavage of the recognition sites unaffected. Cleavage may depend
on the under study sites as well as on the reaction conditions, as it may lead to a partial or
incomplete digestion products when applied in multiple sites.
After conducting some research on the commercially available restriction enzymes that
were either sensitive or insensitive in the existence of methylated DNA, two restriction en-
zymes EcoRII, MvaI (Thermo Fisher Scientific) were finally isolated and an investigation
DNA methylation detection using ISFETs 89
Table 4.1: Restriction digestion protocol set-up for validation of methylated and unmethy-
lated pUC19 plasmid DNA using EcoRII and MvaI restriction enzymes.
Restriction digestion protocol - Components Amounts
Restriction Enzyme EcoRII/MvaI 1µl (10 units sufficient)
DNA dcm+,dcm− 2µl (from 50ng/µl stock purified
DNA prepared in Section 4.3.1)2
10X Buffer O/R3 1µl
Nuclease-free water 6µl
Total reaction volume 10µl
Incubation time 1 hour
Incubation temperature 37oC
was undergone on whether they could recognise and so cleave the methylated recognition
sites (dcm+) while distinguishing them from the unmethylated ones (dcm−), as a prelimi-
nary and indirect way of validating the presence of DNA methylation in pUC19.
More specifically, in the experiments conducted, EcoRII restriction enzyme was selected
based on its ability to protect methylated cytosines from being digested by completely over-
lapping the methylated sites. The methylated pUC19 (dcm+) would therefore be resistant
against cleavage by EcoRII, given that EcoRII has the ability to block the areas of dcm
methylation, by only digesting the unmethylated (dcm−) cytosines respectively as shown
by the recognition sequence 5’.../CC(A or T )GG...3’ 1 [19, 20]. The activity of EcoRII
was then compared with the cleavage effect of a second restriction enzyme, MvaI, which
was able to digest both methylated and unmethylated cytosines (5’...CC/(AorT )GG...3’)
since its activity is not blocked by dcm methylation.
Both the purified DNA templates (dcm+ and dcm−) and the enzymes were kept on ice
prior to the experiment when not in the freezer. The components, as displayed on Table
4.1, were mixed prior to the addition of the enzyme, by pipetting up and down the reaction
mixture for a few seconds. As soon as the enzyme was added, the reaction mixture was
1The symbol / indicates the point of cleavage following the 5’ - 3’ direction of the DNA sequence, with
the internal cytosine (in bold) to be methylated.
2Initial trials have shown that 1µl of DNA template added to the total reaction volume was not sufficient
enough for a complete digestion of the DNA sample. Thus, the volume of the DNA sample was increased
to 2µl of the same concentration (50ng/µl).
3Buffers O and R were supplied for use with the enzymes EcoRII and MvaI respectively.
DNA methylation detection using ISFETs 90
centrifuged and then left in the incubator at 37oC for 1hour. The reaction mixtures were
divided into two groups: the first group included the unmethylated (dcm−) DNA template
chosen to be digested separately by the restriction enzymes EcoRII and MvaI, using each
time the relevant buffer solution for the specific enzyme and nuclease-free water. Undigested
DNA was used as a positive control mixture, also included in the first group of reactions,
containing the dcm− template and water, scaling the reaction mixture up to 10µl. Similarly,
the second group was composed of the methylated (dcm+) DNA template to be validated
for its methylation status by the enzymes EcoRII and MvaI, together with the positive
control, containing the dcm+ template and water. The mixtures additionally contained the
relevant buffers and nuclease-free water. In total, 6 reaction mixtures were produced and
then loaded to agarose gels for electrophoresis, as explained in Appendix E.
Polymerase Chain Reaction (PCR)
PCR is a well-established sequence-specific DNA amplification method first introduced by
Mullis in the early 1980s [9, 10, 23, 24] and has been widely used in the field of molecular
diagnostics and clinical research, combining detection and analysis of DNA amplification
products of an under investigation DNA source. Since its discovery, it has rapidly pro-
gressed in applications such as genetic/epigenetic expression, sequencing, infectious disease
identification (viral, bacterial analysis), forensics and biotechnology.
It is a standard method for exponentially amplifying small copies of DNA molecules
using the law of complementary matching of nucleotide bases in the double-helix DNA
structure. DNA is initially denatured as a result of temperature increase of a DNA sample
in an aqueous solution, resulting in the separation of the two DNA strands and the formation
of two single strands [5, 7]. After lowering the temperature of the solution, DNA fragments
(primers) specifically designed in pairs with the aid of a primer design software (V ector
NTIr Software by Life Technologies was used for the scope of this research [25]) are
used to frame the terminal points of amplification based on specifications reported by [7,
15, 26]. Primers hybridise or anneal to both the sense strand (forward primer: it has
the same sequence as the top or sense strand) and the complementary anti-sense strand
(reverse primer: it has the same sequence as the bottom or antisense strand), following
a complementary alignment between primer and DNA target [5, 27, 28], as can be seen in
Fig. 4.4. The figure illustrates the specific example of methylation-specific primer design to
achieve amplification of methylated pUC19 DNA producing a DNA fragment of 322 base
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         5’-CCAGCTGCATTAATGAATCGGCCA-OH-3’
 3’-GGTCGACGTAATTACTTAGCCGGT 
primer extension
         3’-HO-ACCGCTTTGGGCTGTCCTGATATT-5’
TGGCGAAACCCGACAGGACTATAA-3’  
primer extension
forward primer annealing upstream
Bottom strand
5’
 Top strand
5’
reverse primer annealing downstream
Figure 4.4: Forward and reverse primers designed to amplify the target DNA fragment of
methylated pUC19 plasmid DNA using PCR and pH-PCR.
Table 4.2: Primers designed for methylated pUC19
Primer Sequence
Forward: p19.F6 (5’-3’) CCAGCTGCATTAATGAATCGGCCA
Reverse: p19.R6 (5’-3’) TTATAGTCCTGTCGGGTTTCGCCA
pairs (bp) long, with primers shown in Table 4.2 corresponding to the methylated DNA
target sequence, specific to the region of the methylation site of pUC19.
The temperature then increases for the elongation or extension step to proceed, which
produces two identical DNA strands (often referred to as the amplicon) under the presence
of PCR reagents: thermostable Truestart
TM
Taq DNA polymerase enzyme [29], dNTPs,
PCR buffer consisting of MgCl2 and KCl. This leads to the end of the 1st cycle of
DNA replication and the beginning of the exponential amplification of the DNA target
accumulated in billions of copies [5, 7, 15] after a given number of cycles (in this research
40 cycles were completed). A very elaborated example of the theory of PCR based on
the methylated selected site of pUC19 together with the annealing effect of the designed
primers, Table 4.2, is shown in Fig. 4.5 and continues in Fig. 4.6 illustrating the result of
PCR amplification during the first 3 cycles. It is interesting to note that after the 1st cycle, 4
strands have been produced, the initial 2 used as the DNA template for amplification and 2
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Table 4.3: Thermal cycling program for a 55-66oC temperature annealing investigation
Temperature Duration Function
95oC 1min DNA denaturation
Repeat for 40 cycles the following:
95oC 15sec
primer annealing - DNA extension
55-66oC 10sec
Table 4.4: Primers designed for positive control for the temperature gradient PCR investi-
gation
Primer Sequence
Forward: p19.F4 (5’-3’) CACAATTCCACACAACATACGAGCCG
Reverse: p19.R4 (5’-3’) GAGCCTATGGAAAAACGCCAGCAAC
more as a result of primer extension. The extension starts from a framed position (beginning
of primer) but continues given that the DNA polymerase enzyme keeps adding nucleotides
as far as it can go, covering the distance of a few thousands of bases. Consequently, DNA
fragments of different lengths are produced and only at the 3rd cycle, where 8 DNA strands
are created, does the desired DNA fragment (322-bp) become visible (black box in Fig. 4.6).
The primers (p19.F6/p19.R6) used in this research to amplify the methylated DNA
sequences of pUC19 were initially tested for the optimal annealing temperature to be cho-
sen4. A temperature gradient of 6 temperature values was performed between 55oC and
66oC for the set of primers designed for methylation-specific amplification of pUC19 DNA.
The thermal cycling program performed for the temperature annealing investigation using
a PCR machine (Applied Biosystemsr, Life Technologies) is also summarised on Table 4.3
for 0.1µl of the pUC19 DNA template, equivalent to 106 copies in the reaction volume.
The PCR reaction was performed in 35µl reaction volume with 1.5Units/µl of Truestart
TM
Taq DNA polymerase, 800µM dNTPs, 0.5µM of each primer in the reaction buffer freshly
4The annealing temperature is the temperature chosen for the primer strands to anneal to the comple-
mentary strand of the “parent” template. It is possibly the most critical part for optimising the specificity
of a single PCR reaction per primer set. The higher the annealing temperature, the more exact the match
would be, but the more stringent the conditions for the primers to hybridise on the template [26, 28].
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CCAGCTGCATTAATGAATCGGCCA
 GGTCGACGTAATTACTTAGCCGGT 
ACCGCTTTGGGCTGTCCTGATATT-5’
CCAGCTGCATTAATGAATCGGCCA
 GGTCGACGTAATTACTTAGCCGGT 
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CCAGCTGCATTAATGAATCGGCCA TGGCGAAACCCGACAGGACTATAA
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CCAGCTGCATTAATGAATCGGCCA
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CCAGCTGCATTAATGAATCGGCCA5’- TGGCGAAACCCGACAGGACTATAA
ACCGCTTTGGGCTGTCCTGATATT
 GGTCGACGTAATTACTTAGCCGGT 
CCAGCTGCATTAATGAATCGGCCA5’- TGGCGAAACCCGACAGGACTATAA
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3’
Figure 4.5: Synthesis of a 322-bp fragment of pUC19 DNA used for the demonstration
of the initial steps of a PCR reaction which includes denaturation of the DNA template,
hybridisation of the primers on the DNA template, also referred to as the annealing step,
followed by elongation of the DNA template with the aid of the DNA polymerase enzyme
and of dNTPs, a step also called DNA extension or DNA replication. The figure shows
the sequence of events during 2 PCR cycles which is continued in Fig. 4.6 for the completion
of 3 cycles.
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3’
Figure 4.6: Continuation of Fig. 4.5 resulting in the accumulation of the resulting 322-bp
DNA template, while the PCR amplification exponentially continues.
DNA methylation detection using ISFETs 95
Figure 4.7: Map of pUC19. The location of amplification by the methylation-specific primer
pair p19.F6/p19.R6, Table 4.2, which performs a 100% match with the target pUC19 tem-
plate is displayed together with the location for the primer pair p19.F4/p19.R4, Table 4.4,
used for positive control, performing 100% match with the “parent” template as well.
prepared, containing 3mM MgCl2 and 50mM KCl and Sigma water to reach the total
volume of 35µl. For the positive control mixture, the previously mentioned quantities were
repeated in a new reaction mixture, differing from the previous one only in the use of a
different set of primers p19.F4/p19.R4, Table 4.4, of the same quantity as in the main
reaction mixture prepared for methylation-specific amplification, aiming to hybridise with
the “parent” template of pUC19 at a location away from the methylation sites, producing a
DNA fragment 379-bp long. The amplified product was resolved in a 1.75% agarose gel in
1xTBE buffer and the DNA band of the correct size was then confirmed using the method
of agarose gel electrophoresis as explained in Appendix E, Section E.
pH-PCR
The method of pH-PCR and the principal protocol that describes the procedure followed was
established by Toumazou et al. [1, 12, 13], applied for single base detection in applications
such as Single Nucleotide Polymorphism (SNP) detection [3, 6] and DNA sequencing [30].
Using this as the core basis, the principal method for DNA methylation detection based
on pH-mediated amplification and detection using the ISFET as the pH sensor was herein
developed. The pH-PCR method includes the monitoring of the pH in PCR tubes before and
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Table 4.5: pH-PCR thermal cycling program
Temperature Duration Function
95oC 1min DNA denaturation
Repeat for 40 cycles the following:
95oC 15sec
primer annealing - DNA extension
66oC 10sec
after PCR amplification of a reaction where methylated DNA (pUC19, dcm+) is present
compared to a reaction where unmethylated DNA (pUC19, dcm−) is present, including
pH adjustments using 10M NaOH and 1M HCl (Sigma-Aldrich) in order for the start pH
of the under amplification DNA reaction mixture to be as close as possible to the pH of
the dNTPs [6]. The pH was monitored in sample volumes of 35µl using a commercially
available Al2O3 ISFET sensor containing a Ag/AgCl reference electrode (Sentron Europe
B.V.). The measurements were taken after having checked that the pH probes calibration
slope was within the acceptable values, according to the manufacturer’s guidelines, for a
pH measurement to be valid. The terms of use, preparation and calibration steps of the
Sentron ISFET pH probe combined with an Argus pH-meter (Sentron Europe B.V.) are
included in Appendix C.
Before the start of the PCR amplification, the pH of the DNA reactions was adjusted
to around pH 8.00 at room temperature using 10mM HCl (1M HCl stock solution) or
10mM NaOH (10M stock solution), dependent on the baseline of the pH measurements.
Once the optimal annealing temperature (66oC) of the primers was established through
PCR (experimental validation on Section 4.3.2), the reaction mixtures (35µl in total) were
then prepared for PCR following the protocol: 1.0 Units/µl of Truestart
TM
Taq DNA
polymerase, 800µM dNTPs, 0.5µM of the primer set p19.F6/p19.R6 as displayed on Table
4.2, designed to amplify only the methylated pUC19 dcm+ DNA template at a concentration
of 0.02ng/µl in the PCR reaction or 1ng of 10µg/µl aliquoted pUC19. 3mM MgCl2 and
50mM KCl were further weakly buffered in the 35µl reaction volume to help stabilise the
fluctuation of pH, thus contributing in the kinetics of the reaction. The rest of the pH buffer
was filled with Sigma water. A negative control reaction with no pUC19 DNA template
also known as Non-Template Control (NTC) was setup in parallel as a reference baseline.
The reactions were run in triplicates to evaluate the credibility of the result.
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The PCR reaction was paused initially at the 5th cycle of the PCR program (beginning
of PCR) and then at the 40th cycle (end of PCR) for pH measurements to be taken by the
ISFET sensor. 5 cycles (instead of 0) were selected as a starting reliable point of conducting
the pH measurements, as the pH of the samples measured at 0 cycles compared to 5 cycles
during initial trials was quite high, possibly because of the CO2 trapped in the reaction
tubes. Consequently, the environmental parameters under which the pH measurements
were taken were affecting less the measurements taken after 5 cycles and were thus closer
to the conditions of those taken at 40 cycles.
The ISFET will then be able to sense the expected drop in pH, as a result of the amplifi-
cation of methylated DNA, leading to a pH change produced by the incorporation of dNTPs
in the reaction, as explained in Section 4.2. Hence, the DNA solution post-PCR would be
enriched with hydrogen ions, the presence of which would perform the immobilisation of
the chemically sensitive ISFET surface of the pH probe leading to an observed pH drop.
The amplified products were quantified using Qubit Fluorometer (Qubit Quant-iT HS kit,
Life Technologies) and then resolved in a 1.75% agarose gel in 1xTBE buffer. The DNA
fragments of the correct size were then confirmed with agarose gel electrophoresis following
the procedure as explained in Appendix E.
4.3.2 Results
Restriction Enzyme Cleavage
Restriction enzymes MvaI, EcoRII were chosen to validate the presence or absence of DNA
methylation in a methylated (dcm+) and unmethylated (dcm−) state of pUC19 plasmid
DNA. The results of the restriction enzyme cleavage based on the protocols reported in
Section 4.3.1, Table 4.1 can be seen in Fig. 4.8.
The number of digested fragments expected to be seen through gel electrophoresis were
5 in total, of sizes 13, 121, 191, 288 and 2073 bps, which was validated with the use of
the software Restriction Mapper [31]. This may vary though based on the activity of the
enzymes in presence of DNA methylation. In specific, the restriction enzyme MvaI showed
the capability of digesting both the unmethylated (dcm−) and methylated (dcm+) DNA
targets, with the correct fragment sizes of 121, 191 and 288 clearly seen in Fig. 4.8, the
location of which was assessed by using the DNA ladders of two different sizes. Compared
to the activity of MvaI, the restriction enzyme EcoRII did not cleave the areas where
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Figure 4.8: DNA cleavage using the restriction enzymes MvaI and EcoRII on dcm+/dcm−
pUC19.
methylated DNA was present, but digested as was expected the unmethylated ones. Very
small (13-bp) fragments were unable to be seen because of the sizes of the DNA ladders
used during the electrophoresis. Very large (2073-bp) fragments should sit on the top of
the gel, based on their high molecular weight. Two big fragments that appeared on the
top of the gel, in the case of dcm−, digested by EcoRII, may have been derived from the
fragmented ends (5’ or 3’) of the circular plasmids strands. Also, positive control for both
dcm+ and dcm− was used, including either of the templates (dcm+ or dcm−) and water.
Evidently, the use of the specific pair of enzymes, as described above, was proved to work
successfully as a preliminary method of distinguishing as well as characterising methylated
from unmethylated sequences of pUC19.
PCR: primer annealing temperature
In parallel with the process of validation of pUC19 plasmid DNA via restriction digestion
analysis, a first attempt was made to design gene specific primers that would have the
ability to anneal to targeted methylated sequences and can further be used to detect DNA
methylation through PCR amplification, by amplifying the methylated gene regions selec-
tively and further on through pH-PCR, via detecting the pH changes of the reaction volume
before and after PCR using a commercially available ISFET pH sensor.
A first step was to run a gradient temperature PCR amplification on pUC19, Table 4.3,
in order for the optimal annealing temperature of the designed methylation-specific primers
to be determined, a critical step for the optimisation of amplification using the primer
pair shown on Table 4.2. What was observed was a very good annealing of the primer set
p19.F6/p19.R6 for dcm+ pUC19, which was justified by the fact that there was obtained
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Figure 4.9: Gradient PCR using the primer set p19.F6/p19.R6 for 6 different temperature
values using pUC19 as a DNA template. The primer set p19.F4/p19.R4 was used as positive
control.
100% alignment match with the parent template pUC19, observation that was apparent
from the gel images and the clear bands of Fig. 4.9. The best annealing temperature of
the primer set was found at 66oC with a resulting amplified product of 322-bp long, as
defined by the DNA ladder loaded in the gel. The primer set p19.F4/p19.R4 was used as
the positive control, with an amplified product of 379-bp.
pH-PCR
After having adjusted the pH of the pre-amplification reaction volume in the range of pH
8.00 in order for an amplification to be observed after the completion of the thermocycling
program, displayed in Table 4.5, as explained in Section 4.3.1, pH measurements were taken
after 5 cycles of the initiation of the PCR program and then compared to the ones taken
after the completion of 40 cycles. The results of the pH drop of the reaction mixtures are
shown in Fig. 4.10a.
There is observed a higher pH drop between 5 and 40 cycles for the methylated DNA
(pUC19 dcm+) extension reaction mixture (M1-M3) compared to the unmethylated DNA
(pUC19 dcm−) reaction mixture (U1-U3) that showed no amplification due to the selectivity
of the primers to anneal only to the methylated DNA template. More specifically, it can be
seen that the pH values obtained, post PCR, from the methylation-specific DNA extension
reaction, started from an average value of pH=7.62 at 5 cycles and then experienced a drop
of 0.44 reaching an average of pH=7.18 after 40 cycles.
On the other hand, for the after pH-PCR reaction mixture containing the unmethylated
DNA template, the measured pH values of 5 cycles reached on average a pH=7.69 and then
dropped after 40 cycles to a pH=7.41, with a lower drop of 0.28 pH values being observed
due to the absence of methylated DNA, therefore distinguishing whether the ISFET sensor
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Figure 4.10: Methylation-specific pH-PCR in-tube: (a) average pH drop from 3 trials of
triplicates in the cases of methylated/unmethylated pUC19. Error bars are also adapted
in both charts based on the standard deviation of the pH recordings, (b) results of DNA
extension reaction in triplicates for methylated pUC19 DNA (M1, M2, M3) compared to
no extension reactions taking place for unmethylated pUC19 DNA (U1, U2, U3). Non-
Template Control (NTC) was also clear showing no contamination of the reaction.
Table 4.6: pH average values between 5 and 40 cycles of pH-PCR (3 trials) for methylated
pUC19 DNA (M) vs unmethylated pUC19 DNA (U) together with resulting ∆pH and
standard deviation values for both reaction mixtures.
Cycle no. pH-M (avg) pH-U (avg) std-M std-U ∆pH-M ∆pH-U
5 7.62 7.69 0.02 0.01
0.44 0.28
40 7.18 7.41 0.04 0.11
could detect or not a DNA extension reaction due to the presence of methylated DNA. A
comparison between the pH signals obtained from the result of amplification of methylated
DNA (pUC19 dcm+) versus the non-amplification product due to the presence of unmethy-
lated DNA (pUC19 dcm−) together with calculated standard deviation values from 3 trials
are displayed on Table 4.6.
Finally, after completing the pH measurements, the amplified products were then re-
solved in a 1.75% agarose gel in 1xTBE buffer, where the bands of the correct DNA fragment
size were confirmed through agarose gel electrophoresis for methylated/unmethylated DNA.
The agarose gel was left running for 15min with a constant voltage of 220V. The results are
shown in Fig. 4.10b, illustrating that the methylated DNA template (pUC19 dcm+) was
amplified and so the gene-specific primers designed specifically for the methylated DNA
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target did anneal, producing the correct size of a DNA fragment (322-bp) as appears in the
gel image. Also quantification of the amplified products after the end of the PCR program
was performed, reaching a 104 fold of amplification.
It is therefore clear that the ISFET as a pH sensor can be used for DNA methylation
detection, structuring an initial proof-of-concept approach through the use of pH-PCR,
showing the ability of successfully distinguishing the relatively bigger pH drop derived from
a DNA extension reaction of a methylation-specific DNA template, after being annealed by
a set of gene-specific primers, compared to an unmethylated DNA template, hence providing
a robust tool for differentiating and distinguishing DNA methylation in two DNA samples.
4.4 DNA methylation detection using pH-LAMP
Following to the development of a proof-of-concept multiple-staged method for determin-
ing, validating and detecting methylated DNA using the method of pH-PCR as has been
explained in detail in Section 4.3.1, a DNA methylation assay was also developed, with an
enhanced sensitivity of detection, compared to the assay developed in Section 4.3.1, using
the method of pH-LAMP [1] for the promoters of two genes (DAPK1, CDKN2A/p16-
INK4 (p16)), as shown in [32]. The purpose of this was to prove that DNA methylation
can be detected under isothermal conditions as well, with the signal of amplification to
be sensed by both a commercial ISFET sensor (Sentron Europe B.V.) and ISFET sensors
integrated in CMOS in real-time using the label-free System-on-Chip (SoC) platform, as
described by [1, 3]. The SoC platform is an ion-sensitive semiconductor based platform,
bringing simultaneous amplification and detection of nucleic acids together on a single chip,
by performing real-time monitoring of the pH of the amplification reaction thus sensing the
hydrogen ions generated. In this research, the chemical front end of the SoC platform was
developed especially for the need of DNA methylation detection to achieve optimal condi-
tions for gene-specific isothermal amplification, demonstrating a robust and highly sensitive
method while highlighting the potential for a large multiple gene on-chip methylation anal-
ysis, taking advantage of CMOS technology.
The sequence of the two gene promoters was cloned in the plasmid vector pUC57 by
GeneScript in both a methylated and unmethylated state after bisulfite treatment and
methylated-specific primers were used to amplify only the methylated regions in each gene
case, as reported by [33]. The methylated state of the genes (DAPK1M and p16M ) was
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defined as all methylated cytosines remaining unaltered after bisulfite treatment while un-
methylated cytosines being converted to uracils. The unmethylated state of the genes
(DAPK1U and p16U ) was defined as all cytosines being converted into uracils after bisul-
fite treatment. Non-Template Control (NTC) was used as a negative control (chemical
reference) for the in-tube tests and on the SoC platform (Chamber 2, Fig. 4.12).
4.4.1 Materials and Methods
Chemicals, Biochemicals and Oligonucleotides
Plasmids for pH-LAMP were synthetically generated by GeneScript and oligonucleotides,
as primers for pH-LAMP, were synthesised by Integrated DNA Technology (IDT). Other
agents parts of the LAMP buffer such as KCl, NaOH, NH4Cl, MgSO4, Betaine, Triton-
X 100, BSA, dNTPs and water were supplied by Sigma-Aldrich. Bst polymerase was
supplied by New England BioLabs. Oligonucleotides were dissolved in Sigma water at
desired concentrations upon the first use and stored at -20oC.
DNA targets
Purified synthesised plasmid DNA (pUC57) was used as the DNA target, incorporating the
target sequences of two gene promoters of the genes DAPK1 or Death Associated Protein
Kinase 1 [34] and CDKN2A or Cyclin−Dependent Kinase Inhibitor 2A also known as
p16-INK4 (p16) [35], in a methylated and unmethylated state, emulating the two scenarios
of a gene promoter after bisulfite treatment. These two genes were selected in specific
due to the fact that their disrupted DNA methylation profile has been reported to play
a significant role in influencing several antitumour pathways when hypermethylation in
the CpG islands of their promoters occurs. In more detail, DAPK1 is related to the
stage of apoptosis or programmed cell death [36] also recognised as a tumour suppressor
gene related to metastatic tumour stages, one of the first being found to be methylated in
cancer [37], with the CpG hypermethylation occurring in the promoter regions of the gene
playing a significant role in cancer development of different organs [38–40]. Additionally,
p16 gene takes part in regulatory mechanisms of cell cycle and is a well-characterised tumour
suppressor gene, the promoter methylation of which is considered as a major mechanism
of the gene’s inactivation and loss of transcription in numerous primary tumours when
hypermethylation of normally unmethylated CpG islands in the promoter region of the
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gene occurs [41, 42].
The principle of the LAMP method
The method of Loop-Mediated Isothermal Amplification (LAMP) was first introduced by
Notomi et al. [11], providing fast DNA amplification with high efficiency and specificity for
the target sequence, under isothermal conditions. Due to its design, it is considered as highly
selective for the target sequence given that four different primers (FIP, BIP, F3, B3) are used
to recognise six genetic regions of the targeted gene, bringing the accuracy level relatively
high even when few copies of DNA are available for analysis. The amplification occurs in
loops with the aid of two additional loop primers (LF and LB). Unlike PCR, LAMP does
not require the step of denaturation of the DNA template [43] given the ability of a DNA
polymerase enzyme (Bst polymerase from Bacillus stearothermophilus DNA polymerase
I [44]) to perform auto-cycling strand displacement DNA synthesis. This is initiated by the
inner primers (FIP and BIP), Fig. 4.11, with sequences of the sense and antisense strand of
the DNA target followed by the outer primers (F3, B3) which displace the annealed strand
with the aid of Bst polymerase, releasing a single DNA strand, forming a “dumbbell” shape,
which promotes the cycling amplification process at a constant temperature [11, 45]. The
result of LAMP amplification is consisted of fragments of double-stranded DNA of variable
length, with the initial few copies of DNA been amplified in less than an hour, in high
specificity [11]. We proceed by validating DNA methylation detection using the method of
LAMP using first commercial ISFET pH sensors (Sentron) in PCR tubes (in-tube tests)
and then ISFETs in CMOS using the SoC platform.
Method: pH-LAMP in-tube
pH-LAMP was performed initially for both gene assays (DAPK1M/DAPK1U and p16M/
p16U ), whereby a commercially available Al2O3 ISFET sensor with an Ag/AgCl reference
electrode was used (Sentron Europe B.V.). The ISFET as a pH sensor was used to show
that a methylation-specific LAMP reaction could be monitored given the release of hydrogen
ions as a result of successful incorporation of nucleotides. pH-LAMP was carried out for
both gene assays in triplicates in a total 35µl reaction mixture consisted of 50mM KCl,
2.5mM NH4Cl, 6mM MgSO4, 1M Betaine, 1mM NaOH, 0.1% Triton-X 100, 1mg/ml
BSA, 2.8mM dNTPs, 30U of Bst DNA polymerase, 1.6µM each FIP and BIP, 0.2µM each
F3 and B3, 0.8µM each LoopF and LoopB and 1pg/µl (equivalent of 105 copies after a
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Figure 4.11: Principle of LAMP method adapted from [11]. Steps 1-8 represent the starting
points of LAMP amplification, with DNA synthesis starting with the primer FIP (F2+F1c)
(step 1) whereby the region F2 anneals to the complementary F2c on the DNA target,
initiating DNA extension, with the process to continue with the primer BIP (B2+B1c)
(step 4). Primer F3 anneals to the complementary F3c targeted region, initiating strand
displacement and DNA synthesis (steps 2, 3), while the 5’-3’ single strand is being released
(step 3), forming the first loop structure, creating a “dumbbell” shape (step 5). The cycling
amplification step then starts with the structure of step 5 being used as the template for
DNA synthesis, to continue with primer FIP annealing to a single strand from the 3’ end
of the F1 region to the F2c region (step 6, 7), creating a loop structure. Through step 8,
this leads to step 9 where one more “dumbbell” shape is produced, complementary to the
one of step 5 [11].
3-fold serial dilution from 108) of each methylated/unmethylated DNA, forming the lowest
limit of detection of this assay. The pH of the reaction mixture was adjusted between 8.15
and 8.8 as a pre-amplification pH range based on the DNA methylation assay’s kinetics.
The program was performed with the aid of a PCR machine (Applied Biosystems, Life
Technologies). To increase the buffer capacity of the reaction mixtures and to stabilise
the amplification process, additives including monovalent and divalent ions were contained.
The temperature of the isothermal program was set at 63oC after having been optimised
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Figure 4.12: ISFETs in CMOS for real-time detection of methylated DNA versus unmethy-
lated DNA using pH-LAMP in the 3-chamber SoC with (a,i) indicating the integration of
a microfluidic assembly in chambers interfacing with CMOS ISFETs and (a,ii) showing the
area where CMOS ISFETs, temperature sensors, digital IO and ADCs are embedded. Im-
age of the fabricated CMOS die in 0.35µm process on (b) indicates the 3 reaction chambers
and location of ISFET sensors.
for methylation-specific primer annealing for both gene assays and was maintained stable
throughout the amplification for a duration period of 2100s (35min). The reactions were
interrupted once at 180s (3min) from the starting point of pH measurements. The reaction
was left running for real-time monitoring of the pH signal. After the completion of the
program, the reaction mixtures were cooled down to room temperature and then the final
pH was measured for both methylated and unmethylated reactions of both genes. Finally,
the amplification yield was quantified using the fluorescent based Qubit Fluorometer (Qubit
& Quant-iT HS kit, Life Technologies). Agarose gel electrophoresis was run to confirm the
result of methylation-specific amplification.
Method: Real-time pH-LAMP on semiconductor integrated CMOS chip
Both assays (DAPK1M/DAPK1U and p16M/p16U ) were applied on the CMOS chip to
achieve real-time detection of methylation-specific areas using pH-LAMP. After mixing the
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Table 4.7: pH average values at 180s and 2100s of pH-LAMP in-tube (10 trials) for
DAPK1M vs DAPK1U together with resulting ∆pH and standard deviation values for
both reaction mixtures.
Time pH-M (avg) pH-U (avg) std-M std-U ∆pH-M ∆pH-U
180s 8.24 8.18 0.08 0.06
1.91 0.07
2100s 6.33 8.11 0.05 0.08
Table 4.8: pH average values at 180s and 2100s of pH-LAMP in-tube (10 trials) for p16M vs
p16U together with resulting ∆pH and standard deviation values for both reaction mixtures.
Time pH-M (avg) pH-U (avg) std-M std-U ∆pH-M ∆pH-U
180s 8.29 8.27 0.07 0.05
1.58 0.06
2100s 6.71 8.21 0.05 0.06
reagents including the assay-specific primers, a small fraction was loaded in the chambers
of the IC as seen in Fig. 4.12. For each assay in particular, Chamber 1 contained the
methylated ”version” of each gene (DAPK1M or p16M ), Chamber 2 a chemical reference
control mixture lacking a dNTP (in this case dCTP) and Chamber 3 the unmethylated
”version” of each gene (DAPK1U or p16U ). A common temperature of 63
oC was set through
the heating elements of the IC to allow for isothermal conditions of amplification on the chip.
The pH of the reaction mixture was adjusted between 8.15 and 8.8 as a pre-amplification pH
range based on the DNA methylation assay’s kinetics. After the completion of the program,
the reaction mixture was removed from the chip and fluorescent based quantification of the
amplification yield was performed using the Qubit Fluorometer (Qubit & Quant-iT HS
kit, Life Technologies). Agarose gel electrophoresis was finally conducted to confirm the
amplification observed real-time from the IC’s interface.
4.4.2 Results
pH-LAMP in-tube
To prove the concept of methylation-specific pH-LAMP using ISFETs, initial tests in-tube
were performed (10 trials in total) following the process explained in Section 4.4.1. The pH
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Figure 4.13: Methylation-specific pH-LAMP in-tube: triplicates of pH-LAMP for isothermal
assays designed to detect DAPK1M (a) and p16M (b). Results of DNA chain extension
reactions are shown in both (a) and (b) due to the presence of methylated DNA (M1, M2,
M3). No extension reactions take place due to the presence of unmethylated DNA (U1, U2,
U3). Non-template control also came clear showing no contamination or any nonspecific
amplification in the reaction. A bar chart on the right hand side reveals the average pH
drop from 10 trials of triplicates, in the cases of methylated DNA (DAPK1M , p16M ) as a
result of amplification happening in both DAPK1 and p16 assays. No significant pH change
was detected in cases of unmethylated DNA (DAPK1U , p16U ). Error bars are also adapted
in both charts based on the standard deviation measured values of the pH recordings.
sensitivity of the assays was tested based on the occurrence of a DNA chain extension re-
action happening in the presence of target sequences of methylated DNA. Results as shown
in Fig. 4.13 illustrate that a methylation-specific reaction took place in both gene assays,
using primer sets specifically designed for each methylation-specific gene assay, amplifying
the genetic areas complementary to DAPK1M in Fig. 4.13a and p16M in Fig. 4.13b ac-
cordingly, showing a repeatable signal of detection, with the final pH values of the amplified
reactions to be in the range of 6.3-6.8 pH.
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In parallel to the previous results, reaction mixtures including the unmethylated genes
(DAPK1U or p16U ) in both assays did not produce a signal as a result of the absence of
extension reaction due to the inability of dNTPs to be incorporated since primers were un-
complementary to the unmethylated areas. The results of pH measurements of 10 trials for
both methylation-specific pH-LAMP assays are also shown in Fig. 4.13a,b with the average
pH change between 180s (3min) and 2100s (35min) seen in the presence of DAPK1M reach-
ing the value of 1.91 as seen in Table 4.7, compared to 0.07 seen in presence of DAPK1U .
In parallel to this, the average pH change for the same time duration in presence of p16M
reached the value of 1.58 compared to 0.06 in presence of p16U , Table 4.8. It is therefore
clear that the ISFET as a pH sensor can be used for DNA methylation detection using
pH-LAMP, showing the ability to successfully and repeatedly distinguish the significantly
big pH drop derived from the extension reactions of two methylation-specific genetic areas
annealed by methylation-specific primers, together with an in-parallel amplification quan-
tification. The results of quantification of the 10 trials of the amplified methylated products
showed a good fold of amplification reaching 105 times the initial copy number of the starting
amplicon for DAPK1 and p16 assays.
Real-time pH-LAMP on semiconductor integrated CMOS chip
Furthermore, both gene assays were applied on-chip, as per description in Section 4.4.1,
using the 3-chamber SoC platform as illustrated in Fig. 4.12. 7 chips were run for each
assay. Results from the isothermal pH-LAMP assay appear in Fig. 4.14a for the DAPK1
assay and in Fig. 4.14b for the p16 assay. Results of multiple chip runs are shown with the
real-time traces derived from Chip 1 appearing on the left hand side of both figures. The
reactions exhibited a good amplification response in the time period of 50min, with the final
plateau of amplification of DAPK1M to take place at 2000s and at 2500s for p16M .
In the DAPK1 assay, DNA extension reaction took place due to the presence of primer
sets complementary to DAPK1M , amplifying the targeted methylated region as seen in
Fig. 4.14a, exhibiting a maximum real-time differential signal change of 37mV detected
by the ISFET sensors of Chamber 1 (shown in pink and yellow), being a strong indicator
of DAPK1M detection. Consequently, primers showed an uncomplementary behaviour
towards the target sequence of DAPK1U as shown by the traces derived from the ISFET
sensors output of Chamber 3 (shown in green and orange). Chamber 2 showed a stable
signal at 0mV as it was used as a chemical reference to indicate the validity of the result in
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Figure 4.14: Real-time methylation-specific pH-LAMP on-chip together with gel elec-
trophoresis validation for (a) DAPK1 gene and (b) p16 gene
terms of purity of product.
Similarly, for the p16 assay, primer sets were used complementary to p16M , Fig. 4.14b,
amplifying the targeted region, reaching a maximum real-time differential signal change of
23mV detected by the ISFET sensors of Chamber 1 (shown in pink and yellow), indicating
the detection of p16M . Primers were uncomplementary to p16U as shown by the traces
derived from the ISFET sensors output of Chamber 3 (shown in green and orange) therefore
no DNA extension reaction products were found. Chamber 2 gave a stable signal at 0mV
as should provide a chemical reference.
In both assays, pH-LAMP in-tube tests were performed in parallel from the same re-
action cocktail that was dispensed on the chip, as can be seen in Fig. 4.14 for both genes.
The purpose of this was to validate the result of the on-chip amplification products of
DAPK1M and p16M , confirming accurate real-time DNA methylation amplification and
DNA methylation detection using ISFETs 110
0
5
10
15
20
25
30
35
DAPK1 p16
Di
ﬀ
er
en
ti
al
 s
ig
na
l c
ah
ng
e 
(m
V)
pH-LAMP on-chip statistics
       1        3        3       1
Average ΔV_M
Average ΔV_U
(chamber 1)
(chamber 3)
Figure 4.15: Chip statistics from real-time pH-LAMP results for both assays as has been
shown in Fig. 4.14 for DAPK1 (a) and p16 (b) genes. Chip statistics indicate the average
differential voltage change for DAPK1M and p16M (blue) versus DAPK1U and p16U (red)
respectively. Results from 7 chips are displayed for DAPK1 and p16 assays. Methylated
products are inserted in Chamber 1 and unmethylated products in Chamber 3 of the SoC.
Chamber 2 was used as a negative control chemical reference.
detection using pH-LAMP. Products from Chambers 1, 2 and 3 were removed from the
chip after the end of the pH based monitoring process and a gel electrophoresis was run
to confirm amplification followed by quantification of the products, with the results from
the real-time on-chip pH-LAMP overlapping with the results obtained from the pH-LAMP
in-tube.
Chip statistics were finally performed from the real-time on-chip trials. For both assays,
chips in groups of 7 were running giving us the differential voltage response as shown in
Fig. 4.14. The average values of the differential signals obtained are shown in Fig. 4.15 for
bothDAPK1M/DAPK1U and p16M/p16U targeting a mean of 30mV ±5.25 forDAPK1M ,
3.13mV ±1.18 for DAPK1U , 19.14mV ±2.91 for p16M and 4.37mV ±0.6 for p16U as stated
in Table 4.9 and Table 4.10. It is clearly seen that the signal sensed by the ISFET sensors
in the presence of methylated DNA is more than 5 times bigger than the signal generated
by the unmethylated DNA in both cases.
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Table 4.9: Average values of differential signal change, ∆V (mV), during pH-LAMP on the
SoC platform (7 trials) for DAPK1M vs DAPK1U together with standard deviation values
for both reaction mixtures.
Time Duration (avg) ∆V -M ∆V -U std-M std-U
4000s 30 3.13 5.25 1.18
Sensitivity of the SoC platform has been estimated to be 25mV/pH
Table 4.10: Average values of differential signal change, ∆V (mV), during pH-LAMP on
the SoC platform (7 trials) for p16M vs p16U together with standard deviation values for
both reaction mixtures.
Time Duration (avg) ∆V -M ∆V -U std-M std-U
4500s 19.14 4.37 2.91 0.6
Sensitivity of the SoC platform has been estimated to be 25mV/pH
4.5 Summary
This chapter presents work demonstrating that the ISFET as a pH-sensing device can be
ideally used for DNA methylation detection through methylated specific pH-mediated DNA
amplification under both thermocycling and isothermal conditions. To achieve this, a series
of biochemical protocols were followed to naturally produce methylated/unmethylated DNA
(transformation of plasmid, DNA purification, DNA quantitation) as well as to determine
the presence of DNA methylation in a DNA target (pUC19) which was validated through
the process of restriction enzyme cleavage. This was followed by DNA extension reactions
through the method of PCR to determine the optimal temperature for primer annealing in
targeted methylated areas. The final stage of DNA methylation detection was performed
by using the method of pH-sensitive amplification pH-PCR, specifically optimised for the
methylated state of pUC19 (dcm+). The methylation-specific amplification, occurring as a
result of a DNA extension reaction, was governed by a drop in pH, twice as much as the
pH resulting from no amplification and thus no DNA extension reaction taking place in
presence of unmethylated DNA, with the pH being measured by a commercially available
ISFET sensor (Sentron Europe B.V.). This led to the development of the proof-of-concept
approach of using commercially available ion-sensitive semiconductor technology for DNA
methylation detection using the method of pH-PCR in-tube.
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Moreover, the first semiconductor based label-free electrochemical approach for DNA
methylation detection using CMOS based technology for two well-known tumour suppres-
sor genes (DAPK1 and p16) was demonstrated using the method of pH-LAMP isother-
mal amplification. For each gene, an optimised methylation-specific biochemical platform
was developed leading to pH-sensitive amplification standardised initially in-tube and then
tested real-time on-chip using the fully integrated SoC platform using ISFET sensors in
CMOS [1, 3]. The ability for DNA methylation detection was demonstrated, combined
with sensing of the signal of DNA amplification in pH by the ISFET, generating a strong
differential output signal, therefore distinguishing methylated from unmethylated DNA in
each gene case.
The pH sensitivity of the assays was tested based on the occurrence of a DNA chain
extension reaction happening in the presence of target sequences of methylated DNA. Initial
results of pH measurements from in-tube tests were shown for 10 trials of pH-LAMP assays
of both genes, exhibiting an average pH signal change of 1.91 for DAPK1M and of 1.58 for
p16M achieving a very good discrimination between methylated and unmethylated DNA.
The amplified methylated products of 10 pH-LAMP trials were quantified showing a good
fold of amplification reaching 105 times the initial copy number of the starting amplicon for
both assays. Following on to this proof-of-concept of methylation-specific pH-LAMP using
the ISFET, results of real-time pH-LAMP on-chip from the SoC platform revealed a good
differential voltage change for methylated DNA, reaching 37mV for DAPK1 assay and
23mV for p16 assay compared to no considerable differential voltage change been generated
for unmethylated DNA in both assays. Finally, CMOS chip statistics for 7 dies validated
the sensitivity of the real-time methylation-specific pH-LAMP on-chip, exhibiting average
values of differential voltage signals for methylated DNA more than 5 times bigger than the
signals coming from unmethylated DNA.
The use of the SoC platform brings real-time amplification and detection of DNA methy-
lation into a perspective of highly multiplexed integration of multiple gene methylation-
specific analysis on a single disposable silicon microchip, with the full integration of ISFET
sensor arrays in CMOS combined with sophisticated microfluidics on a single platform, high-
lighting the potential for simultaneous DNA methylation reaction monitoring in presence
of hypermethylated tumour suppressor genes directly correlated to specific tumour types.
This proof-of-concept will now allow us the realisation of novel integrated systems in CMOS
for DNA methylation detection.
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Chapter 5
An analogue ratiometric method
for DNA methylation detection
5.1 Introduction
The need for detection of aberrancies of DNA methylation in tumour suppressor genes,
genes whose partial or complete inactivation leads to an increased likelihood of cancer
development, appears to be one of the most important assays in early cancer diagnosis and
so the demand for prognostic and predictive markers has been strongly desired [1, 2].
Many array based methods for DNA methylation analysis have been developed in the
past at a genome-wide scale or a single-gene level, consisting of methods for chemical pro-
cessing of DNA samples, identification of targeted regions followed by statistical processing
algorithms, aiming to profile DNA methylation patterns as well as process DNA methyla-
tion measurements. A common sequence of events is essentially adopted to achieve that,
consisting of methods that involve the collection of samples in the form of remote media
i.e blood, sputum or urine followed by a sample preparation step including the purification
of samples and DNA extraction. These are then followed by chemical modifications of the
targeted DNA regions, with the most widely used technique, the bisulfite conversion, to
be applied so that DNA is modified in a methylation-dependent way using primers, specific
to the converted sequences. Such methylated sites can be distinguished from unmethylated
ones, with methylated sites to be considered as those with more than 50% methylation
existent compared to unmethylated sites as those with less than 50% methylation existent,
as reported by [3]. This allows DNA methylation information to be preserved during the
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sample processing steps, which is distinguishable from the rest of the highly concentrated
genetic information carried in the genes and then amplified to provide a detectable signal,
ready to be analysed in detail.
Several methods have been adopted for DNA methylation analysis as has been reported
in Chapter 2. One of these which has been proven most important for performing a quan-
titative analysis on DNA methylation is the computation of ratio fractions or percentages
of DNA methylation levels [4]. This can be described as:
%Meth =
M
M + U
× 100% (5.1)
where M stands for the signal from methylated sites and U for the signal from unmethy-
lated sites1. Using this ratio we can formulate a process for detecting the level of aberrancy
of DNA methylation existent in genes of interest, specifically in areas responsible for the
expression of tumour suppressor genes, enabling us to determine the differences between a
pathogenic gene and a healthy gene, whose under investigation genetic areas are unmethy-
lated. This would allow the development of an early detection tool to identify early warning
signs of cancer.
When implementing such a tool for a Point-of-Care (PoC) system, there is a need for
an efficient low power system to detect this ratio. Conceptually, the system will be as
shown in Fig. 5.1. It will include two sensors to measure methylated/unmethylated DNA
and then compute the ratio between the two. If the ratio exceeds a certain percentage, it
will give a YES/NO result, indicating if the under investigation genetic region is aberrantly
methylated (YES) or normally unmethylated (NO). The purpose would be the detection of
the methylation status of genetic sites of interest using a ratiometric approach that would be
able to calculate the ratio between the methylated DNA of a gene site possibly correlated to
pathogenesis and the unmethylated version of the same gene site, showing no aberrancies,
therefore corresponding to the normal status of it. The detection of the level of methylation
is possible with two ISFETs, one to detect methylated DNA and the other unmethylated
DNA respectively.
As demonstrated in Chapter 4, the methylated and unmethylated DNA based informa-
tion needed for the computation of the ratio can be obtained from the amplification of the
1Resulting measurements vary from 0 to 1 or 100%, where 0 indicates that no methylated sites have
been identified while 1 or 100% indicates that all identified sites are methylated.
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Figure 5.1: System level block diagram of the ratiometric computation method towards the
detection of DNA methylation
methylated/unmethylated region of the DNA sample through a hydrolysis reaction, detect-
ing the production of hydrogen ions, which will cause a change in pH as described by the
reaction:
dNTP +DNAn → PPi +DNAn+1 +Mg2 +H+ (5.2)
releasing pyrophosphate and hydrogen ions in the presence of a DNA polymerase en-
zyme, as described in Section 4.2, Chapter 4. For the purpose of DNA methylation detection,
a single-stranded methylation-specific DNA probe can be designed to identify a methylated
site of the DNA target and distinguish it from the equivalent unmethylated one. Hydro-
gen ions will therefore be released in solution, resulting to a pH drop as a result of DNA
amplification taking place when the targeted genetic region containing methylated DNA is
detected, using the methylation-specific primers annealing only the complementary methy-
lated regions in the under investigation gene. This could then allow the implementation of
the ratio using an electronic circuit.
What is required for a Point-of-Care system is circuits capable of continuous calculation
of the methylated/unmethylated DNA ratio, giving a discrete output signal when methy-
lation reaches and exceeds a certain predefined percentage. Additionally, the percentage
threshold should be tunable to the given reaction, operating in low power. A circuit tech-
nique that could allow this by performing division and multiplication of current signals
needed for the ratiometric computation is the “translinear principle”.
This chapter presents a hardware efficient system that can compute the ratio of DNA
methylation. Termed the “Methylation Cell”, it utilises the translinear principle to imple-
ment the system shown in Fig. 5.1. It is able to measure the signal from a DNA extension
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reaction taking place due to the presence of methylated DNA sensed by a CMOS based
ISFET sensor (ISFETX1), compared to a no reaction signal sensed or measured by an
ISFET in a separate reaction chamber (ISFETX2). This is followed by a comparison block
that would provide two alternative ways (voltage-mode or current-mode) to get a binary
answer (YES/NO) based on an applied threshold given the result of the reaction or the
value of the ratio calculated from the “Methylation Cell”. The contents of each block and
the cell’s ability to compute the ratio and to distinguish methylated from unmethylated
DNA sites using the translinear principle shall now be described.
5.2 The translinear principle
In electronics, a very convenient way of conducting multiplication or division of current
signals derived from transistors in saturation is by using circuits that exploit the exponen-
tial current-voltage characteristic of the devices through a process which is known as the
“translinear principle” [5–8].
The term translinear was originally suggested by Barrie Gilbert in 1975 for bipolar
transistors (BJT), based on the fact that their transconductance is linearly proportional to
the collector current of a BJT so as to aim for ”fundamentally exact, temperature-insensitive
algebraic transformations” [5]. Not until the early 1990s, did Gilbert distinguish the use of
translinear circuits for general application purposes based on the original definition, from
circuits whereby both inputs and outputs are in the current domain, enclosing one or more
closed translinear loops, therefore offering an effective way for building current-mode circuits
and systems with small voltage variations [6].
The translinear circuit principle was extended for implementation by MOS transistors
operating in strong inversion in 1991 by [7] followed by [8] to weakly inverted MOS transis-
tors, exploiting the exponential relationship between current and voltage in this region. The
principle of operation can be described by considering diodes connected in a loop, Fig. 5.2,
whereby each diode represents the VGS of a MOS transistor in weak inversion. These can
form single or multiple loops whereby the number of transistors arranged clockwise equals
to the number of transistors arranged counterclockwise, with the loop containing an even
number of devices [5, 7]. Applying Kirchhoff’s voltage law, the gate-source voltages of the
MOS transistors around the loop now follow the expression [7]:
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Figure 5.2: Translinear loop consisted of four diodes
∑
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∑
CCW
VGS (5.3)
where CW and CCW stand for clockwise and counterclockwise connected MOS tran-
sistors respectively. This is more clearly illustrated in Fig. 5.2 whereby the VGS drop of
the MOS transistors is represented by the voltage across a forward biased diode which also
follows an exponential relationship. A closed loop is then formed where the summation
of the VGS of the devices connected clockwise equals to the summation of the VGS of the
devices connected counterclockwise:
VCW1 + VCW2 = VCCW3 + VCCW4 (5.4)
Given that VGS expressed as:
VGS = nUtlog
IDS
Io
(5.5)
is logarithmically related to the devices drain-source current, IDS , the addition of VGS
leads to products of currents through the addition of logarithms, which leads to a rela-
tionship between the current densities (current/area) in the clockwise direction, being also
equal to the current densities in the counterclockwise direction [5, 8]:
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∏
CW
current density =
∏
CCW
current density (5.6)
If we now replace the diode connected voltages or the gate-source voltages of the weakly
inverted MOS transistors with their respective drain currents, ID, which are expressed
by [9]:
ID = IoSe
VGS
nUt e
(n−1)VBS
nUt (5.7)
where Io is a characteristic current, S = W/L is the size of the transistors, VGS is the
voltage between the gate and the source, n is the subthreshold slope coefficient, VBS is the
voltage between the bulk and the source and Ut is the thermal voltage, then the summation
of voltages of Eq. 5.4 will be transformed into a summation of natural logs of currents:
ln
IDCW1
Io
+ ln
IDCW2
Io
= ln
IDCCW3
Io
+ ln
IDCCW4
Io
(5.8)
where each current represents the drain current of the MOS transistor in the translinear
loop. The addition of natural logs will then be expressed as the multiplication of currents:
IDCW1IDCW2 = IDCCW3IDCCW4 (5.9)
which may represent the inputs and outputs of the translinear circuit.
Research has shown that the translinear principle can be applied with ISFETs in weak
inversion, thus having a direct application in the field of biomedical engineering [10, 11],
facilitating its use in calculating ratios from biochemical input signals using low power
current-mode methods. The investigation of using the translinear principle in designing
relevant circuits to detect biochemical signals from DNA methylation related reactions
follows in the next section.
5.2.1 The translinear “Methylation Cell”
The translinear “Methylation Cell” shown in Fig. 5.3, as has been first introduced by [12],
is an ISFET based translinear cell, capable of computing the ratio between the output
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Figure 5.3: ISFET based translinear current divider using voltage-mode switching
currents of two ISFET sensors, X1 and X2, implementing the function of the system shown
in Fig. 5.1.
Signals obtained due to the presence of aberrantly methylated tumour suppressor genes
are sensed by the first ISFET sensor, X1 and signals representing the unmethylated version
of the same gene derived from a healthy control are sensed by the second ISFET sensor,
X2. The signal from X1 is then compared to the one from X2 and a ratio is computed,
expressed as an output current, Iratio, formulating a process of using the ISFET to sense
and indicate the level of aberrancy of methylation existent in tumour suppressor genes,
directly correlated with early stages of tumour development. Moreover, a reference current,
Iperc, is used to set a threshold with which Iratio will be compared to, to give a binary
answer when methylation exceeds a predetermined percentage. This is implemented using
a current comparator consisting of a current mirror, a reference current source and a CMOS
inverter, as can be seen in Fig. 5.3.
The theory behind the operation of the translinear “Methylation Cell” is primarily based
on the principles of the ISFET’s operation, as has been described in Chapter 3. In principle,
the ISFET transduces a chemical signal to electrical to give a drain current dependent on
the ionic concentration of the under test solution, while offering an exponential relationship
to pH. The generalised drain current, ID, of the ISFET sensors is expressed by:
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ID = Ioe
VGS
nUt Kchem[H+]
a
n (5.10)
whereby Io stands for the intrinsic current in the device, VGS is the voltage between the
gate and the source, n is the subthreshold slope coefficient and Ut is the thermal voltage,
kT/q, with k the Boltzmann constant, T the absolute temperature and q the electronic
charge. Finally, Kchem is a grouping of constant chemical potentials, a is the sensitivity
parameter for the sensed ions, both of which are temperature independent and [H+] is the
concentration of hydrogen ions in solution.
For the case of methylated and unmethylated DNA, the drain currents, ID, of the ISFET
devices generated in the presence of methylated DNA (X1=meth) and unmethylated DNA
(X2=unmeth) are defined as Imeth and Iunmeth respectively:
Imeth(X1) = Ioe
VGS
nUt Kmeth[meth]
ameth
n (5.11)
and
Iunmeth(X2) = Ioe
VGS
nUt Kunmeth[unmeth]
aunmeth
n (5.12)
The rest of the system is composed of an ISFET based translinear cell (M3, M4, M5, M9)
capable of computing the division between the drain currents, Imeth and Iunmeth. Current
mirrors (M1-M2-M6, M7-M8) are used to input sensor currents Imeth and Imeth+Iunmeth
into the translinear loop in a way such that the ratio can be calculated.
We can see how the ratio is calculated by performing a KVL on the loop indicated by
the arrows of Fig. 5.3 on devices M3, M4, M5, M9:
VGS3 + VGS4 = VGS5 + VGS9 (5.13)
and after substituting for the weak inversion drain current and dividing by nUt we have:
ln
Igain
Io
+ ln
Imeth
Io
= ln
Imeth + Iunmeth
Io
+ ln
Iratio
Io
(5.14)
By using the basic relation of adding natural logs we get the final expression for the
computation of the ratio between methylated and unmethylated DNA represented by Iratio:
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Figure 5.4: ISFET based translinear current divider using current-mode switching
Iratio = Igain
Imeth
Imeth + Iunmeth
(5.15)
whereby Igain is a pre-defined gain term for the ratio computation and Iratio is the
output ratio current. With this calculation, the ratio derived from the “Methylation Cell”
can now be compared to a threshold value set by Iperc showing if it has passed a preset
tunable value.
To implement the comparison block which would allow us to compare Iratio with a
defined percentage value, Iperc, we consider two approaches. These consist (a) of a voltage-
mode switching configuration, as shown in Fig. 5.3, which uses a CMOS inverter (M12,
M13) leading to a voltage output Vout, whereby a logic decision (YES/NO) is based on
a voltage output signal and (b) of a current-mode switching configuration, as shown in
Fig. 5.4, using a winner-take-all (WTA) circuit for a current comparator (M10, M11, M12,
M13), providing a current output Iout and so a logic decision (YES/NO) based on a current
output signal. In voltage-mode switching, the CMOS inverter is switched at a cut-off point
according to the relationship shown in Table 5.1, giving Vout=3.3V when Iratio exceeds Iperc,
whereas in current-mode switching, the WTA comparator causes switching of the output
current giving Iout=1µA when Iratio exceeds Iperc.
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Table 5.1: Cut-off point of the CMOS inverter and voltage/current output of the translinear
cell
Iratio : Iperc Logic Vout Iout
≥ 1 1 3.3V 1µA
< 1 0 0 0
• Voltage-out operation:
In the case of the voltage-mode switching, an increase in [H]+ percentage will lead
to an increase in Imeth and thus in Iratio, resulting in a discharge of the parasitic
capacitance on the input node of the CMOS inverter when the current exceeds the
current Iperc used to set the threshold. This will in turn cause the voltage output,
Vout, to go high giving a discrete indication of a YES/NO answer.
• Current-out operation:
Similarly, for the current-mode switching, when an increase in Iratio exceeds a value of
a preset current, Iperc, the output current of the comparator, Iout, is activated by the
winner-take-all (WTA) regulator to give a discrete logic decision (YES/NO) based on
current determined by Iwta.
The current comparison offered by the ‘comparison block’ can now be used to distinguish
the critical ratio values from the normal ones, for given genetic regions of investigation.
Consequently, this implementation of the ratio of methylation derived from Eq. 5.15 would
be an indication of the level of aberrancy of methylation existent in tumour suppressor
genes of interest, therefore defining an epidemiological factor based on the disruption of
normality of the function of such genes correlated with the level of methylation accordingly.
5.3 Simulation results
The translinear “Methylation Cell” was designed in a typical 0.35µm 2P4M CMOS technol-
ogy using Cadence Spectre (5.1.41isr2) simulator. The design specifications were, a supply
voltage of 3.3V and device sizes optimised at (W/L) 10µm/10µm for all transistors so that
matching errors were minimised and 1/f noise was reduced in weak inversion.
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The translinear “Methylation Cell” characteristics using the voltage-mode switching
comparator were initially tested by applying current values to the current inputs based on
the expected ISFET drain current range for the given device operating dimensions in weak
inversion [13]. The ratio computation was tested by applying a current ramp starting from
1nA as the methylated DNA input, Imeth, and a current source of 10nA, used to simulate
the unmethylated DNA input, Iunmeth. This selection was made to emulate the scenario of
a reaction taking place due to the presence of methylated DNA, monitored as a change in
Imeth, while a steady signal is monitored by Iunmeth due to the absence of methylated DNA
or presence of unmethylated DNA.
For the computation of Iratio, the fixed gain term Igain was set at 10nA in order for a
range of 0-100% to be mapped to Iratio=0-10nA, whereby no methylation present would
indicate 0% ≈ 0nA or methylation at full coverage of the gene site would indicate 100%,
10nA. Also, Iperc was set at 5nA so that the limit of detection was fixed at 50% based
on the definition of methylated sites given in Section 5.1. The results of the simulated
computation of Iratio are shown in Fig. 5.5 with the voltage-mode current comparator to
be switched through the use of the CMOS inverter. For a value of Iratio being above a
desired threshold, set by Iperc, the discrete voltage output Vout of the inverter is interpreted
as a logic YES/NO decision, which in this case means that the voltage output Vout of the
comparator will switch from 0V to 3.3V, when the level of methylation exceeds 50%, as
shown in Fig. 5.5 when Iratio=5nA.
Furthermore, the “Methylation Cell” was simulated for varying incremental percentage
changes in the reference current, Iperc, to demonstrate the effect of tunability on Iratio
and the voltage-mode switching of Vout for different percentages of methylation. Starting
from 0%, the threshold levels increased to 20, 40, 60 and 80% respectively in order for
the transient response of the “Methylation Cell” to be monitored towards the maximum
Iratio that the cell could achieve. The results of the transient response of the “Methylation
Cell” are shown in Fig. 5.6, illustrating the capability of the comparator of the translinear
circuit to compare Iratio to Iperc and thus to switch at a current level as has been set by
the percentage increase.
Additional simulations of the translinear “Methylation Cell” using the current-mode
switching comparator, Fig. 5.4, were conducted, as shown in Fig. 5.7. A current ramp of
1nA to 100nA was applied as the methylated DNA input, Imeth while Iunmeth remained
fixed at a value defined by a current source of 20nA. Igain and Iperc were set at 20nA and
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Figure 5.5: Transient response of the translinear “Methylation Cell” with voltage-mode
switching
15nA respectively. As Imeth is increasing, Iratio is being computed and once a threshold is
reached, defined by Iperc, Iout switches from 0-Iwta indicating a YES/NO answer.
5.4 Fabricated system
The “Methylation Cell” was fabricated, as seen in Fig. 5.8 (bottom), with each ISFET sensor
designed2 with a sensing area of 34µm×100µm and an electrical area of 200µm×1µm, as
shown in Fig. 5.9. The area covered by circuit was 7725µm2 (309µm×25µm).
The fabricated system was encapsulated using a standard epoxy encapsulation proce-
dure, described in Appendix F, with the experimental set-up used for the electrical charac-
terisation of the ISFETs and the common pH buffer solution tests shown in Fig. C.1 and
Fig. C.2, Appendix C. In parallel, a microfluidic assembly in a Lab-on-Chip set-up involving
two isolated chambers, as seen in Fig. 5.10, was used, adapted on the ISFET based CMOS
microchip, with the set-up for electrical characterisation of ISFETs using such configuration
as shown in Fig. C.3, Appendix C.
2ISFET sensors were designed based on measured devices fabricated within the Centre for Bio-Inspired
Technology [14].
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Figure 5.7: Transient response of the translinear “Methylation Cell” with current-mode
switching
The latter set-up was used to expose the ISFET sensors to separate solutions for real-
time monitoring of reactions occurring in isolated chambers. This intends to facilitate
the isolation of a signal monitored from a reaction taking place in one chamber due to the
presence of methylated DNA, compared to no reaction occurring in the twin chamber, due to
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Figure 5.8: Top: Microphotograph of the floorplan of the fabricated die, highlighting in
black the relevant circuit area. Bottom: Magnification of the “Methylation Cell” and of the
two ISFETs connected to it.
the absence of methylated DNA. The platform was also used to prevent cross contamination
of fluid through the chambers, offering a more accurate signal derived from the “Methylation
Cell”.
Both ISFETs were spaced at 500µm from each other to allow ease of integration with
a microfluidic device mounted on top of the silicon microchip, Fig. 5.10a, consisting of two
microchambers, 400µm in diameter, both of a size of 1mm×0.4mm×0.4mm. The sensing
area exposing the ISFETs was defined by the maximum volume of fluid inserted in both
micro-chambers, which was reaching 0.3µl. To define the potential of the electrolyte solu-
tion inserted in the micro-chambers, an Ag/AgCl reference electrode was inserted, passing
through both chambers, Fig. 5.10b, biasing the ISFETs, shown in chambers on Fig. 5.10c,
in the weak inversion region of operation.
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Figure 5.9: Single ISFET sensor with pixel dimensions. Left: Chemical sensing area of the
ISFET. Right: Electrical dimensions of the gate.
5.5 Measured results
Measured results were obtained using (a) an epoxy encapsulation set-up and (b) a mi-
crofluidic manifold Lab-on-Chip set-up. Epoxy encapsulation was initially used to test the
functionality of the electronics and the ISFET sensors in the bucket solutions followed by the
development of a microfluidic manifold to allow in parallel pH sensing using two chambers
with separable pH.
The Lab-on-Chip was experimentally tested using a semiconductor parameter analyser
(Keithley 4200SCS). During all experiments the system was biased at 3.3V and ISFET
currents were biased at a current optimised for weak inversion operation. The ability of the
translinear “Methylation Cell” to perform the computation of ratio in buffer solutions of pH
5-9 was tested as well as during a pH jump between 8.8 and 6.8, indicating the maximum
pH difference that a DNA reaction can produce when DNA methylation is present, shown
by the biochemical reactions produced in Section 4.4, Chapter 4.
pH buffer solutions 5, 6, 7, 8 and 9 were prepared using 100mM Tricine and 1M KCl,
adjusting the pH using 10M NaOH and 1M HCl. All four solutions were provided by Sigma-
Aldrich. A commercially available Al2O3 ISFET sensor with an Ag/AgCl reference electrode
was also used as a pH probe (Sentron Europe B.V.) for conducting the pH measurements
after having completed a calibration process as described in Appendix C. The pH solutions
were titrated in the microfluidic chambers using 20µl Eppendorf micropipette tips.
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Figure 5.10: (a) ISFET based CMOS microchip mounted and encapsulated on pcb with
microfluidic assembly adapted on top. (b) Magnification of the manifold and the two
microfluidic chambers. An Ag/AgCl reference electrode is passing through the chambers,
creating a stable potential to the solution added in chambers. (c) ISFETs visible in both
chambers integrated in the manifold area. The two chambers were spaced at 300µm from
each other.
Experimental results are presented in this section and demonstrate the electrical func-
tionality of the ISFETs in weak inversion as well as their sensitivity under different pH
solutions. The capability of the “Methylation Cell” using a common pH buffer solution is
also proven through a detailed experimental analysis on the computation of Iratio and the
comparator’s switching mechanism through various pH steps.
5.5.1 Measured results using epoxy encapsulation
The initial experimental set-up to test the response of the “Methylation Cell”, involved the
ISFET based CMOS chip covered with epoxy, mounted on pcb with ISFETs exposed in a
common pH buffer solution. The experimental setup is shown in more detail in Fig. C.1
and Fig. C.2, Appendix C. A fixed potential to the solution was set through the use of a
glass Ag/AgCl reference electrode (Sentron Europe B.V.), which was also used to set the
operating point of the ISFET, by applying a suitable bias for the individual devices.
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Figure 5.11: Measured ID-VGS sweep of a pMOS ISFET for pH buffer solutions of 4, 7 and
10 showing the relationship between the drain current, the source gate voltage and the shift
in the threshold voltage for strong inversion (left) and weak inversion (right).
• pH sensitivity :
The DC characteristics of the ISFETs were observed through the ID-VGS measure-
ments, as displayed in Fig. 5.11, which were conducted at three different pH values
(pH 4, 7 and 10) and at room temperature. The ISFET sources were biased exter-
nally and independently at 3.3V and the reference electrode’s voltage was swept from
0V to 3V. The y-axis shows the drain current of the ISFET and the x-axis the gate
voltage subtracted from the source voltage (VGS) of the ISFETs. ID-VGS character-
istics were generated for both strong inversion, Fig. 5.11 (left) and weak inversion
Fig. 5.11 (right), whereby the weak inversion linear region of the drain current can
be observed, for a source gate voltage spreading for approximately 500mV for all
pH values. Moreover, a shift in the characteristic of 90mV due to a change in the
threshold voltage is observed as the pH buffer becomes less acidic, which by relative
calculations shows a sensitivity of 30mV/pH, which is in line with ISFETs fabricated
in unmodified CMOS [14]:
SISFET =
∆VGS
∆pH
=
0.09
3
V/pH = 30mV/pH (5.16)
• Computation of ratio:
After confirming the pH sensitivity of the ISFET and its ability to show a good linear-
ity in weak inversion, the ability of the translinear “Methylation Cell” and specifically
of the translinear circuit to compute the ratio, Eq. 5.15, was tested.
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– Iratio vs Imeth for fixed Igain and Iunmeth:
The ratiometric computation of the translinear cell was tested initially in a buffer
solution of pH 7. The ISFETs source voltages were set at 2V and the voltage
of the Ag/AgCl reference electrode was set at 1.8V, establishing a VGS=200mV.
The output current of the translinear circuit, Iratio, was measured by initially
applying electrically incremental and decremental steps in Imeth by changing VGS ,
while leaving Iunmeth constant for a fixed Igain of 50nA, as seen in Fig. 5.12a,
with the absolute values of the output ratio current Iratio changing as the ratio
is computed, shown in Fig. 5.12c. The steps resulting in increasing or decreasing
the currents were applied by inducing a 50mV change to the ISFET sources
related to Imeth and Iunmeth.
– Iratio vs Iunmeth for fixed Igain and Imeth:
Alternatively, the same procedure was followed by applying changes to Iunmeth
while leaving Imeth constant for the same value of Igain as used previously,
shown in Fig. 5.12b, resulting in absolute changes in Iratio accordingly, shown in
Fig. 5.12d.
For the experiments illustrated in Fig. 5.12a and Fig. 5.12b, it can be observed that Imeth
in Fig. 5.12a was drifting less than Iunmeth in Fig. 5.12a, something that can be portrayed
in the respective current output changes of Fig. 5.12c and Fig. 5.12d. However, what can
be seen from both is that the output of the cell computing the ratio of the input currents
of the ISFETs, Imeth and Iunmeth, given a fixed Igain of 50nA was experimentally validated.
Fig. 5.13 shows more clearly how Iratio was following the changes in Imeth and Iunmeth
during the increasing and decreasing values of the respective ISFET currents in a buffer
solution of pH 7. Fig. 5.13a shows the relationship between Iratio and Imeth and Fig. 5.13b
shows the relationship between Iratio and Iunmeth. The values of Iratio for different Imeth
points during six incremental steps for a constant Iunmeth are shown in Table 5.2. Similarly,
the values of Iratio for different Iunmeth points during four decremental steps are shown in
Table 5.3, taking into account that the constant values of Imeth and Iunmeth respectively
followed different drift trends as shown in Fig. 5.12.
• Iratio vs Igain for fixed Imeth and Iunmeth:
The dependence of Iratio to Igain was also tested for a constant value of Imeth and
Iunmeth set at 100nA, as can be seen in Fig. 5.14, in a buffer solution of pH 7. Igain
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Figure 5.12: Measured transient response of the “Methylation Cell”: shown are (a) varia-
tions in Imeth for constant Iunmeth resulting in Iratio in (c) and (b) variations in Iunmeth for
constant Imeth resulting in Iratio in (d).
Table 5.2: Iratio for different Imeth values and Iunmeth=23.59±0.63(nA)
Imeth(nA) 28.8 40.62 52.85 67.06 84.08 103.6
Iratio(nA) 33.47 35.28 36.90 38.43 39.8 41.07
Table 5.3: Iratio for different Iunmeth values and Imeth=18.14±2.75(nA)
Iunmeth(nA) 31.91 19.98 13.76 9.54
Iratio(nA) 42.82 45.95 47.67 48.94
values varied from 20nA to 200nA. Imeth and Iunmeth were chosen at such value given
the information obtained from the ID-VGS characteristics for both ISFETs in weak
inversion, as seen in Fig. 5.11. It can be seen that there is a linear relationship
between Iratio and Igain, as expected from Eq. 5.15 of Iratio, which is determined by the
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Figure 5.13: Transient response of the “Methylation Cell” illustrating the current loops
between Iratio and Imeth in (a) and between Iratio and Iunmeth in (b) during increasing and
decreasing values of Imeth and Iunmeth as shown in Fig. 5.12.
translinear principle. The value of 100nA was chosen as a DC bias for both ISFETs,
which achieves the most linear operation of the translinear circuit and contributes in
producing the most noticeable and closest to the theoretical value current of Iratio
for a given Igain of 100nA for one pH step, demonstrating the best operation of the
“Methylation Cell” with a minimum offset of recordings. Shown in Fig. 5.14 is a result
of 50% (50nA) when all currents are equal.
The ability of the current comparator to compare Iratio with a current threshold set by
Iperc was tested, by emulating a 1 pH change scenario by applying a change of 50mV in
the VGS of the ISFETs. For the voltage-mode switching circuit, Fig. 5.3, the experimental
analysis on the switching effect of the CMOS inverter included in Section G.2.1, Appendix G,
showed that certain limitations may have arisen such as delays in the discharge time of
the inverter’s node producing a less accurate response. For this reason, the current-mode
switching of the circuit of Fig. 5.4 was used for a more detailed analysis on the response of
the comparator.
To investigate the performance of the current-mode comparator, an initial experiment
was conducted to see how the output of the comparator, Iout, can change as Iratio increases.
The voltage bias for measuring Iout and Iratio was set at 2V to allow the output devices to
be in saturation and the current bias for Iwta was set at 1µA for good output drive strength.
The reference electrode voltage was set to 1.8V. What can be seen in Fig. 5.15 is that Iout
switches from 0µA to 1µA when the reaction of Iratio increases above 50nA, with Iperc set
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Figure 5.14: Measured response of Iratio for varying values of Igain while both Imeth and
Iunmeth are set at 100nA.
at 50nA and Igain=50nA. Specifically for the case of Imeth and Iunmeth, with drain currents
of both ISFETs set at 100nA and Igain=100nA, we can see in Fig. 5.16 that an incremental
change of 1 pH causes Iratio to change from 49nA to 59nA. From this, we deduce that to
best demonstrate the functionality of the circuit for 1 pH change, we can set Iperc=56nA
which will cause Iout to switch.
The information collected from the experimental performance of the “Methylation Cell”
when epoxy encapsulation was selected was taken into account so that the best performance
characteristics of the translinear circuit were to be used under the Lab-on-Chip set-up.
5.5.2 Measured results on Lab-on-Chip set-up
Based on the Lab-on-Chip set-up, Fig. 5.10 (assembly detailed in Section 5.4), the response
of the “Methylation Cell” was tested using retrospective data from the biochemical experi-
ments analysed in Chapter 4. This means that a methylation reaction is to be represented
by a change in pH from 8.8 to 6.8.
Initially, the computation of the current output, Iratio, of the translinear circuit was
experimentally measured in real-time through the microfluidic assembly shown in Fig. 5.10
to confirm functionality. This was achieved by changing the pH of the solution of Ch 1
within a range of fixed pH values, while keeping the pH of the solution of Ch 2 steady at
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Figure 5.16: Iout vs Iratio during 1 pH change for Iperc=56nA and Igain=100nA
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pH 7, emulating the scenario of a chemical reaction taking place in Ch 1, where the ISFET
sensors producing the current Imeth lie underneath the chamber. The solutions selected to
test the response of the circuit were varied from pH 5 to pH 9. Experiments were conducted
separately for the range pH 7 to pH 9 and pH 5 to pH 7 with ascending and descending
steps of ∆pH of 1. Both ISFET sources were biased at 1V due to shifting of the ISFET
operating point by induced trapped charge as a result of assembling using the manifold.
The reference electrode was kept steady at 1.5V based on the ISFET DC characteristics as
shown in Fig. 5.11 to give VGS=500mV, IDS=100nA, focusing on the weak inversion region
of operation, and Igain was tuned at 100nA.
Results are shown in Fig. 5.17 for the range pH 7 to pH 9 and pH 5 to pH 7 with
sequence of display, whereby the response of Imeth and Iratio is observed during ascending
and descending pH values, with Iunmeth kept constant at 100nA. Specifically, Fig. 5.17a,b
illustrate the current response of Imeth and of the absolute values of Iratio during the pH
7-9 steps whereas Fig. 5.17c,d illustrate Imeth and the absolute values of Iratio during the
pH 5-7 steps respectively. This analysis confirms that Iratio is computed experimentally
at a very good precision as expected from the translinear theory and from the theoretical
values derived from Eq. 5.15, showing good response to changes in pH and good resolution,
with a maximum error across all pH values to be found to be 2% from the ideal. Also,
the average, absolute values of Iratio for increasing and decreasing pH values, as shown in
Fig. 5.17, are interpreted in Fig. 5.18 with respect to the range of pH values used (pH 5-9),
separated in pH 7-9 in Fig. 5.18a and pH 5-7 in Fig. 5.18b, showing the cycle of currents
during the rise and fall of pH, also highlighting the effect of drift during the rise and fall of
pH while Iratio is being monitored. The line in red which represents the average of Iratio in
both cases, is giving an indication of the average of the current values for the same pH steps
in both ascending and descending cases. What can be seen is that the ratio is computed
accurately but the drift can distort the result, which can be overcome using techniques such
as differential measurements, as introduced in the next chapter, or letting the ISFETs burn
in.
Additionally, a detailed summary of the average values of Imeth, Iunmeth and Iratio
together with the standard deviation points for the two repeats during the pH steps 7-9
and 5-7 are summarised in Table 5.4 and Table 5.5 accordingly. For the pH range of 7-9
shown in Table 5.4, the standard deviation values observed for the two repeats for a given
pH are within the range of 0nA to 2.828nA with a mean of 0.801nA, given the time frame
of 700sec and the minimum effect of drift.
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Figure 5.17: Transient response of Imeth and absolute Iratio during decremental pH steps
Table 5.4: Average values with standard deviation results of Iratio and Imeth for given
Iunmeth values for two repeats during ascending and descending pH steps from pH 7 to pH
9 for Igain=100nA.
pH=7 pH=8 pH=9 pH=8 pH=7
Imeth(nA) 100 111.5±0.707 128.5±0.707 117±1.414 104±2.828
Iunmeth(nA) 100 101±1.414 103±1.414 103±1.414 103±1.414
Iratio 49.6 51.5±0.707 54 52 49
A more detrimental effect of drift in the same experiment of two more repeats under
different time frames can be seen in Table G.1 in Appendix G. For the pH range of 5-7
shown in Table 5.5, the standard deviation values are slightly larger achieving a mean of
0.942nA, although the values varied from 0nA to 2.828nA. The effect of drift in this case
seems slightly less, an observation that can be correlated with the fact that the drift tends
to decrease in acidic conditions [15].
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Table 5.5: Average values with standard deviation results of Iratio and Imeth for given
Iunmeth values for two repeats during ascending and descending pH steps from pH 5 to pH
7 for Igain=100nA.
pH=7 pH=6 pH=5 pH=6 pH=7
Imeth(nA) 100 91±2.828 81.5±2.121 85.5±2.121 94.5±2.121
Iunmeth(nA) 100 98.5±2.121 94.5±2.121 96 95
Iratio 49 47 45 46.5±0.707 50
Power Consumption
The “Methylation Cell” under test operated in the weak inversion region. The total power
in the system may be calculated as:
P = VDD(3IISFETX1 + 2IISFETX2 + Igain + Iratio + Iperc + Iwta) (5.17)
The system achieves a power consumption of 2.3µW for a biasing current IDC=100nA
for both ISFETs and a gain current Igain=100nA, operating at 3.3V supply, without the Iwta
part which is determined by the drive strength of the circuit. The chip can be operated with
biasing currents of below 10nA, as can be seen in Fig. 5.11, leading to further reductions in
power.
5.5.3 Validation based on real methylated data
After proving the computation of Iratio during a sequence of pH values of ∆pH of 1, the
ability of the translinear circuit during a change in pH from 8.8 to 6.8 was tested. The
selection of these pH values was decided according to the pH values obtained before and
after a DNA reaction occurring when DNA methylation is present in given genetic areas
under investigation, as has been explained in Section 4.4, Chapter 4, where ∆pH was shown
to be able to reach a maximum difference of almost 2 pH.
But above all, in this occasion, the primary aim was to prove that the ratio of two
signals obtained from two separate reactions could be successfully calculated on a Lab-on-
Chip microfluidic environment. The results of such hypothesis are displayed in Fig. 5.19,
with Fig. 5.19a representing the transient response of absolute Iratio from two superimposed
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Figure 5.18: Average values of two repeats of Iratio with respect to the range of pH values
7-9 and 5-7. The red line illustrates the average of Iratioavg values collected from the data
during decremental ascending and descending pH steps for pH 7-9 in (a) and pH 5-7 in (b)
drawn as dashed lines. The best linear fit equations are displayed in both figures, with the
one in (a) to overlap with the average of Iratio of both ascending and descending pH values
and the one in (b) to overlap with the blue line representing the response of the average
values of Iratio during incremental pH steps.
normalised trials where 8.8 is the pH of both chambers Ch 1 and Ch 2 (before DNA reaction)
and 6.8 is the pH of Ch 1 (after DNA reaction) while the pH of Ch 2 stayed the same as in the
beginning of the experiment. The same experiment was conducted with opposite starting
pH in chambers, as shown in Fig. 5.19b, with pH 6.8 being induced in both chambers at
the beginning of the experiment and pH 8.8 induced only in Ch 1 for no other reason
other than to test the reproducibility of the computation of Iratio during a pH step of the
opposite direction. Both ISFET sources were biased initially at 100nA with VS=1V and
reference electrode voltage set at 1.5V, while Igain was fixed at 100nA leading to starting
point of around Iratio=49nA, 1nA deviation from the theoretical calculation of Iratio, based
on Eq. 5.15.
What can be seen from Fig. 5.19 is that the transient change in Iratio during both pH
steps results in a ∆Iratio change of about 7nA to 9nA, with both repeats following almost
the same trend over time. Moreover, the aim of this experiment was also to provide with
the essential information on the values at which Iperc should be set, based on the observed
change on Iratio, for the current comparator of the translinear circuit to be activated as
soon as a new buffer of lower or higher pH is induced. The range of values of Iperc to be set
for the pH step change from 8.8 to 6.8, based on the information obtained from Fig. 5.19a,
would be around 49nA to 46nA and for a pH step change from 6.8 to 8.8 would be around
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Figure 5.19: Transient response of absolute Iratio of two repeats during (a) a pH step change
from 8.8 to 6.8 and (b) a pH step change from 6.8 to 8.8.
49nA to 52nA, based on the information provided by Fig. 5.19b.
The ability of the current comparator to switch from 0µA to 1µA during a pH step
change from 6.9 to 7.9 was tested for two repeats, one followed by the other, within a
time frame of 400sec. The current bias for Iwta was set at 1µA as the maximum current
observed when a pH step change occurs, giving a discrete indication of the pH change when
Iratio exceeds a preset current value set by Iperc. The results of the transient response of
Iout through changes in absolute Iratio, derived for the given pH step change, are shown in
Fig. 5.20 for Iperc=52nA. It can be seen that the translinear circuit’s capability of switching
current state during a ∆pH of 1 has been successful, with the results being reproducible
twice in two consecutive runs. The values of Iratio started from 49nA when the pH in both
chambers was the same and then jumped to 52nA when the change was induced in Ch 1.
Iratio was brought down to 49nA after 135sec, while Iout jumping down to 0nA, and the
same experiment was repeated once again. The time duration of this experiment was as
short as 400sec so that the risk of evaporation of the pH buffers in the 0.3µl chambers was
reduced.
As the ability of the current comparator, Iout, to indicate discretely a change in pH
based on a preset Iperc was proven to work for a ∆pH of 1, as seen in Fig. 5.20, and
the computation of Iratio was successfully achieved for a ∆pH of 2, as seen in Fig. 5.19,
defining a range of currents for Iperc given the values of Iratio during that pH step change,
the combination of both features are finally left to be proven. Fig. 5.21 shows the results
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Figure 5.20: Transient response of the current comparator Iout and absolute Iratio of two
consecutive repeats during an incremental and decremental pH step change of 6.9 to 7.9.
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Figure 5.21: Absolute Iratio and Iout of two repeats with respect to time, during a pH step
change from 8.8 to 6.8 and a preset Iperc value during descending (a) and ascending (b)
directions of the pH step change, followed by the values of Iperc for a reaction to take place
(YES) or not (NO).
reported on Fig. 5.19, with the additional feature of using the current comparator set at a
specific value based on the information gathered by Fig. 5.19.
More specifically, Iperc was set at 49nA during the descending pH step from 8.8 to 6.8
and at 52nA during the ascending pH step from 6.8 to 8.8. An indication of ’NO’ was made
when no reaction was happening, when the pH of the reaction chamber (Ch 1) was 8.8,
which turned into a ’YES’ when Ch 1 was induced with 6.8, confirming that the sample
induced was methylated DNA. The comparator was tested for both pH directions to prove
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Table 5.6: System properties and performance characteristics
Technology AMS 0.35µm 2P4M CMOS
Die dimensions 2.5mm × 2.81mm
Passivation Si3N4/SiO2 1030nm/1000nm (about 120fF)
ISFET pixel: W×L (electrical) 200µm × 1µm
ISFET pixel: W×L (chemical) 34µm × 100µm
Sensing area 3400µm2
Transistor sizes (W×L) 10µm × 10µm
Transistors per pixel 37
Power supply 3.3V
Chamber size 1mm × 0.4mm × 0.4mm
Chamber diameter 400µm
Chamber volume 0.3µl
pH sensitivity 30mV/pH
ISFET drain current 100nA
Igain @ (IDC=100nA) 100nA
Power consumption @ (IDC=100nA, Igain=100nA) 2.3µW
its functionality as well as to validate the selection of the values of Iperc accordingly.
5.6 Summary
In this chapter, the concept of a ratiometric approach using the translinear “Methylation
Cell” towards DNA methylation detection was presented, simulated, fabricated and tested
using (a) an epoxy encapsulation set-up to demonstrate the computational functionality of
the circuit and (b) a microfluidic manifold Lab-on-Chip set-up to allow real-time sensing of
pH signals derived from two separate and isolated from each other microfluidic chambers.
The signals were originated from (i) DNA reactions taking place in presence of methylated
DNA existent in genetic areas responsible for tumour suppression compared to (ii) no reac-
tions taking place due to the absence of DNA methylation or the presence of unmethylated
DNA in the same under investigation genetic regions. Some of the system’s properties and
performance characteristics are summarised in Table 5.6.
Based on this concept, a novel ISFET based readout has been proposed for the contin-
uous computation of the ratio between methylated and unmethylated DNA in the form of
current signals sensed by two ISFET sensors, by adopting the circuit technique known as
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the “translinear principle”. The readout is then followed by a comparison block (voltage-
mode or current-mode) that would give a discrete output when methylation reaches and
exceeds a predetermined, tunable percentage.
Simulation results demonstrated the capability of the translinear “Methylation Cell” to
compute the ratio between two currents, also defined as the output current of the translinear
circuit, Iratio, which represents the ratio of methylation, amplified by a fixed gain term, Igain.
For a value of Iratio above a threshold, set to define the limit of detection, a discrete boolean
value was given as an output of the ISFET pair of the cell, utilising voltage-mode and
current-mode switching techniques, able to indicate whether the level of methylation exceeds
50%. This can thus highlight that the corresponding genetic areas appear hypermethylated,
implying that the tumour suppressor function of the regulatory region of the gene may be
hindered, leading to the potential inactivation of the gene which can be associated with
early stages of tumour development.
The capability of the translinear “Methylation Cell” for ratio computation was validated
experimentally, focusing on the current-mode switching through the realisation of a fabri-
cated system, while assessing experimentally the performance of the current comparator by
emulating a scenario of 1 pH change and thus selecting the best performance characteristics
for the translinear circuit (Imeth, Iunmeth and Igain set at 100nA) to compute Iratio. Addi-
tionally, a range of values for the threshold current, Iperc, were experimentally selected for
further use and validation of the current switching by the Lab-on-Chip microfluidic set-up
that was also developed. The Lab-on-Chip consisted of two microchambers, ideal for in par-
allel monitoring of chemical pH signals generated by the two ISFETs. The computation of
Iratio was validated experimentally firstly in various pH buffers and then during a pH jump
of given values of pH obtained before and after a DNA reaction taking place when DNA
methylation was present. Finally, the functionality of the current comparator was tested as
well as its ability to indicate the event of a reaction taking place due to methylated DNA
being present, concluding with the values that need to be used for Iperc so that the output
of the current comparator, Iout, accurately switches from 0µA to 1µA with a minimum time
delay.
The “Methylation Cell” successfully sets the basis for a system integrating ISFET sen-
sors for detecting epidemiological ratios of DNA methylation in real-time, giving as an
output a discrete indication of the level of normality of DNA methylation. It can also be
efficiently scaled to address CMOS ISFET arrays for in parallel detection of DNA methyla-
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tion in multiple tumour suppressor genes that appear as hypermethylated in genetic regions
responsible for their control, associated with the early development as well as progression
of cancer. This method would primarily contribute in forming a powerful tool as well as a
novel approach in early diagnosis of cancer, ultimately in predicting the clinical outcome,
reducing the data bandwidth requirements for an array based platform to just 1 bit per
pixel pair due to the use of a discrete boolean value as an output and finally leveraging the
needs for power due to the operation in the weak inversion region, a significant requirement
for a Point-of-Care implementation.
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Chapter 6
A current-mode approach for
differential DNA methylation
detection
6.1 Introduction
Advances in semiconductor technology during the last decade have provided novel solutions
in healthcare, especially in the fields of early detection, diagnosis and therapy of disease.
Specifically CMOS technology has enabled next generation fully integrated Lab-on-Chip
systems due to the inherent advantages of large scale integration, low cost of fabrication
and intelligent processing on-chip [1]. When such systems are designed for applications
such as DNA testing at the point of care, additional requirements of miniaturisation and
low power consumption are needed to ensure that portability and maximum battery life of
the medical device can be achieved [2]. In order for these systems to be realised, a basic
sensing element, capable of being miniaturised in CMOS, integratable with standard circuits
and scalable to multiple sensor arrays is needed. This is realised using a CMOS based ion
sensor called the Ion-Sensitive Field-Effect Transistor (ISFET), introduced in Chapter 3.
The ISFET has gained significant popularity for use as a chemical, solid-state, pH sensing
element since it has been adopted in various chemically driven applications [3–5], including
auto-calibrated Lab-on-Chip platforms [6], but also in biomedically driven ones [7, 8], with
a significant role in the field of genetics [9–12] as well as of epigenetics [13, 14], through
the use of DNA methylation as a biomarker for cancer detection, as has been described in
Chapter 4. They have therefore shown great capability for measuring ionic concentration
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changes resulting from biochemical reactions, forming front-ends for applications that use
a pH change as a marker to indicate the presence of a reaction. Such applications have
highlighted the benefits of using ISFETs, letting us now exploit the simplicity given by well-
known current-mode techniques, such as the translinear principle, with the possibility to
fabricate fully integrated Lab-on-Chip systems for real-time monitoring of pH signals. This
offers great potential for in parallel biochemical reaction detection and monitoring, ideal
for the scope of this research which is focusing on approaches towards DNA methylation
detection.
Although CMOS ISFETs have been widely used in fully integrated sensing systems,
certain non-idealities limit their wide usage as pH sensors. These include drift, temperature
instability and threshold voltage variation [15]. Given the challenges that these bring in
sensing absolute pH concentration, applications which require monitoring of changes in
reaction rather than absolute pH [10] are more suited.
Furthermore, the need for differential pH measurements instead of absolute pH values
is required to guarantee steady and robust circuit operation independent of temperature
and common-mode noise. This is especially important when DNA amplification meth-
ods are used such as thermocycling (PCR) or isothermal (LAMP) amplification, whereby
controlling temperature conditions is a matter of great importance given that such types
of reactions are very sensitive to temperature. This can be achieved through differential
ISFET measurement [15] and topologies that could be used for monitoring differentially
derived changes in pH from ISFET sensors using low power current-mode methods. One
such topology is the “Gilbert Gain Cell” which is well suited for differential measurement
and will be utilised for the scope of this research.
This chapter presents a low power, current-mode approach for DNA methylation de-
tection in CMOS, the ISFET based Chemical Gilbert Cell, which combines a microfluidic
assembly that achieves monitoring of differentially derived changes in pH, sensed using
ISFET sensors, and suitable for applications that require differential monitoring in small
volumes, such as DNA amplification as result of the presence or absence of DNA methyla-
tion. By adopting the Chemical Gilbert Cell, certain significant non-idealities that ISFETs
have by nature, such as drift and temperature dependence are tackled and in parallel de-
tection of separate pH signals is achieved. Furthermore, through the inclusion of a tunable
gain on the monitored output, a method for amplification is realised. The system has been
designed and fabricated, with simulation and experimental results reported and analysed,
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confirming functionality and demonstrating the capabilities of the front-end at a microscopic
level through integration in a Lab-on-Chip (LoC) set-up. The chapter then concludes with
the summary of the results, highlighting the capabilities of such system which facilitates its
use for large scale integration and applications that require robust, low power differential
chemical measurement and monitoring.
6.2 Differential CMOS ISFET topologies
The ISFET sensor has been commonly used as part of microsystems (eg. Lab-on-Chip) for
its ability to measure the pH of a solution where a reaction may take place. In various
biomedical applications, some of the requirements of sensor based Lab-on-Chip systems
have been (a) temperature stability and control due to the expectations of operation of
such systems in different temperature conditions, [16], as well as (b) good common-mode
rejection to reduce drift and common-mode noise through the use of differential topologies,
such as the differential ISFET-REFET front-end proposed by [17]. Also given the need
for minimum instrumentation, (c) integration of multiple sensors per chip is required to
allow high density integration, therefore achieving low area and power, with a very recent
example presented in [12].
For overcoming common non-idealities such as the threshold voltage variation as a re-
sult of the time dependent variation of the ISFET’s sensed signal (drift) or the tempera-
ture dependence, various differential topologies have been proposed in the past, instead of
single-ended ISFET read-out circuits. Such topologies have reported to offer compensation
schemes with an effort to improve the signal stability of the ISFET sensor while reducing
the effect of fluctuations of the experimental conditions. To date, current differential CMOS
ISFET topologies tend to use ISFET pairs or ISFET/reference FET (REFET) configura-
tions through interfacing to one or more operational amplifiers (OTAs), mainly operating
in voltage-mode [18–25]. Current-mode implementations have on the other hand shown
strong potential, replacing the use of OTAs, and provide novel interfaces for differential
measurements [26, 27] with [17] achieving low transistor count and low power consumption
when the weak inversion mode of operation is used. We now proceed in describing these.
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6.2.1 Voltage-mode topologies
The concept of a differential measuring system using ISFETs was initially suggested by
Bergveld in 1989. This consisted of an ISFET/REFET pair providing a differential voltage
output, as result of changes in the pH of the analyte solution sensed by the ISFET, relative
to an ion-insensitive FET (REFET) [18]. A platinum (Pt) electrode was used as an on-
chip pseudo-reference electrode, implemented using an evaporated platinum layer on the
substrate that the ISFET or REFET were fabricated on. Its role was to bias both ISFET
and REFET in the differential measurement set-up, with any instability caused by the
varying composition of the electrolyte translated into variations in Vref to be rejected as
common-mode noise through the differential configuration. Fig. 6.1 illustrates a schematic
representation of the differential arrangement, with the ISFET and REFET sensors being
the inputs of a differential amplifier, which provides the output of the system.
Figure 6.1: A differential ISFET/REFET measuring system [15]
Palan et al. [20] proposed a CMOS differential configuration with a sensor interface
of two ISFETs, each covered with a different ion sensitive layer (ISFET1 with Si3N4 and
ISFET2 with SiO2), adopting the source-drain follower circuit configuration, using two
OTAs per ISFET, as can be seen in Fig. 6.2, and Pt as the reference electrode. A similar
arrangement proposed by Hammond et al. [23] is shown in Fig. 6.3, with an ISFET/REFET
pair as part of the differential arrangement in unmodified CMOS in a System-on-Chip set-
up. Si3N4 was used as the sensing membrane of the ISFET and a PVC polymer membrane
was added in the case of the REFET, following a post-processing procedure, to create a
non-sensitive layer by preventing hydrogen ions immobilising in the membrane’s surface.
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Figure 6.2: Differential ISFET interface for measurement of sensors [20]
Figure 6.3: Differential circuit schematic [23]
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A CMOS based approach for differential read-out of ISFET and REFET sensors was
also proposed by Ravezzi et al. [21] with the schematic diagram appearing in Fig. 6.4. It
consisted of a CMOS read-out circuit based on switched-capacitor techniques, providing
a low-impedance analog output signal proportional to the differential input between the
ISFET/REFET sensors, performed by the “differential stage”. Si3N4 was used as the
ISFET’s sensing membrane and a buffered hydrogel layer was used to form the REFET’s
ion insensitive layer. A Pt reference electrode was also used to create the electrical contact
to the solution. The proposed read-out’s aim was to provide compensation strategies, to
allow reduction of the sensor’s dependence on temperature fluctuations and drift, achieving
high resolution.
Figure 6.4: A differential ISFET/REFET read-out using switched capacitors [21]
Wei et al. [24] proposed a fully integrated interface circuit in CMOS for pH measurement
using an ISFET/REFET differential pair and amplifiers in symmetry leading to a differential
output voltage. The schematic of the ISFET amplifier can be seen in Fig. 6.5 with the drain-
source voltage to be kept constant. A pseudo reference electrode was used to provide with
biasing conditions independent to the sensor’s input or to any variations in temperature
conditions. For the ISFET/REFET pair, Ta2O5 and PVC were used respectively as inputs
of the ISFET and REFET.
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Figure 6.5: Schematic of the ISFET amplifier used in the differential read-out circuit [24]
Finally, Chodavarapu et al. [22] proposed a pseudo-differential read-out architecture
consisting of two ISFETs in the forms of OTAs integrated as the input stage (ISFET OTAs
or IOTAs), as illustrated in Fig. 6.6, by applying indirect feedback to the floating gates
which were shared by more than one devices. The ISFETs of the IOTAs are reported to
be identical [25], with the sensitivity of each ISFET to vary based on the size of the PMOS
load, instead of using two ISFETs with different pH sensitivities, therefore avoiding any
post-processing steps. It therefore achieves different pH sensitivities on the same chip by
only adjusting the dimensions of the PMOS loads in the two IOTAs. Si3N4 was used
as the sensing layer of the ISFETs and a gold wire was adopted as the pseudo reference
electrode to bias the solution. Such a differential read-out proposes an architecture that
achieves constant bias operational conditions with the ability to track changes in the ISFET
threshold voltage and therefore in pH.
To summarise on the voltage-mode topologies, from the very fundamental architecture
of differential measurement system suggested by Bergveld in 1989 to the latest CMOS-
integrated ISFET interfaces for differential read-outs, they all share the use of power hun-
gry operational amplifiers to achieve constant bias conditions and read-out, for following
potential changes in ionic concentration of the solution. There are however several restric-
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Figure 6.6: CMOS ISFET differential read-out system architecture [22]
tions in the proposed interfaces regarding the operating range, the power consumption, as
well as the transistor count. The current-mode topologies reviewed in the next section are
presenting alternative CMOS ISFET interfaces able to achieve differential measurement,
allowing for low power consumption by avoiding the use of operational amplifiers providing
with the ability to perform computation using simple techniques such as the translinear
principle.
6.2.2 Current-mode topologies
In current-mode topologies, a differential read-out has been reported in 2004 by Ghallab et
al. [26, 27] proposing the use of current conveyors instead of operational amplifiers. By using
two operational floating current conveyors (OFCCs) per ISFET and REFET respectively,
the input currents were conveyed through the ISFET and REFET to the output, providing
with a differential current output, linearly proportional to any changes in pH sensed by
the ISFET. The current-mode differential measurement read-out circuit was preferred as
a method to reduce the impact of common-mode instabilities generated by the reference
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electrode or the temperature dependency of the ISFET. Such topology is reported to have
the potential for use in Lab-on-Chip and biomedical applications.
A current-mode topology offering differential measurements has also been proposed by
Shepherd et al. [17] using a CMOS integrated differential ISFET/REFET front-end biased
by a quasi-reference electrode (Pt), avoiding the use of OTAs, as seen in Fig. 6.7, providing
with a low power method for a differential implementation. The reported method provides
capability for voltage regulation by clamping the drain voltage of the ISFET therefore
achieving a fixed bias point applied in a pseudo-differential arrangement through subtrac-
tion of currents from the ISFET/REFET pair. It shows great potential for implementation
in large scale ISFET arrays, achieving low power consumption when operated in weak inver-
sion, with the capability to apply further on-chip processing steps and gain stages, making
it suitable for biomedical implementations. Finally, Pookaiyaudom et al. [28] presented the
concept of a chemical current conveyor with the ability to perform differentiation of pH
signals derived from ISFETs.
Figure 6.7: CMOS based differential ISFET/REFET read-out [17]
These current-mode topologies proposed differential arrangements highlighting the need
for additional gain stages to amplify the sensed read-out signal in order to achieve a good
resolution. In this research, a CMOS integrated interface for differential pH measurement
is proposed using the ISFET based Chemical Gilbert Gain Cell, integrating an adjustable
gain by using single tuning current, providing a scalable differential output measurement
between two ISFETs. The topology proposed is fundamentally based on the “Gilbert Gain
A current-mode approach for differential DNA methylation detection 159
Cell”, a current-mode circuit, the analysis of which follows in the next section.
6.3 Gilbert Gain Cell
The “Gilbert Gain Cell” shown in Fig. 6.8, first introduced in 1968 by Barrie Gilbert [29],
is a current-mode circuit with the ability to differentially measure currents with a tunable
gain in a compact way of using only four transistors. As has been explained by Gilbert in
1990 [30], a differential input current signal, Iin, is sensed by the two transistors M3 and
M4, as can be seen in Fig. 6.8, and is added in phase with the outputs coming from M1
and M2. Such configuration can provide the advantage of broadband amplification without
affecting the differential input, by cascading a series of “Gain Cells”, with the output stage
of one cell adding up as the input of the next, providing the driving current for operation,
thus contributing to the total output signal. An additional advantage is that the gain is
linearly dependent on any of the input currents of the cell, achieving a minimum net gain of
1 given an inner stage gain of less than 1, which increases the speed of the output response
of the circuit [29, 30].
The expressions of the input current, Iin, and the output current, Iout, as defined by [30],
are given by:
Iin = (1 + x)Ix − (1− x)Ix = 2xIx (6.1)
and
Iout = I
+ − I− = (1 + x)(Ix + Iy)− (1− x)(Ix + Iy)
= 2x(Ix + Iy)
(6.2)
leading to the definition of the modulation index x as:
x =
Iin
2Ix
(6.3)
where x represents the normalised differential input signal amplified by a gain, dependent
on a DC bias, Ix, and I
+, I− are the two output currents as shown in Fig. 6.8. Iy is an
entity proportional to the gain current, Igain, according to the expression:
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Figure 6.8: The Gilbert Gain Cell
Igain = 2Iy (6.4)
Therefore, by tuning Iy, adjustments to the gain term can be facilitated, achieving a
continuous control on the gain of the cell. The description of the “Gilbert Gain Cell” as a
differential cascode with gain can be therefore justified since it provides a differential output
current, Iout, through a gain stage defined by Igain.
The “Gilbert Gain Cell” is one example of applying the translinear principle to MOS
circuits to multiply/divide currents derived from transistors operating in the weak inversion
region. The term translinear and the benefits of using translinear circuits has been analysed
in detail in Section 5.2, Chapter 5. The use of ISFETs as ion sensors in the subthreshold
region in combination with the inherent benefits of the “Gilbert Gain Cell” is presented in
the following sections.
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6.4 Chemical Gilbert Cell
Further to the development of the “Gilbert Gain Cell”, an ISFET based Chemical Gilbert
Cell is presented herein and shown in Fig. 6.9 [31], fundamentally based on the use of the
“Gilbert Gain Cell” as mentioned in Section 6.3. This consists of two ISFET sensors acting
as probes, capable of principally detecting pH signals from separate reaction chambers.
Chemical changes are detected and transduced to the drain currents, ID, of the ISFET
due to the presence of hydrogen ions in solution, as described in Eq. 3.21, Section 3.5.1 in
Chapter 3.
The use of the Chemical Gilbert Cell provides advantages such as differential measure-
ments, offering drift reduction and temperature stability as well as a linearly tunable current
gain as has been firstly shown in [32]. The theory behind the operation of the Chemical
Gilbert Cell is derived by the translinear loop of PMOS transistors (M1-M2 and M3-M4)
operating in weak inversion, with the input currents of M3 and M4 been added in phase
with the output currents of M1 and M2. The ISFETs are biased by applying a suitable bias
at the reference electrode (indicated as stable potential VG) for weak inversion operation.
The gain, A, of the Chemical Gilbert Gain Cell is represented by the equation:
A =
Ix + Iy
Ix
(6.5)
where Ix is the input DC biasing current signal and Iy is the gain term. Considering its
operation for differential pH measurement whereby one ISFET sensor (ISFET1, Fig. 6.9)
is used to detect the pH change generated from a reaction taking place in chamber 1 (Ch
1) generating an IpH1 or IISFET1 and the other ISFET sensor (ISFET2, Fig. 6.9) is used
to detect the pH of the buffer solution in chamber 2 (Ch 2) generating an IpH2 or IISFET2,
the current expressions can be defined as:
IpH1 = IISFET1 = IDC + Idrift + I∆pH
}
reaction chamber (Ch 1) (6.6)
and
IpH2 = IISFET2 = IDC + Idrift
}
buffer chamber (Ch 2) (6.7)
so that:
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Figure 6.9: The ISFET based Chemical Gilbert Gain Cell. ISFET1 is sensing pH1 gen-
erated from the reaction chamber (Ch 1) and ISFET2 is sensing pH2 generated from the
buffer chamber (Ch 2).
IISFET1 − IISFET2 = IpH1 − IpH2
= I∆pH
(6.8)
where I∆pH is a real-time change in pH sensed by the drain currents of the ISFETs,
differentially monitored by Ch 1 and Ch 2.
In parallel to these, the expressions of the input, Iin, and output, Iout, currents of the
Chemical Gilbert Cell, based on the fundamental definition given by the “Gilbert Gain
Cell”, will be represented by:
Iin = IISFET1 − IISFET2
= 2xIx
(6.9)
leading to the definition of x for the Chemical Gilbert Cell as:
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Figure 6.10: Transient response of the Chemical Gilbert Cell
x =
Iin
2Ix
=
I∆pH
2Ix
(6.10)
Thus the differential output current Iout of the Chemical Gilbert Cell will be following
the principles proposed by Eq. 6.10 and Eq. 6.2 and will be expressed as:
Iout =
Ix + Iy
Ix
Iin = AIin = AI∆pH (6.11)
where Iout varies linearly with the current change, I∆pH , generated due to the pH
difference created between the two ISFET sensors, and this is multiplied by a discrete gain
value A.
6.4.1 Simulation results
The circuit was designed and simulated in a typical 0.35µm 2P4M CMOS technology using
Cadence Spectre (5.1.41isr2) simulator. The design specifications for the Chemical Gilbert
Cell were, a supply voltage of 3.3V and device sizes optimised at (W/L) 10µm/10µm for
all transistors so that matching errors were minimised and 1/f noise was reduced. ISFET
sensors were used with an electrical size of 200µm x 1µm.
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Figure 6.11: Parametric analysis on Igain at 5 steps, from 1nA to 50nA
In order to test the Chemical Gilbert Cell, we used real ISFET data measured from an
experiment in which pH was varied from 7.7 to 8.3 in steps of 0.3 pH. For this we used
Ix=10nA, Iy=5nA and Igain=10nA. Transient simulation results are shown in Fig. 6.10,
using normalised values of simulated drift as well as the real extracted data from a pH
dependent reaction, applied as inputs to sensors ISFET1 and ISFET2 respectively. The
outputs of two ISFETs are subtracted, producing a current change due to the change in
pH stated as I∆pH , and then multiplied by a gain value set by the parameter A, as shown
in Eq. 6.11, providing with a differential output current. Furthermore, what we can see in
Fig. 6.10 is that the differential measurement simulation results show a drift reduction from
0.36nA/min for the single ISFET to just 3fA/min for the differential output.
A parametric analysis was also conducted on the gain current, Igain, as is defined through
Eq. 6.5. This was varied from 1nA to 50nA in a time window of less than 500s, as is seen in
Fig. 6.11. What we can see is that the gain can be tuned within a range of required current
steps for a given pH change. As can be seen by Eq. 6.5, the gain can be dependent on both
the Igain and the bias current of the ISFET, which for an Ix of 1nA can be as much as 40dB
for this configuration.
The temperature stability of the system is shown in Fig. 6.12 for varying temperature
conditions from 0oC by up to 100oC. For the clarity of the temperature variation effect, we
display only 4 temperature changes. It can be observed that the response remains consistent
within the temperature range applied, with the maximum absolute temperature percentage
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Figure 6.13: Monte Carlo analysis
change to be around 0.7% from the mean output current at room temperature conditions.
Finally, a Monte Carlo analysis of the circuit was conducted in order to test the variations
of the devices in terms of process and mismatch parameters, after applying a DC current of
10nA as a differential input. The results of 1000 runs for the values of the cell’s differential
output current Iout are illustrated in Fig. 6.13, producing a resulting Imean of 30.1nA with
a standard deviation of 363.7pA, showing that the ISFET based Chemical Gilbert Cell is
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rather robust to process and mismatch variation.
6.5 Fabricated system
The Chemical Gilbert Cell was fabricated in a typical 0.35µm 2P4M CMOS process, as
seen in Fig. 6.14 (bottom), with each ISFET sensor designed1 with a sensing area of
34µm×100µm and an electrical area of 200µm×1µm, as shown in Fig. 6.15. All sizes of
PMOS devices used were optimised at (W/L) 10µm/10µm so that matching errors were min-
imised and 1/f noise was reduced. The area covered by circuit was 1960µm2 (70µm×28µm).
The microfluidic assembly adapted on the ISFET based CMOS microchip in the form
of a Lab-on-Chip as introduced in Section 5.4, Chapter 5, was used to achieve exposure of
the ISFET sensors in buffers of different pH for the differential reaction monitoring. The
same platform was used as in Fig. 5.10 to prevent cross contamination of fluid through the
chambers, offering a more accurate signal derived from the Chemical Gilbert Cell. Both
ISFETs were biased in the weak inversion mode of operation.
6.6 Measured results
The Lab-on-Chip was experimentally tested using a semiconductor parameter analyser
(Keithley 4200SCS). During all experiments the CMOS chip was biased at 3.3V and IS-
FETs were biased at a static drain current of 20nA, optimised for weak inversion operation.
pH solutions 8.15 and 6.83 were obtained from DNA reactions, as detailed in Section 4.4,
Chapter 4, with 8.15 indicating the resulting pH of a DNA reaction not occurring when
DNA methylation is absent in given genetic areas and 6.83 to indicate the pH of a DNA
reaction taking place when DNA methylation is present in the given genetic areas. The
∆pH of 1.32 indicates the minimum change in pH that was observed in the experimental
section, Section 4.4, Chapter 4, used as a limit of detection for the experimental validation
of the Chemical Gilbert Cell.
pH buffer solutions 5, 6, 7, 8 and 9 were prepared using 100mM Tricine and 1M KCl,
adjusting the pH using 10M NaOH and 1M HCl. All four solutions were provided by Sigma-
Aldrich. A commercially available Al2O3 ISFET sensor with an Ag/AgCl reference electrode
1ISFET sensors were designed based on measured devices fabricated within the Centre for Bio-Inspired
Technology [33].
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Figure 6.14: Top: Microphotograph of the floorplan of the fabricated die, highlighting in
black the relevant circuit area. Bottom: Magnification of the ISFET based Chemical Gilbert
Cell and of the two ISFETs connected to it.
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Figure 6.15: Single ISFET sensor with pixel dimensions. Left: Chemical sensing area of the
ISFET. Right: Electrical dimensions of the gate.
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was also used as a pH probe (Sentron Europe B.V.) for conducting the pH measurements
after having completed a calibration process as described in Appendix C. The pH solutions
were titrated in the microfluidic chambers using 20µl Eppendorf micropipette tips.
The output current Iout was measured after applying a voltage bias of 1V to the output
to allow the current mirror of M5 and M6 (Fig. 6.9) to work in saturation. Both ISFETs in
chambers were externally and independently biased with Ix=20nA in a buffer environment
of pH 7. Ix=20nA was chosen based on the linear weak inversion operating region. After
each pH change was induced by inserting a pH buffer (5-9) in Ch 1, both chambers were
flushed with pH 7 and ISFETs were biased at Ix=20nA so that (a) the conditions for each
recording remain the same before every pH change being induced and (b) the chamber is
refilled with buffer solution in case of evaporation of fluid during the previous recording,
providing both ISFETs with a maximum volume of exposure in fluid.
Experimental results are presented in this section, demonstrating the electrical function-
ality of the ISFETs in weak inversion as well as their sensitivity under different pH solutions
in each chamber. The capability of the Chemical Gilbert Cell under the Lab-on-Chip set-up
is also demonstrated by producing a differential output current read-out during one pH step
change (induction of different pH buffer in Ch 1, see Fig. 5.10b) for a constant gain at first.
Also, the pH sensitivity of the cell is shown during four pH step changes, followed by the
results of a gain experimental analysis on the cell’s differential output current Iout for one
pH step change, followed by the gain tunability characteristics for four pH step changes.
Finally, the drift minimisation of the cell is shown, pointing out a 100 times reduction of
drift when a differential current output is computed in comparison to the drift observed at
a single ISFET’s current output signal.
6.6.1 DC characteristics
Initially, the ID-VGS characteristics for both ISFETs were conducted, as seen in Fig. 6.16,
at a buffer solution of pH 7 at room temperature, to confirm the behaviour of ISFETs in
weak inversion. The sources of both ISFETs were biased independently at 3.3V and the
voltage applied on the reference electrode, VG, was swept from 0V to 5V.
The y-axis shows the drain current and the x-axis the gate voltage subtracted from the
source voltage of the ISFETs. It can be seen that the linearity of the exponential drain
current characteristic is for currents from 0.1nA to 200nA for a range of source gate voltage
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Figure 6.16: Measured ID-VGS sweep of the two pMOS ISFETs for pH buffer solution of 7,
showing the relationship between the drain current and the applied source gate voltage.
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Figure 6.17: Transconductance with respect to source gate voltage for pH buffer solution
of 7. The operational area of linear weak inversion range is highlighted.
of -1.7V to -0.5V. This means that weak inversion operation can be safely guaranteed for
measured currents below 200nA. The validity of this assumption was confirmed in Fig. 6.17,
showing the transconductance efficiency for pH 7. It is clearly shown that weak inversion
can be reliably achieved in the area defined by the dotted lines, which is approximately
covering an area of up to 10% reduction in the maximum peak of the linear transconductance
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Figure 6.18: Transient response of 15 repeats over the course of two days of the Chemical
Gilbert Cell’s differential output Iout during a pH step change from 8.15 to 6.83 for Igain
at 10nA. Standard deviation bars of the pH recordings are also displayed for all repeats,
seconds before the pH jump and towards the end of the recording.
efficiency range. This corresponds to source gate voltage of -0.84V to achieve optimal
conditions of operation at an ISFET drain current of 20nA, which is our chosen ISFET DC
current (Ix) for all experiments.
6.6.2 pH change
To test the response of the Chemical Gilbert Cell to pH changes, an experiment was con-
ducted using pH values chosen as such according to the minimum range of values to dis-
criminate the event of amplification, before and after a DNA chain extension reaction [14].
At first pH 8.15 was added in both chambers, depicted in Fig. 5.10b. Both ISFET sources
were biased to give an Ix of 20nA, which corresponds to source gate voltage of -0.84V based
on the DC characteristics extracted from Fig. 6.16.
The reference electrode voltage was kept steady at 3V and Igain was tuned at 10nA.
An injection of pH 6.83 was then applied to Ch 1 where ISFET1 was located, leading to
a ∆pH of 1.3 between chambers. The experiment was repeated 15 times within the period
of 48 hours and the transient measured response of the Chemical Gilbert Cell’s differential
output current, Iout, was monitored as shown in Fig. 6.18.
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Figure 6.19: pH sensitivity of the Chemical Gilbert Cell showing the transient response of
the differential output Iout for Igain=10nA during four steps of pH change.
Table 6.1: ∆Iout for Igain=10nA during four pH step changes
pH 5 6 7 8 9
∆Iout(nA) -7.564 -4.754 0 7.566 14.25
It is shown that the differential current Iout undergoes a positive change from around
1.2nA at pH 8.15 to 8.3nA at pH 6.83, creating a ∆Iout of 7nA for a ∆pH of 1.32. The
standard deviation values before and after the pH jump, as can be seen in Fig. 6.18, were
obtained from the data values at 40sec (just before the pH jump) for pH 8.15 and at 110s for
pH 6.83 (after the pH jump towards the end of the pH recording). Their values satisfy the
variation tolerance of the data obtained since they apply a less than 10% variation in the
data values. As for the pH sensitivity of the ISFETs during this pH step, the average value
of the ISFET source currents calculated during the 15 repeats was found to be 14.25nA
which corresponds to -0.84V from the DC characteristics seen in Fig 6.16.
Following on from the single pH step change, four steps of pH changes were performed
to confirm the system’s sensitivity to all pHs, using a starting pH of 7 in both chambers,
followed by injecting pH 5, 6, 8 and 9 in Ch 1. The results are shown in Fig. 6.19 and the
values of ∆Iout with respect to the pH changes are summarised in Table 6.1. In between
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Table 6.2: Average values of three repeats of ∆Iout for different Igain values as seen in
Fig. 6.20 with standard deviation results
Igain(nA) 10 20 50 100 200
∆Iout(nA) 6.89±0.46 7.96±0.49 13.24±0.40 18.74±0.08 30.2±0.52
the injections of different buffers, the volume of Ch 1 was flushed with pH 7 while Ch 2 was
filled up with the same pH buffer during the process of the sensitivity experiment. Flushing
Ch 2 with pH 7 before any recording was managed continuously during this experiment to
eliminate evaporation of the buffer as realistically as possible leading to better diffusion of
ions in the sensing surface of the ISFET. ISFET currents were also biased at 20nA before
a new pH was inserted in Ch 1. After the currents were stabilised at a post pH change
phase, the sources of both ISFETs were reduced to achieve 20nA independently, through
an external biasing configuration, so that the experimental conditions were kept as similar
as possible before flushing Ch 1 with a new buffer.
What can mainly be derived from Fig. 6.19 is that the output current Iout, for a given
gain value (Igain=10nA), responds to pH step changes derived from the chemical response
of ISFET1, achieving a pH sensitivity of 45mV/pH, which is in agreement with ISFETs in
unmodified CMOS [5]. Additionally to that, the current change observed for the pH step
changes of pH 7 to 8 and 7 to 9 is relatively higher than the equivalent step changes of 7
to 6 and 7 to 5, which can be explained from the exponential characteristic of the ISFETs
operating in weak inversion.
6.6.3 Tunable gain
An experimental analysis was also conducted on the gain current Igain to demonstrate the
gain tunability of the system. Gain current values varying from 10nA to 200nA were used,
for a pH step change of 8.15 to 6.83. Each step was repeated three times resulting in
collecting recordings within the time frame of 48 hours. The time window of each recording
was 120s. For each gain value, ISFETs were initially biased with currents of 20nA and
then Iout was monitored over time for the given pH step for all Igain values. The values of
Iout were normalised for purposes of clarity of differentiation of the output currents for the
different gain values under the given pH change.
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Figure 6.20: Experimental analysis on Igain from 10nA to 200nA during a transient response
of the Chemical Gilbert Cell’s differential output Iout for a pH step change from 8.15 to
6.83. 3 repeats were performed per pH change.
Results are shown in Fig. 6.20 and values for Igain from 10nA to 100nA are summarised
in Table 6.2. The average values of all three repeats, as shown in Fig. 6.20, are collected at
t=100s. Standard deviation values are also calculated for all repeats for each Igain value for
the given pH change. The results of the analysis show that for a minimum gain current of
Igain=10nA and Ix=20nA, a minimum ∆Iout=6.89nA is achieved. Similarly, for a maximum
gain current of Igain=200nA a maximum ∆Iout=30.2nA is achieved. This analysis confirms
that the gain can be tuned for a given pH change, which in turn proves experimentally
that the gain of the Chemical Gilbert Cell, as defined in Eq. 6.5, is dependent on the input
biasing current, Ix, and the gain current Igain, Eq. 6.4.
Moreover, further gain tunability experiments were conducted, covering four pH step
changes, as described in Section 6.6.2, but instead of applying a fixed gain term, the gain
values were varied from 10nA to 200nA. Initially, pH 7 was inserted in both chambers (Ch
1, Ch 2) followed by biasing both ISFETs, exposed in both chambers, at 20nA. Each pH
buffer from the range 5, 6, 7 and 9 was then induced in Ch 1, creating a ∆pH and thus a
∆Iout. Fig. 6.21 illustrates the experimental results of the transient response of the cell’s
differential output Iout for five gain values. Two repeats are shown with the average value
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Figure 6.21: Transient response of the Chemical Gilbert Cell’s differential output Iout for
different values of Igain following 4 pH step changes. In both chambers a buffer of pH 7
was initially induced giving a differential output current of 0nA, followed by a step change
of pH when pH buffers of 5, 6, 8 and 9 were induced. The experimental results shown are
confirmed after two repeats. The average value is also displayed as a dotted line.
of which been displayed as a dotted line in each subfigure.
The results of Fig. 6.23 can be summarised in Fig. 6.22 which illustrates more clearly the
experimental analysis conducted on gain tunability. This was conducted for the purposes
of depicting a better correlation between Iout and pH for varying values of Igain, leading
to the observation that the differential current produced during the pH change of 5 to 7
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Figure 6.22: Experimental analysis on the differential output Iout in the range of four pH
values.
Table 6.3: Average values of two repeats of ∆Iout in nA for different Igain values as seen in
Fig. 6.22 for each pH step
Igain(nA) pH=5 pH=6 pH=7 pH=8 pH=9
10 -7.282 -4.592 0 7.441 14.05
20 -9.999 -6.219 0 8.678 16.42
50 -14.04 -9.16 0 13.44 21.77
100 -20.39 -12.39 0 17.92 30.5
200 -29.45 -18.1 0 25.62 45.78
was smaller than that during the pH change of 7 to 9, which can be understood from the
exponential relationship between current and [H+], as described in Eq. 3.21, Section 3.5.1
in Chapter 3.
Finally, a different view on the results of Fig. 6.22 is shown in Fig. 6.23 whereby the
differential output Iout is summarised in each subfigure focusing on one pH change per figure
while varying Igain from 10nA to 200nA. Two repeats are displayed for each gain value in
every pH step change conducted, with the average of two shown in each case. It can be
seen that the gain value that provided the minimum deviation in between repeats occurred
for Igain=10nA for all pH step changes. The same value was chosen for monitoring the
transient measured response of the Chemical Gilbert Cell’s differential output current Iout,
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Figure 6.23: Gain variability for four pH steps change in the range of incremental current
gains. The average value of two repeats is also displayed as a dotted line.
as seen in Fig. 6.18 and for testing the cell’s pH sensitivity for different pH steps, as seen
in Fig. 6.19. The biggest deviation on the other hand can be seen for Igain valued 100nA
or 200nA regardless the pH of the solution before and after the change.
Shown in Table 6.3 are the results of a differential pH change from 5 to 9 relative to pH
7, with both chambers starting with pH 7. What can be seen is that as Igain increases from
10nA to 200nA, the differential output current Iout follows such increase relative to a rise in
gain of as much as 15.56dB for a drain current Ix=20nA. This gain however could be made
larger by reducing our DC operating current as defined by equation Eq. 6.5. Nevertheless,
this still demonstrates efficient gain tunability and sensing capability over a large range of
four pH values for very low current consumption.
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6.6.4 Drift
Experiments were also conducted in an attempt to monitor the single-ended drift of IISFET ,
in comparison to the differential drift, Iout, as a result of the Chemical Gilbert Cell’s function
and thus to investigate the capability of the cell to minimise drift. Since drift varies between
ISFETs, given that the threshold voltage of each device is not identical, we ensured the
experimental conditions (biasing, temperature, light, pH) constant for both ISFETs during
drift monitoring. A buffer solution of pH 7 was inserted in both microfluidic chambers for
the scope of the drift monitoring experiment with both ISFETs left to drift for a period of
1000s, with the resuIts of the drift test illustrated in Fig. 6.24.
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Figure 6.24: Single-ended drift IISFET in comparison to differential drift Iout for pH 7.
Drift values are indicated for both current outputs.
To indicate the reduction of drift between the drift value at the beginning of the recording
(t=0s) and the same at the end (t=1000s), the term ∆I/min is introduced to show the
transient change of current throughout the course of the experiment, used in this instance
to characterise drift. As can be seen from Fig. 6.24, the drift derived from a single ISFET
reached the value of 99.5pA/min compared to the drift derived from the differential read
out of the Chemical Gilbert Cell, which reached the value of 1.28pA/min for the given pH
(pH=7) inserted in both chambers. The currents of both ISFETs were normalised so that
the observation of the differential drift over the single-ended was more clear. It can be
observed that the differential current output, Iout, resulted in almost 100 times reduction
of drift in comparison to the drift derived from a single ISFET’s current output.
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Figure 6.25: Single-ended drift IISFET in comparison to differential drift Iout for pH 7
corresponding to figure indicators (1) and (3) and pH 9 corresponding to figure indicators
(2) and (4). Drift values are indicated for both current outputs.
Additionally, a closer comparison on single-ended and differential drift values was made
for a buffer solution of pH 9, commonly inserted in both microfluidic chambers. The drift
experiment conducted for pH 9 followed the same preparation and set-up as used for pH 7,
with both microfluidic chambers starting at the same pH and with the transient response
of currents having the same duration of 1000s. The results for pH 9 are superimposed with
the results for pH 7 as presented in Fig. 6.25. Drift values, ∆I/min, appear as well for pH
9 for both single-ended and differential output currents. Also, it may be useful to mention
that the drift experiment for pH 9 was conducted 5 hours after the one for pH 7, allowing
significant time for the ISFETs to ‘burn in’.
The results of drift minimisation for pH 9, were comparable to those for pH 7 with the
single-ended drift reaching a value of 110pA/min, slightly higher than the value obtained
for pH 7. Also, the differential drift obtained for pH 9 reached the value of 7.55pA/min,
around 7 times higher than the differential drift measured for pH 7. The results on drift for
pH 7 and pH 9, as seen in Fig. 6.25, represent the average values of two repeats of recordings
within the course of a day.
An additional observation on these results could be that there seems to be a slightly
small pH dependence of the initial drift (single-ended/differential), recorded during the first
few minutes of the experiment, on the pH of the solution. This may be explained based
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on theory behind changes of the ionic diffusion on an insulator’s surface correlated to the
pH of the solution that the insulator is exposed to [34]. This may explain the observation
of the slightly higher drift in the presence of an alkaline solution. The challenges of the
microfluidic set-up including the incredibly small chamber volume (0.3µl) and the oxidation
of the Ag/AgCl wire over time didn’t allow a further investigation of such observation on
the pH dependence of drift. Also, the comparison of drift (single-ended/differential) for
pH 7 and pH 9 may not be as fair given that the buffer solution was not re-flushed in
chambers to allow replenishment due to evaporation. However, what can be deduced from
both Fig. 6.24 and Fig. 6.25 is that there is a clear comparison between the single-ended
drift obtained as an output of a single ISFET and the differential drift obtained as an output
of the Chemical Gilbert Cell for both pH solutions, demonstrating an additional capability,
amongst the previously mentioned, which is drift minimisation.
6.6.5 Power consumption
The system under test operated in the weak inversion region. The total power in the system
may be calculated as:
P = VDD(IISFET1 + IISFET2 + Igain) (6.12)
The system achieves a very low power consumption of 165nW for a biasing current
Ix=20nA for both ISFETs and a gain current Igain=10nA, operating at a 3.3V supply. The
chip can be operating with biasing currents of as low as 1nA as can be seen in Fig. 6.16
leading to further reductions in power. Nevertheless, with a power consumption of 165nW,
this is the lowest reported power consumption for an integrated front-end with ISFET
differential monitoring and a tunable gain.
6.6.6 Temperature stability
In this section, the temperature stability of the Chemical Gilbert Cell was attempted to
be assessed experimentally without the use of the microfluidic device since the microfluidic
chambers’ maximum volume capability was 0.3µl and thus the solution available to be
heated would not be in excess for a fair comparison with respect to temperature stability
between a single ISFET’s output and a differential output of the Chemical Gilbert Cell. As
a result, the experimental set-up involved the ISFET based CMOS chip covered with epoxy
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resin, mounted on pcb, with both ISFETs exposed in the buffer solution used (pH 7). A
detailed view on the experimental set-up can be found in Fig. C.4, Appendix C. A fixed
potential to the solution was set through the use of a glass Ag/AgCl reference electrode at
3V, to set the operating point of the chip, setting the bias points of the individual ISFETs
by applying a suitable bias for weak inversion operation. The sources of the ISFETs were
set at 10nA and the gain current of the Chemical Gilbert Cell, Igain, was tuned at 1nA for
comparison with the simulation results.
The experimental set-up consisted of a hot plate (RCT basic IKAr-VERKE) used as
a heating element of a glass beaker filled with the buffer solution. The hot plate was
essential to initially create a stable room temperature condition for the solution in which
the chip was dipped in and also to set two temperature points needed to conduct the
stability test. The temperature was controlled manually and was monitored using a mercury
laboratory thermometer inserted in the solution. A magnetic stirring flea was also used to
stir the solution so that the temperature generated by the hot plate was evenly distributed
throughout the surface of exposure.
The initial temperature was manually set at 32oC followed by an increase reaching 42oC,
achieving a ∆T=10oC units followed by a similar decrease of the same amount of units.
The results of the temperature stability experiment are shown in Fig. 6.26 whereby it can
be seen that there is a reduced temperature dependence on the differential signal compared
to the single-ended one, with a change in the differential output current to be around 7
times less than for the single ISFET as given by:
IISFETT1 − IISFETT2
T1− T2 = 570pA/
◦C
}
Single-ended (6.13)
IoutT1 − IoutT2
T1− T2 = 85pA/
◦C
}
Differential (6.14)
The ISFETs source currents showed an increase from 10nA to approximately 20nA as the
temperature increased from 32oC to 42oC following a decreasing trend as the temperature
decreases from 42oC to 32oC. This happens due to the temperature dependence of the
threshold voltage of the ISFET (Chapter 3) and thus of the drain current. This applies
respectively to the decrease of the temperature leading to the decrease of the drain current
of the ISFET. There was also observed a small offset in the measured ISFET currents of
around 0.5nA to 1nA which can be explained due to the trapped charge [5] before heating
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Figure 6.26: Temperature stability for a single ISFET in comparison to the differential out-
put Iout for (a) ascending temperature from 32
oC to 42oC and (b) descending temperature
from 42oC to 32oC.
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the sensors, charge that was potentially released after heating the chip.
It needs to be mentioned that keeping the temperature stable was one of the main con-
straints of using a hot plate that didn’t exhibit a linear behaviour since the heating element
was applied to the glass beaker and therefore to the total volume of the solution. As a re-
sult, the exponential temperature increase profile, as seen in Fig. 6.26, is not a result of the
use of the Chemical Gilbert Cell but is due to the nonlinearity of the heater. This resulted
to a significant time lag of several minutes between tuning the temperature manually and
observing the actual change in the thermometer without exceeding the maximum/minimum
targeted temperature value, which could explain the existence of spikes in Fig. 6.26 as well.
6.7 Summary
In this chapter, the idea of an ISFET based Chemical Gilbert Cell was presented, simulated,
fabricated and finally integrated in a Lab-on-Chip implementation, demonstrating its ability
for monitoring differentially derived changes in pH required for DNA amplification taking
place in cases of existence of DNA methylation in the DNA target. The system’s properties
and performance are summarised in Table 6.4.
Simulation results showed the capability of the ISFET based Chemical Gilbert Cell for
computing a differential current output amplified by a gain value, set by a gain parameter,
A, allowing stable drift reduction. Simulations of the designed circuit based on real ISFET
data demonstrated a capability for drift reduction, temperature stability and tunable ampli-
fication by the linearly dependent gain of the “Gilbert Gain Cell”. These results highlighted
an ideal application of the proposed circuit, such as applications where discrete pH changes
occur due to a reaction taking place as a result of DNA amplification through methods such
as Polymerase Chain Reaction (PCR) or Loop-Mediated Isothermal Amplification (LAMP),
as has been explained in Chapter 4.
The theory behind the proposed circuit was then experimentally validated with the
concept of the ISFET based Chemical Gilbert Cell proved by demonstrating its capabilities
in the form of a fabricated system. Its capabilities mainly focus (a) on the ability to achieve
continuous differential current-mode measurements of pH signals obtained from biochemical
reactions of DNA amplification sensed by ISFET sensors, (b) on gain tunability through the
use of an adjustable gain by tuning a single current with results confirming 15.56dB gain at
20nA of ISFET bias current, (c) on drift reduction reaching a ratio of 100:1 in favour of the
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Table 6.4: System properties and performance characteristics
Technology AMS 0.35µm 2P4M CMOS
Die dimensions 2.5mm × 2.81mm
Passivation Si3N4/SiO2 1030nm/1000nm (about 120fF)
ISFET pixel: W×L (electrical) 200µm × 1µm
ISFET pixel: W×L (chemical) 34µm × 100µm
Sensing area 3400µm2
Transistor sizes (W×L) 10µm × 10µm
Transistors per pixel 10
Power supply 3.3V
Chamber size 1mm × 0.4mm × 0.4mm
Chamber diameter 400µm
Chamber volume 0.3µl
pH sensitivity 45mV/pH
Gain @ (IDC=20nA, Igain=200nA) 15.56dB
Drift reduction -37.8dB
Static ISFET drain current 20nA
Power consumption @ (IDC=20nA, Igain=10nA) 165nW
differential drift produced versus the single-ended drift derived from a single ISFET, making
it ideal for robust, low power chemical measurement and (d) on temperature stability in
favour of the differential output of the cell in comparison to a single ISFET output.
To achieve the cell’s abilities mentioned above, a Lab-on-Chip interface was introduced
with a microfluidic configuration developed, consisting of two micro-chambers, enabling the
precise monitoring of chemical signals of certain pH produced by separate reactions gener-
ated in each chamber, therefore bringing the privilege of using two ISFETs independently.
This allowed for differential monitoring of signals that could not be detected otherwise if a
common “bucket solution” approach was chosen to be followed, exposing both ISFETs in
the same buffer solution. In the current Lab-on-Chip interface, changes in the pH profile
were applied in Ch 1, while Ch 2 was kept chemically stable, keeping the same pH solution
in chamber. This resulted in the computation of differential current-mode output signals,
proving the concept of the Chemical Gilbert Cell’s operation.
The Chemical Gilbert Cell performed good, repeatable, differential operation, achieving
a ∆Iout of around 7nA, for a given pH change, with a less than 10% variation in 15 repeats.
The system’s sensitivity was confirmed for 4 pH step changes for a given gain value achieving
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a good differential pH sensitivity of 45mV/pH, derived from a chamber volume of 0.3µl.
Moreover, the gain tunability of the system was tested, showing that the gain of the system
can be efficiently tuned for a large range of pH, using only a single and adjustable current,
Igain, for very low current consumption. Finally, drift minimisation of continuously recorded
pH signals was achieved leading to an almost 100 times reduction of drift in the differential
current output produced by the cell compared to the drift derived by from a single ISFET’s
output current. The system achieved a measured low power consumption of 165nW due to
the weak inversion operation regime.
The advantages of using a differential current-mode configuration as the Chemical
Gilbert Cell can be exploited for any biomedical application, such as DNA methylation
detection which includes the processing step of DNA amplification, which requires large
scale integration especially when multiple genes need to be processed in parallel. It can
also be combined with differential monitoring and ease of gain tunability combined with
reduction of drift and high resolution. The use of such configuration can be a solution to
several challenges found in DNA amplification and detection such as chemical noise, sensi-
tivity of detection and good signal acquisition, facilitating its use for large scale integration.
Looking forward into the future, we see many potential applications of using the Chemical
Gilbert Cell for large sensing arrays in biomedical driven areas, such as in Single Nucleotide
Polymorphism (SNP) detection, DNA sequencing and in general in low power Lab-on-Chip
systems, with the potential of integration for ratiometric detection, as described in Chap-
ter 5, the “Methylation Cell”, to be one of these, improving the robustness of the approach
by eliminating the effects of the non-idealities of ISFETs.
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Chapter 7
Conclusion
This thesis introduced the application of semiconductor technology for detection of DNA
methylation based biomarkers, laying down the foundation of a Point-of-Care (PoC) system
for the early screening of cancer. A proof-of-concept approach was developed using a CMOS
based ion sensor, the ISFET, enabling the detection of DNA methylation using the methods
of pH-PCR and pH-LAMP, with the latter to be applied on a commercially available fully
integrated System-on-Chip platform. Furthermore, the concept of real-time ratiometric
detection of DNA methylation was developed and demonstrated using novel low power
interfaces, integrating both electrical and chemical front-ends under a Lab-on-Chip (LoC)
set-up. A hardware efficient system, referred to as the “Methylation Cell”, able to compute
the ratio of DNA methylation is designed, allowing real-time sensing of pH signals originated
from DNA reactions. In addition to this, a novel differential monitoring system capable
for differential reaction monitoring of pH signals combined with gain tunability and drift
reduction, termed the ISFET based Chemical Gilbert Cell, was developed, achieving ultra
low power operation.
Through the developments in this thesis, we are now one step closer into realising the
technological vision introduced in Fig. 1.2 of Chapter 1, which sees a future where early
screening of cancer will occur at a genetic level at the GP clinic, revolutionising the current
methods of prevention of this disease.
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7.1 Contributions
Chapter 2 introduces the field of epigenetics focusing on its significant role in cancer de-
velopment. Emphasis is given on the role of DNA methylation as one of the most studied
epigenetic events, with aberrations in DNA methylation patterns been actively involved in
gene silencing contributing in the processes of tumour initiation and progression. Events of
hypermethylation in the promoter regions of genes responsible for tumour suppression are
also correlated with frequently reported cancer cases, used as credible diagnostic markers.
Furthermore, an overview is given on the frequently used methods for DNA methylation de-
tection at a genomic or genome-wide level, followed by other novel approaches with varying
sensitivities and limitations based on the principles of detection, combined with computa-
tional tools used for enhancing the methylation signal resolution, providing a deeper analysis
on the methylation information. The chapter concludes with thoughts on the current needs
of DNA methylation based detection systems and the potential of CMOS based semicon-
ductor technologies to satisfy these needs, due to their capabilities for development of large
scale fully integrated platforms.
Chapter 3 presents the theory and fundamental principles behind the Ion-Sensitive Field-
Effect Transistor (ISFET) as a CMOS based solid-state ion sensor, which provides the
sensing capability for DNA methylation detection, as was shown in Chapter 4. Analysis of
the ISFET model and its pH sensitivity characteristics is then described, followed by the
principle behind the weak inversion region of operation used for low power chemical sensing
and efficient analogue computation.
Chapter 4 describes the proof-of-concept approach of using commercially available ion-
sensitive semiconductor technology for DNA methylation detection using the method of
pH-PCR under thermocycling conditions. In addition to this, the first ISFET based label-
free approach for DNA methylation detection was developed using the method of pH-LAMP
under isothermal conditions, with results being demonstrated in real-time using the CMOS
based System-on-Chip (SoC) platform for DNA detection. The platform was tested in two
tumour suppressor genes (DAPK1 and p16), generating a strong signal, allowing clear
differentiation of methylated from unmethylated DNA on-chip, bringing real-time ampli-
fication and detection of DNA methylation into a perspective of methylation analysis of
multiple genes under a multiplexed highly integrated semiconductor platform.
Chapter 5 introduces the concept of a ratiometric approach for detecting DNA methy-
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lation using the “Methylation Cell”, a novel ISFET based readout as part of a hardware
efficient system fabricated in CMOS due to the advantages of miniaturisation and low cost
of fabrication. The “Methylation Cell” was integrated with a LoC set-up, allowing real-
time sensing of pH signals derived from two isolated microfluidic chambers of the LoC, while
performing continuous computation of the DNA methylation ratio. This was achieved by
utilising the “translinear principle”, a current-mode circuit technique applied to weakly
inverted ISFETs, thus enabling the multiplication and division of currents for the compu-
tational analysis of DNA methylation ratio. The signals derived from the ISFETs were
originated from DNA reactions occurring in presence of methylated DNA while being com-
pared to the signals obtained as a result of no reactions taking place due to the absence
of methylated DNA, with the ratio being used as an indication of the level of methyla-
tion existent in genes of interest. The “Methylation Cell” had also an additional feature
of a comparison block capable of giving a discrete answer on the output in the form of a
boolean value when methylation levels exceeded a threshold, which could further be used
for epidemiological identification of DNA methylation ratios in real-time, given the dynamic
nature of DNA methylation as an epigenetic marker.
Chapter 6 proposed a low power current-mode approach in CMOS, the ISFET based
Chemical Gilbert Cell, for continuous differential reaction monitoring of pH changes derived
from DNA amplification reactions taking place as result of the presence of DNA methyla-
tion in a DNA sample. The system was integrated with a LoC set-up combined with a
microfluidic assembly that could offer separate control of reaction measurements and anal-
ysis combined with gain tunability through the use of a programmable gain term, achieving
amplification of the output signal of the sensing cell. With respect to some non-idealities of
ISFETs such as drift and temperature variation, the system achieved drift reduction reach-
ing a ratio of 100:1 in favour of the differential ISFET front-end, opposed to the single-ended
drift and stability in temperature, making it ideal for monitoring of reactions that require
temperature control, sensitivity of detection and good differentiation of the reaction’s signal
from the background noise.
7.2 Recommendations for Future Work
Future recommendations based on the contributions of this work are proposed in the fol-
lowing sections. These include the prospects of realisation of large scale arrays for DNA
methylation detection and analysis as well as of ISFET based Chemical Gilbert Cell arrays
Conclusion 192
for gain tunability control of multiple cells.
7.2.1 Large scale arrays for DNA methylation detection
Cancer susceptibility is related to hypermethylation of specific genes. Also, hypermethyla-
tion of a particular gene is usually specific to more than one cancer types generated from
more than one organ sites. Multiplexed integration of in parallel analysis of methylation-
specific gene assays using arrays of ISFET sensors is one of the main future objectives
towards the realisation of a portable, lab-free DNA methylation based assay for screen-
ing of DNA methylation levels of tumour specific genes. The number of genes analysed
per cancer type may considerably increase the sensitivity of detection, therefore parallel
investigation of the methylation status of multiple genes is a desired feature for the identifi-
cation of the stage of tumour progression. This could contribute in applying a personalised
and effective treatment to the patient which could thus increase the chances for a better
therapeutic targeting and a guided therapy using the epigenetic profile of the patient.
To accommodate this need, a CMOS ISFET based high reaction throughput platform
technology needs to be utilised using integrated circuits scaled in arrays, with each array con-
sisting of ISFET sensors under a flow cell, creating individually controlled chambers, offering
a fast and simple way to monitor nucleotide incorporations generated by separate methy-
lation specific reactions. This, in combination with targeted sequencing of methylation of
specific areas and the use of computational analysis tools, such as the DNA methylation
ratio, may allow for high-throughput DNA methylation analysis of a large range of samples
at a sequence-specific level, since methylated patterns would be already differentiated from
the unmethylated ones using bisulfite based DNA sample analysis.
7.2.2 Clinical validation of the system
As soon as the large scale realisation of DNA methylation analysis and monitoring is
achieved, we aim to clinically validate the use of this technology in case groups of patients
with firstly confirmed diagnosed cancer of all stages (I-IV) using a panel of genes correlated
to chosen cancer types. A control group would also be needed consisting of healthy sub-
jects with no previous history of malignancy occurrence. This will enable the use of DNA
methylation as a biomarker for cancer screening, providing with the information for the
tumour status (indolent or aggressive) and dependent on its aggressiveness, the possibility
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of a tumour metastasis.
Matters related to the integration of the step of sample preparation and DNA extraction
in the lab-free platform are to be investigated as well. Also possible ways for fast processing
of data collected from the detection results are to be considered to provide maximum clinical
benefit during several phases of cancer screening.
7.2.3 ISFET based Chemical Gilbert Cell arrays
The ISFET based Chemical Gilbert Cell, as presented in Chapter 6, was developed for
differential monitoring of two reactions sensed by two ISFET sensors. For each differen-
tial output produced as a result of a given reaction, a fixed gain term was set, with the
potential for maximum differential output signal to be achieved while tuning the gain of
the cell at a range of values. Fabricating arrays of ISFET based Chemical Gilbert Cells
could thus contribute in tuning independently the gain terms of all cells while minimising
device mismatches, enhancing and matching the sensitivity of detection per cell, per array
while acting as a calibration mechanism. This could also compensate for common non-
idealities of ISFETs such as drift given the cell’s inherent advantage for drift reduction, as
has been proven in Chapter 6. Such arrangement would bring great benefits for in paral-
lel monitoring of DNA amplification reactions, enhancing the amplification-specific output
signals thus positively affecting the detection resolution. Potential future integration with
the “Methylation Cell” can also be investigated.
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Figure B.1: Chips fabricated during the course of this thesis.
Appendix C
CMOS ISFET Experimental set-up
For the device characterisation of the CMOS ISFET sensors, a semiconductor parameter
analyser (Keithley 4200SCS) was used in combination with a switching matrix and three
external source meter units as can be seen in Fig. C.1 or in more detail in Fig. C.2 for
experiments where ISFETs were exposed in a common buffer solution.
 
 Keithley 
4200SCS 
Ag/AgCl  Reference Electrode 
CMOS ISFET 
Beaker with pH solution 
Faraday cage 
Dipstick with mounted chip Epoxy encapsulated chip
Source 
 meter 
 units
Switching 
  matrix
Ag/AgCl
  ref. el.
Figure C.1: Set-up for electrical characterisation of ISFETs using a glass beaker filled with
pH buffer solution.
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Figure C.2: Instrumentation set-up for electrical characterisation of ISFETs in a buffer
solution.
manifold
   Ag/AgCl
ref. electrode
pH buers
micropipette tip
Lab-on-Chip
microuidic
 chambers
Figure C.3: Set-up for electrical characterisation of ISFETs using a microfluidic assembly
in a Lab-on-Chip set-up.
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The experimental set-up for the temperature stability test analysed in Section 6.6.6,
Chapter 6 is shown below:
dipstick
thermometer
Ag/AgCl ref. el.
hot plate
stirrer
pH buer
Figure C.4: Temperature stability experimental set-up
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ISFET pH probe/Argus pH meter preparation
A pH measurement set-up consisting of a Sentron Argus pH-meter (Sentron Europe B.V.),
in combination with a Sentron ISFET microelectrode (Sentron Europe B.V.) was used for
the pH adjustments of the buffer solutions and DNA reaction mixtures in use during this
thesis. Specifically, such a set-up was part of the experimental processes of pH-PCR and
pH-LAMP as explained in Chapter 4 and for the electrical characterisation of ISFETs seen
in Chapter 5 and Chapter 6.
Sentron pH microelectrodes have been reported to be very robust for laboratory use
applications that involve highly accurate pH measurements of very small volumes, which
can hardly be made by a conventional glass electrode, as well as fast and reliable for pH
determination and temperature measurement. The Sentron sensing microelectrode is made
of peek material, having a diameter of only 3 mm, with the measuring sensing part covering
the tip of the electrode, a big advantage for small volume measurements. No inner buffer
solution was used in that type of sensor design (Sentron Europe B.V.) compared to the
conventional glass electrodes, with the whole microchip been embedded in plastic so that
only the gate electrode would be in contact with the sample to be measured [1].
In more detail, the actual pH meter combines an ISFET pH sensor, a miniature Ag/AgCl
reference electrode, a temperature sensor and a narrow tube [2], with the ISFET being able
to monitor the pH of sample volumes. The coatings for the insulating layer of the pH
sensor were Al2O3 based, as this has been reported to increase the selectivity of the sensor
in [H+] detection, and thus influencing the IDS current, leaving the overall response of the
pH probe directly related to the pH. This principle provides a considerably higher stability
under light exposure and high electrostatic discharges.
Prior to the first use of the Argus system, the pH probe was placed in a buffer solution
(preferably of pH 7.00) for 10 minutes, with the meter switched on, as an initiating time
for the probe to set itself for use, therefore ensuring future stable readings. After the first
use, it was advised by the manufacturer that the pH electrode was left dry, for an extended
period of inactivity, or in saturated KCl solution for frequent use, so as to achieve maximum
accuracy and stability in measurements. Prior to daily use, the pH meter was flushed with
distilled water and then while laid on a soft sponge, it was cleaned with a soft toothbrush
(provided with the Argus system), using a drop of a mild detergent, then rinsed again with
distilled water and wiped using a soft cotton wipe. It was then placed in pH 7.00 for 10 min
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(with the meter on) and was calibrated using pH buffers 7.00 and 4.00 at room temperature.
Fresh buffer solutions were used for calibration to avoid any possibilities of contamination.
Before calibration, the probe was rinsed with distilled water and then wiped. A 2-point
calibration measurement was accordingly performed, using 2 buffers of close pH values. At
first, a buffer solution of pH 7.00 was used, followed by a solution of pH 4.00, therefore
targeting for increasing measurement accuracy over a certain pH range. After completing
that step, the slope percentage was briefly displayed, with a resulting 98.0-105.0% slope
(safe range), indicating that the probe is having the capability to perform at its maximum
further on.
Appendix D
The multichannel pH-sensing SoC
platform
(a)
Fig.~\ref{g:
Figure D.1: The IC mounted on a test card (a) connected to an electronic analyser (b) [3]
The System-on-Chip (SoC) platform for DNA detection, as reported by [3, 4], consists
of an integrated circuit combined with 40 ISFETs, 10 temperature sensors, heaters, signal
processing and control circuitry all integrated on a single chip, fabricated using unmodified
standard CMOS 0.35µm process. The Integrated Circuit (IC), sized 5.5mm x 4.8mm, is
mounted on a disposable test card, as can be seen in Fig. D.1a, using an SD memory card
format, connected to an electronic analyser, shown in Fig. D.1b, which is powering and
controlling the IC, providing with a read-out interface for processing the reaction taking
place on the CMOS chip, while transferring the results real-time to a tablet or PC. The IC
is also combined with a microfluidic assembly through which the delivery of the reaction
mixture for DNA amplification is performed through micro chambers and fitted access
channels [3, 4].
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DNA based methods
DNA separation - agarose gel electrophoresis
DNA separation was carried out by agarose gel electrophoresis using a Power Pac
TM
Bio−
Rad unit in order to visualise the location of the small fragments of the base pairs of our
DNA amplicon produced during a method of DNA amplification (i.e. PCR or LAMP),
according to either one of the two universal templates (size markers), the GeneRulerTM
TM
Low Range DNA ladder (25-700bp) or the O′GeneRulerTM Low Range DNA ladder (100-
1000bp) (Thermo Fisher Scientific) [5, 6]. In most of the experiments the amplicon size that
was expected to be seen was between 100 and 300bp and so the DNA ladder of the smaller
bp range was preferred to be used when running the gel. What is more, a DNA loading dye
was used, supplied by Thermo Fisher Scientific, combined with a SY BRr Green I nucleic
acid gel stain, supplied by Invitrogen. Both the dye and the stain formed a loading buffer,
giving colour and density to the sample, making it easy to be loaded into the wells. The
dye is negatively charged in neutral buffers (TBE in our case) and thus moves in the same
direction as the DNA (negatively charged) during electrophoresis, allowing us to monitor
the progress of the gel. The more the voltage applied in the electrophoretic unit, the closer
the fragments migrate in the gel.
1.8-2.0% agarose gels of around 100µl of 1xTBE buffer were employed, dependent on
the experimental requirements. In each run, a gel was placed in a gel tank and submerged
in 1xTBE buffer. 1µl of the DNA loading dye, for each sample, was mixed with a 10% of
SY BRr Green I stain, of the relative loading dyes volume (most of the times the volume
didnt exceed the amount of 0.1µl). The mixture of the loading dye and the SY BRr Green
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I stain was also added to the relative amount of the DNA ladder used (0.8-1.3µl). Then, 5µl
of the DNA reaction mixture after PCR amplification or 0.5µl of the DNA reaction mixture
after LAMP amplification (dependent upon the nature of the experiment) were added to
the loading buffer. Upon mixing, the total volume of the sample mixtures was loaded into
the wells of the gel. The gel was left running for around 12-15min with a constant voltage
of 220-240V for PCR and around 20min with a constant voltage of 300V for LAMP. After
checking that current was flowing in the gel tank, by checking the evolving gas (i.e. bubbles)
in the tank, the gel was stopped when the blue loading dye had run 3/4 of the length of the
gel. DNA bands from gel electrophoretic images were then visualised using a UV light-box
and analysed using the image acquisition software GeneSnap [7].
Appendix F
Encapsulation Procedures
Epoxy Encapsulation
Epoxy encapsulation was used for the AMS 0.35µm technology die. The die was glued, using
EPO-TEK H20E conductive epoxy on a commercially manufactured printed circuit board
as shown in Fig. C.1. It was wirebonded using a 25µm wire consisting of 99% aluminium
and 1% silicon. The bonded die was then encapsulated using glob topping epoxy by EPO-
TEK (Ref: T7139), with only the chemically sensitive areas being exposed. The epoxy was
cured in the oven at 120oC for 60 minutes.
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Supplementary Material
G.1 Chemical Gilbert Cell: Supplementary Experiments
Fig. G.1 shows supplementary results on the experimental analysis conducted in Fig. 6.21,
Section 6.6.3, Chapter 6. These illustrate the transient response of the Chemical Gilbert
Cell differential output Iout for different values of Igain for 4 pH steps confirmed after three
repeats. The 3rd repetition may not be entirely credible due to the evaporation of the
solution in the reaction chambers.
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Figure G.1: Transient response of the Chemical Gilbert Cell’s differential output Iout for
different values of Igain following 4 pH step changes. In both chambers a buffer of pH 7
was initially induced giving a differential output current of 0nA, followed by a step change
of pH when pH buffers of 5, 6, 8 and 9 were induced. The experimental results shown are
confirmed after three repeats. The average value is also displayed as a dotted line.
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G.2 Ratiometric method: Supplementary Experiments
G.2.1 Voltage-mode switching
Fig. G.2 and Fig. G.3 show the results of voltage-mode switching for ascending and descend-
ing values of Iperc within the range of 1nA to 10nA, with both Imeth and Iunmeth fixed at
10nA and Igain at 10nA. The point of switching of the inverter is indicated in both figures
with the values of Iratio been highlighted.
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Figure G.2: Transient response of the voltage output, Vout, of the inverter and the current
output, Iratio, of the translinear cell in pH 7, for varying ascending values of Iperc starting
from 1nA up to 10nA.
What is more, the transient response of the inverter, Vout, with respect to changes in
Iratio as results of changes in Imeth is shown in Fig. G.4. Iperc was set at 4.7nA based on
the information acquired from the two previous experiments. As Imeth varies from 10nA to
40nA, the inverter switches after a delay, with the switching point indicated in the figure.
After a period of some seconds, Imeth decreases from 40nA to 10nA and similarly the inverter
switches with a relative delay. This shows that there was not given enough time to the node
of the inverter to discharge, providing with a delay during switching.
Supplementary Material 210
0 100 200 300 400 500 600 700
0
5
Time (sec)
4.6
4.65
4.7
x 10 −9
X: 316
Y: 4.645e−009
Figure G.3: Transient response of the voltage output, Vout, of the inverter and the current
output, Iratio, of the translinear cell in pH 7, for varying descending values of Iperc starting
from 10nA down to 1nA.
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Figure G.4: Transient response of the voltage output, Vout, of the inverter and the current
output, Iratio, of the translinear cell in pH 7, while Imeth is electrically tuned from 10nA to
40nA and back to 10nA, for a given Iunmeth=10nA for an Igain of 10nA.
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G.2.2 Iratio computation during pH 7-9
Shown is a supplementary table on the experimental analysis conducted in Section 5.5.2,
Chapter 5. Additional experiments on the computation of Iratio and Imeth with Iunmeth
being constant were monitored during ascending and descending pH steps (pH 7-9) following
two repeats, similar to the ones displayed in Table 5.4. This example is to show how Iratio
was affected by drift due to the lack of time given to the ISFETs to ’burn in’ during the
pH test.
Table G.1: Results of average and standard deviation values of two repeats of Iratio, Imeth
under given Iunmeth values during ascending and descending pH steps from pH 7 to pH 9
showing the effect of drift on Iratio.
pH=7 pH=8 pH=9 pH=8 pH=7
Imeth(nA) 100 113.5±0.707 132.5±4.949 122±5.656 105.5±6.363
Iunmeth(nA) 100 96.5±0.707 95± 93.5±0.707 91±
Iratio(nA) 49.5±0.707 53±1.414 57.5±0.707 56±1.414 53±1.414
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